

Pathological hypertrophy and cardiac interstitium. Fibroblasts and the renin-angiotensin-aldosterone system.

Circulation

83, 1849-1865

DOI: [10.1161/01.cir.83.6.1849](https://doi.org/10.1161/01.cir.83.6.1849)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Diastolic Dysfunction in Congestive Heart Failure. <i>New England Journal of Medicine</i> , 1991, 325, 1557-1564.	13.9	323
3	The Heart in Hypertension. <i>New England Journal of Medicine</i> , 1992, 327, 998-1008.	13.9	653
4	Reactive and reparative myocardial fibrosis in arterial hypertension in the rat. <i>Cardiovascular Research</i> , 1992, 26, 671-677.	1.8	249
5	Captopril enhances intracellular calcium handling and beta-adrenergic responsiveness of myocardium from rats with postinfarction failure.. <i>Circulation Research</i> , 1992, 71, 797-807.	2.0	85
6	Coronary haemodynamics in hypertensive heart disease. <i>European Heart Journal</i> , 1992, 13, 44-49.	1.0	76
7	Fibrosis of the Human Heart and Systemic Organs in Adrenal Adenoma. <i>Blood Pressure</i> , 1992, 1, 149-156.	0.7	55
8	Regulatory Mechanisms of Myocardial Hypertrophy and Fibrosis: Results of in vivo Studies. <i>Cardiology</i> , 1992, 81, 266-273.	0.6	34
9	Biological basis of diastolic dysfunction of hypertensive heart. <i>European Heart Journal</i> , 1992, 13, 2-8.	1.0	23
10	Hypertension, left ventricular hypertrophy, ventricular arrhythmias and sudden death. <i>European Heart Journal</i> , 1992, 13, 66-69.	1.0	45
11	Morphometric investigation of human myocardium in arterial hypertension and valvular aortic stenosis. <i>European Heart Journal</i> , 1992, 13, 17-23.	1.0	98
12	Pharmacotherapeutic effects of antihypertensive agents on myocardium and coronary arteries in hypertension. <i>European Heart Journal</i> , 1992, 13, 100-106.	1.0	13
13	Pathologic Hypertrophy with Fibrosis: The Structural Basis for Myocardial Failure. <i>Blood Pressure</i> , 1992, 1, 75-85.	0.7	85
14	Vasodilators. <i>Drugs</i> , 1992, 43, 15-36.	4.9	9
15	From cardiac to vascular protection: the next chapter. <i>Lancet, The</i> , 1992, 340, 1197-1198.	6.3	11
16	Increased Incidence of Arrhythmias with Aging in Normal and Pathological Rat Hearts. <i>Annals of the New York Academy of Sciences</i> , 1992, 673, 311-320.	1.8	2
17	Projecting the future size and health status of the US elderly population. <i>International Journal of Forecasting</i> , 1992, 8, 433-458.	3.9	63
18	Remodeling and reparation of the cardiovascular system. <i>Journal of the American College of Cardiology</i> , 1992, 20, 3-16.	1.2	298
19	Diastolic function of the nonfilling human left ventricle. <i>Journal of the American College of Cardiology</i> , 1992, 20, 1524-1532.	1.2	37

#	ARTICLE	IF	CITATIONS
20	The Prevention of Heart Failure – A New Agenda. <i>New England Journal of Medicine</i> , 1992, 327, 725-727.	13.9	102
21	Differential growth of neonatal WKY and SHR ventricular myocytes within sympathetic co-cultures. <i>Journal of Molecular and Cellular Cardiology</i> , 1992, 24, 1479-1489.	0.9	6
22	Reversal of Cardiovascular Structural Changes When Treating Essential Hypertension. <i>American Journal of Hypertension</i> , 1992, 5, 900-911.	1.0	61
23	Left ventricular hypertrophy: An initial response to myocardial injury. <i>American Journal of Cardiology</i> , 1992, 69, 3-9.	0.7	63
24	Ventricular remodeling following myocardial infarction. <i>American Journal of Cardiology</i> , 1992, 70, 20-26.	0.7	31
25	Prospects for cardioreparation. <i>American Journal of Cardiology</i> , 1992, 70, 27-36.	0.7	50
26	Gene expression in cardiac hypertrophy. <i>Trends in Cardiovascular Medicine</i> , 1992, 2, 176-182.	2.3	68
27	Direct extraction and estimation of collagenase(s) activity by zymography in microquantities of rat myocardium and uterus. <i>Clinical Biochemistry</i> , 1993, 26, 191-198.	0.8	163
28	Renin-angiotensin system and myocardial collagen matrix remodeling in hypertensive heart disease: in vivo and in vitro studies on collagen matrix regulation. <i>The Clinical Investigator</i> , 1993, 71, S35-41.	0.6	63
29	Coronary microcirculation in hypertensive heart disease: functional significance and therapeutic implications. <i>The Clinical Investigator</i> , 1993, 71, S42-5.	0.6	5
30	In vitro evaluation of diltiazem on hypothermic injury to immature myocytes. <i>Cardiovascular Drugs and Therapy</i> , 1993, 7, 713-720.	1.3	1
31	Role of extracellular matrix proteins in heart function. <i>Molecular and Cellular Biochemistry</i> , 1993, 129, 101-120.	1.4	142
32	Aldosterone and antialdosterone therapy in congestive heart failure. <i>American Journal of Cardiology</i> , 1993, 71, A3-A11.	0.7	92
33	Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. <i>American Journal of Cardiology</i> , 1993, 71, A12-A16.	0.7	238
34	Influence of arterial blood pressure and aldosterone on left ventricular hypertrophy in moderate essential hypertension. <i>American Journal of Cardiology</i> , 1993, 71, A17-A20.	0.7	113
35	Influence of systemic arterial blood pressure and nonhemodynamic factors on the brachial artery pulsatility index in mild to moderate essential hypertension. <i>American Journal of Cardiology</i> , 1993, 71, 350-353.	0.7	9
36	Systemic hypertension and the renin-angiotensin system in diabetic vascular complications. <i>American Journal of Cardiology</i> , 1993, 72, H14-H21.	0.7	26
37	Cardioprotection with angiotensin-converting enzyme inhibitors: Redefined for the 1990s. <i>Clinical Cardiology</i> , 1993, 16, 95-103.	0.7	13

#	ARTICLE	IF	CITATIONS
38	Structural basis for pathologic left ventricular hypertrophy. <i>Clinical Cardiology</i> , 1993, 16, 10-14.	0.7	40
39	The source of epifluorescence in isolated perfused heart loaded with fura 2-AM or indo 1-AM. <i>Heart and Vessels</i> , 1993, 8, 79-84.	0.5	9
40	Differentiating systolic from diastolic heart failure: Pathophysiologic and therapeutic considerations. <i>American Journal of Medicine</i> , 1993, 95, 645-655.	0.6	70
41	Cardiac effects of trandolapril in hypertension. <i>American Heart Journal</i> , 1993, 125, 1536-1541.	1.2	11
42	The treatment of heart failure—what next?. <i>British Journal of Clinical Pharmacology</i> , 1993, 35, 557-563.	1.1	2
43	Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype.. <i>Circulation Research</i> , 1993, 73, 413-423.	2.0	1,266
44	Identification of functional angiotensin II receptors on rat cardiac fibroblasts.. <i>Circulation</i> , 1993, 88, 2849-2861.	1.6	339
45	Effect of Captopril on Changes in Rats' Hearts Induced by Long-Term Irradiation. <i>Radiation Research</i> , 1993, 133, 187.	0.7	49
46	Quantification of ventricular remodeling in the tight-skin mouse cardiomyopathy with acoustic microscopy. <i>Ultrasound in Medicine and Biology</i> , 1993, 19, 365-374.	0.7	26
47	Diastolic dysfunction in post-cardiac surgical management. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 1993, 7, 18-20.	0.6	11
48	Relation of pathophysiologic mechanisms to outcome in heart failure. <i>Journal of the American College of Cardiology</i> , 1993, 22, A22-A29.	1.2	45
49	Diastolic dysfunction as a cause of heart failure. <i>Journal of the American College of Cardiology</i> , 1993, 22, A49-A55.	1.2	110
50	Influence of collagen network on left ventricular systolic and diastolic function in aortic valve disease. <i>Journal of the American College of Cardiology</i> , 1993, 22, 1477-1484.	1.2	208
51	Long-term oral nitrate therapy prevents chronic ventricular remodeling in the dog. <i>Journal of the American College of Cardiology</i> , 1993, 21, 514-522.	1.2	70
52	Diastolic failure: Pathophysiology and therapeutic implications. <i>Journal of the American College of Cardiology</i> , 1993, 22, 318-325.	1.2	301
53	Myocardial fibrosis: functional significance and regulatory factors. <i>Cardiovascular Research</i> , 1993, 27, 341-348.	1.8	420
54	Aldosterone Action. <i>Annual Review of Physiology</i> , 1993, 55, 115-130.	5.6	80
55	Cardioreparation and the Concept of Modulating Cardiovascular Structure and Function. <i>Blood Pressure</i> , 1993, 2, 6-21.	0.7	31

#	ARTICLE	IF	CITATIONS
56	Effects of Enalaprilat on Hemodynamics and Ventricular Activation Duration in Hypertensive Patients With Left Ventricular Hypertrophy: Clinical Evidence of Improved Excitation-Contraction Coupling With Angiotensin Converting Enzyme Inhibition in Human Hypertension. <i>American Journal of Hypertension</i> , 1993, 6, 570-578.	1.0	2
57	Structural and functional alterations of the intramyocardial coronary arterioles in patients with arterial hypertension.. <i>Circulation</i> , 1993, 88, 993-1003.	1.6	368
58	Estimates of Change in Chronic Disability and Institutional Incidence and Prevalence Rates in the U.S Elderly Population From the 1982, 1984, and 1989 National Long Term Care Survey. <i>Journal of Gerontology</i> , 1993, 48, S153-S166.	2.0	365
59	Left Ventricular Mass and Geometry Before and After Etiologic Treatment in Renovascular Hypertension, Aldosterone-Producing Adenoma, and Pheochromocytoma. <i>American Journal of Hypertension</i> , 1993, 6, 907-913.	1.0	76
60	Ventricular remodelling: consequences and therapy. <i>European Heart Journal</i> , 1993, 14, 24-29.	1.0	66
61	Left ventricular systolic and diastolic dysfunction in the acute phases of myocardial ischaemia and infarction, and in the later phases of recovery. Function follows morphology. <i>European Heart Journal</i> , 1993, 14, 48-56.	1.0	16
62	Pathologic Remodeling of the Myocardium in a Weightlifter Taking Anabolic Steroids<i>Case Report</i>. <i>Blood Pressure</i> , 1993, 2, 213-216.	0.7	30
63	Normal ultrasonic myocardial reflectivity in hypertensive patients. A tissue characterization study.. <i>Hypertension</i> , 1993, 21, 329-334.	1.3	21
64	Vasodilator Therapy for Congestive Heart Failure. <i>Archives of Internal Medicine</i> , 1993, 153, 445.	4.3	17
65	Collagen remodelling in myocardia of patients with diabetes.. <i>Journal of Clinical Pathology</i> , 1993, 46, 32-36.	1.0	201
66	Angiotensin I and II exert inotropic effects in atrial but not in ventricular human myocardium. An in vitro study under physiological experimental conditions.. <i>Circulation</i> , 1993, 88, 1228-1237.	1.6	92
67	Angiotensin II is mitogenic in neonatal rat cardiac fibroblasts.. <i>Circulation Research</i> , 1993, 72, 1245-1254.	2.0	365
68	Myocardial Fibrosis in the Rat With Mineralocorticoid Excess Prevention of Scarring by Amiloride. <i>American Journal of Hypertension</i> , 1993, 6, 487-495.	1.0	77
69	Prevalence of Extracranial Carotid Artery Lesions at Duplex in Primary Aldosteronism. <i>American Journal of Hypertension</i> , 1993, 6, 8-14.	1.0	28
70	Modulation of cardiac myocyte beating rate and hypertrophy by cardiac fibroblasts isolated from neonatal rat ventricle.. <i>Japanese Circulation Journal</i> , 1993, 57, 912-920.	1.0	27
71	Effect of Calcium Antagonists on RNA Synthesis of NIH 3T3 Cells. <i>American Journal of the Medical Sciences</i> , 1993, 306, 137-140.	0.4	6
73	ACE inhibitors after myocardial infarction.. <i>BMJ: British Medical Journal</i> , 1993, 306, 531-532.	2.4	11
74	Role of aldosterone in congestive heart failure. <i>Postgraduate Medicine</i> , 1993, 93, 203-221.	0.9	18

#	ARTICLE	IF	CITATIONS
75	Pathophysiology and clinical aspects of hypertensive hypertrophy. <i>European Heart Journal</i> , 1993, 14, 2-7.	1.0	25
76	Effects of angiotensin-converting enzyme inhibition on mitochondrial number in the aging mouse. <i>American Journal of Physiology - Cell Physiology</i> , 1993, 265, C15-C18.	2.1	80
77	Collagen characterization in volume-overload- and pressure-overload-induced cardiac hypertrophy in minipigs. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 1993, 265, H434-H438.	1.5	9
79	Copper deficiency alters collagen types and covalent cross-linking in swine myocardium and cardiac valves. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 1993, 264, H2154-H2161.	1.5	13
80	Left ventricular adaptation to gradual renovascular hypertension in dogs. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 1993, 265, H22-H38.	1.5	14
81	Diastolic heart failure. <i>European Heart Journal</i> , 1994, 15, 1689-1697.	1.0	55
82	Time-varying Covariates in Models of Human Mortality and Aging: Multidimensional Generalizations of the Gompertz. <i>Journal of Gerontology</i> , 1994, 49, B169-B190.	2.0	70
83	Relation of regional cross-fiber shortening to wall thickening in the intact heart. Three-dimensional strain analysis by NMR tagging.. <i>Circulation</i> , 1994, 89, 1174-1182.	1.6	290
84	Myocardial scintigraphic characteristics in patients with primary aldosteronism.. <i>Hypertension</i> , 1994, 23, 1164-7.	1.3	23
85	The renin-angiotensin system and volume overload-induced changes in cardiac collagen and elastin.. <i>Circulation</i> , 1994, 90, 1989-1996.	1.6	67
86	Cellular mechanisms of captopril-induced matrix remodeling in Syrian hamster cardiomyopathy.. <i>Circulation</i> , 1994, 90, 1334-1342.	1.6	32
87	Relative effects of alpha 1-adrenoceptor blockade, converting enzyme inhibitor therapy, and angiotensin II subtype 1 receptor blockade on ventricular remodeling in the dog.. <i>Circulation</i> , 1994, 90, 3034-3046.	1.6	98
88	Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat.. <i>Circulation</i> , 1994, 89, 2273-2282.	1.6	415
89	Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease. Comparative effects of ACE inhibition and calcium channel blockade.. <i>Circulation</i> , 1994, 90, 2786-2796.	1.6	314
90	Structural basis of end-stage failure in ischemic cardiomyopathy in humans.. <i>Circulation</i> , 1994, 89, 151-163.	1.6	551
91	Growth Hormone and the Heart. <i>Endocrine Reviews</i> , 1994, 15, 555-573.	8.9	493
92	Diagnosis of mild hypertension by ambulatory blood pressure monitoring.. <i>Circulation</i> , 1994, 90, 2291-2298.	1.6	106
93	Alterations in cardiac gene expression during the transition from stable hypertrophy to heart failure. Marked upregulation of genes encoding extracellular matrix components.. <i>Circulation Research</i> , 1994, 75, 23-32.	2.0	337

#	ARTICLE	IF	CITATIONS
94	Insights from animal models of myocardial infarction: do ACE inhibitors limit the structural response?. <i>Heart</i> , 1994, 72, S61-S64.	1.2	10
95	Treatment With Lisinopril Normalizes Serum Concentrations of Procollagen Type III Amino-Terminal Peptide in Patients With Essential Hypertension. <i>American Journal of Hypertension</i> , 1994, 7, 52-58.	1.0	39
96	Angiotensin-converting enzyme inhibition prolongs survival and modifies the transition to heart failure in rats with pressure overload hypertrophy due to ascending aortic stenosis.. <i>Circulation</i> , 1994, 90, 1410-1422.	1.6	219
97	Synthesis of corticosterone in the vascular wall.. <i>Endocrinology</i> , 1994, 135, 2283-2286.	1.4	57
98	Effect of collagen on the anisotropy of quasi-longitudinal mode ultrasonic velocity in fibrous soft tissues: A comparison of fixed tendon and fixed myocardium. <i>Journal of the Acoustical Society of America</i> , 1994, 96, 1957-1964.	0.5	39
99	Distribution of angiotensinogen in diseased human hearts. <i>Molecular and Cellular Biochemistry</i> , 1994, 132, 15-23.	1.4	21
100	Left ventricular dysfunction in ischemic heart disease: Fundamental importance of the fibrous matrix. <i>Cardiovascular Drugs and Therapy</i> , 1994, 8, 305-312.	1.3	22
101	Is the senescent heart overloaded and already failing?. <i>Cardiovascular Drugs and Therapy</i> , 1994, 8, 581-587.	1.3	27
102	Discrepancy between pre- and post-transplant diagnosis of end-stage dilated cardiomyopathy. <i>American Journal of Cardiology</i> , 1994, 74, 921-924.	0.7	34
103	Role of neurohormones in ventricular adaptation and failure. <i>American Journal of Cardiology</i> , 1994, 73, C36-C39.	0.7	5
104	Disparate structural effects on left and right ventricles by angiotensin-converting enzyme inhibitors and calcium antagonists in essential hypertension. <i>American Journal of Cardiology</i> , 1994, 73, 483-487.	0.7	29
105	CGS 24128: A Long-Acting Inhibitor of Neutral Endopeptidase 3.4.24.11. <i>Cardiovascular Drug Reviews</i> , 1994, 12, 271-285.	4.4	5
106	ANGIOTENSIN RECEPTORS IN CARDIOVASCULAR DISEASES. <i>Clinical and Experimental Pharmacology and Physiology</i> , 1994, 21, 811-818.	0.9	25
107	Angiotensin-converting enzyme inhibition and beta-adrenoceptor blockade regress established ventricular remodeling in a canine model of discrete myocardial damage. <i>Journal of the American College of Cardiology</i> , 1994, 24, 1762-1768.	1.2	82
108	Markedly different effects on ventricular remodeling result in a decrease in inducibility of ventricular arrhythmias. <i>Journal of the American College of Cardiology</i> , 1994, 23, 505-513.	1.2	102
109	Myocardial bioenergetic abnormalities in a canine model of left ventricular dysfunction. <i>Journal of the American College of Cardiology</i> , 1994, 23, 786-793.	1.2	34
110	Abnormalities of contractile structures in viable myocytes of the failing heart. <i>International Journal of Cardiology</i> , 1994, 43, 287-297.	0.8	28
111	Fibrosis and myocardial ACE: Possible substrate and independence from circulating angiotensin II. <i>Journal of Cardiac Failure</i> , 1994, 1, 81-89.	0.7	3

#	ARTICLE	IF	CITATIONS
114	An in vitro evaluation of prostaglandin E1 and E2 on hypothermic injury to immature myocytes. <i>Surgery Today</i> , 1994, 24, 713-718.	0.7	0
115	Role of left ventricular geometry in the alteration of initial QRS vectors due to concentric ventricular hypertrophy. <i>Journal of Electrocardiology</i> , 1994, 27, 301-309.	0.4	3
116	Angiotensin Converting Enzyme Inhibition with Quinapril and Left Ventricular Mass in the Hypertensive Patient. <i>Drug Investigation</i> , 1994, 8, 38-48.	0.6	2
117	Hypertension and Age-Related Changes in the Heart. <i>Drugs and Aging</i> , 1994, 5, 102-115.	1.3	14
118	Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection.. <i>Circulation</i> , 1994, 90, 2056-2069.	1.6	459
119	Structural remodeling in hypertensive heart disease and the role of hormones.. <i>Hypertension</i> , 1994, 23, 869-877.	1.3	219
120	Short-term cardiac adaptation to severe haemodilution: an echocardiographic study in normal and hypertensive subjects. <i>European Heart Journal</i> , 1994, 15, 637-640.	1.0	6
121	Regulation of the Structural Remodelling of the Myocardium: from Hypertrophy to Heart Failure. <i>European Heart Journal</i> , 1994, 15, 45-52.	1.0	115
122	Functional Significance of Angiotensin Receptors in Human Myocardium: Significant Differences Between Atrial and Ventricular Myocardium. <i>European Heart Journal</i> , 1994, 15, 88-91.	1.0	23
123	The cardiac structure-function relationship and the renin-angiotensin-aldosterone system in hypertension and heart failure. <i>Current Opinion in Cardiology</i> , 1994, 9, S2-S11.	0.8	33
124	Angiotensin II induces fibronectin expression associated with cardiac fibrosis in the rat.. <i>Circulation Research</i> , 1994, 74, 727-739.	2.0	211
126	The lonely failing heart: a case for ECM genes. <i>Cardiovascular Research</i> , 1995, 30, 836-840.	1.8	9
127	Shifting the paradigm for the treatment of dilated cardiomyopathy. <i>European Heart Journal</i> , 1995, 16, 176-179.	1.0	5
128	Directions in antihypertensive treatment--our future from the past. <i>European Heart Journal</i> , 1995, 16, 74-83.	1.0	12
129	Sex-dependent differences in left ventricular function and structure in chronic pressure overload. <i>European Heart Journal</i> , 1995, 16, 1410-1419.	1.0	153
130	Remodelling of intramyocardial arterioles and extracellular matrix in patients with arterial hypertension and impaired coronary reserve. <i>European Heart Journal</i> , 1995, 16, 82-86.	1.0	36
131	Aldosterone and heart failure. <i>European Heart Journal</i> , 1995, 16, 98-102.	1.0	59
132	The renin-angiotensin-aldosterone system and myocardial collagen matrix remodelling in congestive heart failure. <i>European Heart Journal</i> , 1995, 16, 107-109.	1.0	87

#	ARTICLE	IF	CITATIONS
133	Hypertensive heart disease: Cardioreparation by reversal of interstitial collagen in patients. <i>European Heart Journal</i> , 1995, 16, 69-73.	1.0	10
134	ACE inhibitor co-therapy in patients with heart failure: Rationale for the Randomized Aldactone Evaluation Study (RALES). <i>European Heart Journal</i> , 1995, 16, 107-110.	1.0	61
135	Effects of Angiotensin-Converting Enzyme Inhibitor and Aldosterone Antagonist on Myocardial Collagen in Cardiomyopathic Hamsters.. <i>Japanese Circulation Journal</i> , 1995, 59, 213-218.	1.0	11
136	Changes in Extracellular Matrix Components in Cardiomyopathic Syrian Hamster, BIO 14.6.. <i>Japanese Circulation Journal</i> , 1995, 59, 631-640.	1.0	6
137	Heart Failure with Normal Systolic Function: A Common Disorder in Older People. <i>Journal of the American Geriatrics Society</i> , 1995, 43, 1035-1042.	1.3	136
138	Prevention of Cardiac Hypertrophy in Experimental Chronic Renal Failure by Long-Term ACE Inhibitor Administration: Potential Role of Lysosomal Proteinases. <i>American Journal of Nephrology</i> , 1995, 15, 129-136.	1.4	31
139	Hormonal regulation of cardiac fibroblast function. <i>European Heart Journal</i> , 1995, 16, 45-50.	1.0	87
140	ACE inhibitors in non-ischaemic heart failure: Results from the MEGA trials. <i>European Heart Journal</i> , 1995, 16, 133-136.	1.0	6
141	Differential influences of carnitine palmitoyltransferase-1 inhibition and hyperthyroidism on cardiac growth and sarcoplasmic reticulum phosphorylation. <i>European Heart Journal</i> , 1995, 16, 15-19.	1.0	11
142	The genotype of the angiotensin-converting enzyme gene and global left ventricular dysfunction after myocardial infarction. <i>American Journal of Cardiology</i> , 1995, 76, 326-329.	0.7	22
143	Pathophysiologic aspects of end-stage heart failure. <i>American Journal of Cardiology</i> , 1995, 75, 11A-16A.	0.7	47
144	Role of angiotensin II and prostaglandin E2 in regulating cardiac fibroblast collagen turnover. <i>American Journal of Cardiology</i> , 1995, 76, 8D-13D.	0.7	93
145	Response off hypertensive left ventricular hypertrophy and coronary microvascular disease to calcium antagonists. <i>American Journal of Cardiology</i> , 1995, 76, 24D-30D.	0.7	20
146	Systolic ventricular dysfunction and heart failure due to coronary microangiopathy in hypertensive heart disease. <i>American Journal of Cardiology</i> , 1995, 76, 48D-53D.	0.7	35
147	Quantitative study of the myocardium in human embryos. <i>Annals of Anatomy</i> , 1995, 177, 179-184.	1.0	10
148	Activation of the Renin-Angiotensin System in Dogs With Asymptomatic and Mildly Symptomatic Mitral Valvular Insufficiency. <i>Journal of Veterinary Internal Medicine</i> , 1995, 9, 328-331.	0.6	60
149	Breed differences in the Plasma Renin Activity and Plasma Aldosterone Concentration of Dogs. <i>Transboundary and Emerging Diseases</i> , 1995, 42, 435-441.	0.6	17
150	Progression of heart failure: A role for interstitial fibrosis. <i>Molecular and Cellular Biochemistry</i> , 1995, 147, 29-34.	1.4	156

#	ARTICLE	IF	CITATIONS
151	Chronic hibernating myocardium: Interstitial changes. <i>Molecular and Cellular Biochemistry</i> , 1995, 147, 35-42.	1.4	69
152	?Escape? of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: Implications for therapy. <i>Cardiovascular Drugs and Therapy</i> , 1995, 9, 145-149.	1.3	189
153	New concepts regarding events that lead to end-stage heart disease. <i>Cardiovascular Drugs and Therapy</i> , 1995, 9, 489-492.	1.3	4
154	Angiotensin II receptor antagonists in heart failure: Rationale and design of the evaluation of losartan in the elderly (ELITE) trial. <i>Cardiovascular Drugs and Therapy</i> , 1995, 9, 693-700.	1.3	38
155	Effects of lisinopril on congestive heart failure in normotensive patients with diastolic dysfunction but intact systolic function. <i>European Journal of Clinical Pharmacology</i> , 1995, 49, 15-9.	0.8	14
156	The ACE-inhibitor captopril improves myocardial perfusion in spontaneously diabetic (BB) rats. <i>Diabetologia</i> , 1995, 38, 509-517.	2.9	39
157	Left ventricular diastolic function: Physiology, methods of assessment, and clinical significance. <i>Journal of Nuclear Cardiology</i> , 1995, 2, 525-543.	1.4	22
158	DIFFERENCES IN CULTURED CARDIAC FIBROBLAST POPULATIONS ISOLATED FROM SHR AND WKY RATS. <i>Clinical and Experimental Pharmacology and Physiology</i> , 1995, 22, S265-S267.	0.9	6
159	Effects of ACE inhibition on the hypertrophied heart-implications for reversal and prognosis: An updated review. <i>Clinical Cardiology</i> , 1995, 18, I-12-I-22.	0.7	0
160	Critical review of heart failure: The role of left ventricular remodeling in the therapeutic response-Cohn: Remodeling in heart failure. <i>Clinical Cardiology</i> , 1995, 18, IV4-IV12.	0.7	27
161	Cell death in the failing heart: Role of an unnatural growth response to overload-Cell death in the failing heart. <i>Clinical Cardiology</i> , 1995, 18, IV36-IV44.	0.7	31
162	Angiotensin-Converting Enzyme Inhibition and Ventricular Remodeling After Myocardial Infarction. <i>Annual Review of Physiology</i> , 1995, 57, 805-826.	5.6	122
163	Evaluation of Cardiac Damage in Hypertension. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 1995, 2, 16-26.	3.1	1
164	Biological adaptation of the myocardium to chronic mechanical overload. Molecular determinants of the autonomic nervous system. <i>European Heart Journal</i> , 1995, 16, 64-73.	1.0	35
165	Does ACE inhibition limit structural changes in the heart following myocardial infarction?. <i>European Heart Journal</i> , 1995, 16, 46-51.	1.0	60
166	Sarcoplasmic reticulum and myofilament function in chemically-treated ventricular trabeculae from patients with heart failure. <i>Cardiovascular Research</i> , 1995, 30, 377-385.	1.8	3
167	Aldosterone Levels and Cardiac Hypertrophy in Professional Cyclists. <i>International Journal of Sports Medicine</i> , 1995, 16, 475-477.	0.8	6
169	Pathophysiological Aspects of the Renin-Angiotensin-Aldosterone System in Acute Myocardial Infarction. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 1995, 2, 389-395.	3.1	10

#	ARTICLE	IF	CITATIONS
170	Myocardial fibrosis in hypertensive heart disease: an overview of potential regulatory machanisms. <i>European Heart Journal</i> , 1995, 16, 24-28.	1.0	126
171	Fibronectin accumulation within cardiac myocytes in rats with elevated plasma angiotensin II. <i>Cardiovascular Pathology</i> , 1995, 4, 57-67.	0.7	5
172	Recovery of left ventricular function in acute nonischemic congestive cardiomyopathy. <i>American Heart Journal</i> , 1995, 129, 24-30.	1.2	13
173	Superoxide dismutase and glutathione peroxidase activities are increased by enalapril and captopril in mouse liver. <i>FEBS Letters</i> , 1995, 361, 22-24.	1.3	78
174	Inhibition by angiotensin II type 1 receptor antagonist of cardiac phenotypic modulation after myocardial infarction. <i>Journal of Molecular and Cellular Cardiology</i> , 1995, 27, 1905-1914.	0.9	85
175	Bradykinin receptor and tissue ACE binding in myocardial fibrosis: Response to chronic angiotensin II or aldosterone administration in rats. <i>Journal of Molecular and Cellular Cardiology</i> , 1995, 27, 813-822.	0.9	23
176	Transition from asymptomatic left ventricular dysfunction to congestive heart failure. <i>Journal of Cardiac Failure</i> , 1995, 1, 409-419.	0.7	8
177	Ischemic Cardiomyopathy: Myocyte Cell Loss, Myocyte Cellular Hypertrophy, and Myocyte Cellular Hyperplasia. <i>Annals of the New York Academy of Sciences</i> , 1995, 752, 47-64.	1.8	19
178	Empiric determination of the transition from concentric hypertrophy to congestive heart failure in essential hypertension. <i>Journal of the American College of Cardiology</i> , 1995, 25, 888-894.	1.2	16
179	Combined captopril and isosorbide dinitrate during healing after myocardial infarction. <i>Journal of the American College of Cardiology</i> , 1995, 25, 1089-1096.	1.2	25
180	Dilated cardiomyopathy is associated with an increase in the type I/type III collagen ratio: A quantitative assessment. <i>Journal of the American College of Cardiology</i> , 1995, 25, 1263-1272.	1.2	183
181	Effect of captopril and enalapril on left ventricular geometry, function and collagen during healing after anterior and inferior myocardial infarction in a dog model. <i>Journal of the American College of Cardiology</i> , 1995, 25, 1718-1725.	1.2	44
182	The ageing spontaneously hypertensive rat as a model of the transition from stable compensated hypertrophy to heart failure. <i>European Heart Journal</i> , 1995, 16, 19-30.	1.0	84
183	Left Ventricular Hypertrophy. <i>Drugs and Aging</i> , 1995, 6, 301-311.	1.3	6
184	Connective tissue: a metabolic Entity?. <i>Journal of Molecular and Cellular Cardiology</i> , 1995, 27, 107-120.	0.9	77
185	The cellular basis of dilated cardiomyopathy in humans. <i>Journal of Molecular and Cellular Cardiology</i> , 1995, 27, 291-305.	0.9	245
186	Prolyl hydroxylation regulates intracellular procollagen degradation in cultured rat cardiac fibroblasts. <i>Journal of Molecular and Cellular Cardiology</i> , 1995, 27, 1459-1473.	0.9	26
187	Temporal differences in fibroblast proliferation and phenotype expression in response to chronic administration of angiotensin II or aldosterone. <i>Journal of Molecular and Cellular Cardiology</i> , 1995, 27, 1545-1560.	0.9	131

#	ARTICLE	IF	CITATIONS
188	Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure. <i>Journal of Cardiac Failure</i> , 1996, 2, 47-54.	0.7	200
189	Effects of an AT ₁ receptor antagonist, an ACE inhibitor and a calcium channel antagonist on cardiac gene expressions in hypertensive rats. <i>British Journal of Pharmacology</i> , 1996, 118, 549-556.	2.7	74
190	Influence of humoral and neurohormonal factors on cardiovascular hypertrophy in intreated essential hypertensives. <i>American Journal of Hypertension</i> , 1996, 9, 207-215.	1.0	24
192	Collagen content and distribution in the normal and transplanted human heart: A postmortem quantitative light microscopic analysis. <i>Cardiovascular Pathology</i> , 1996, 5, 61-68.	0.7	8
193	Absent septal q wave on electrocardiogram: A forgotten marker of myocardial disease. <i>International Journal of Cardiology</i> , 1996, 53, 1-4.	0.8	30
194	Genetic basis of left ventricular remodeling after myocardial infarction. <i>International Journal of Cardiology</i> , 1996, 53, 265-272.	0.8	32
195	Carrier-mediated transport controls hydroxyproline catabolism in heart mitochondria from spontaneously hypertensive rat. <i>FEBS Letters</i> , 1996, 396, 279-284.	1.3	5
196	Cellular and Extracellular Remodeling with the Development and Recovery from Tachycardia-induced Cardiomyopathy: Changes in Fibrillar Collagen, Myocyte Adhesion Capacity and Proteoglycans. <i>Journal of Molecular and Cellular Cardiology</i> , 1996, 28, 1591-1608.	0.9	86
197	Enhanced Galactosyltransferase Expression in the Failing Hearts of Spontaneously Hypertensive Rats. <i>Biochemical and Biophysical Research Communications</i> , 1996, 218, 320-324.	1.0	7
198	Treatment with angiotensin-converting-enzyme inhibitor for epirubicin-induced dilated cardiomyopathy. <i>Lancet, The</i> , 1996, 347, 297-299.	6.3	88
199	Fish oil and other nutritional adjuvants for treatment of congestive heart failure. <i>Medical Hypotheses</i> , 1996, 46, 400-406.	0.8	8
200	Angiotensinogen: Molecular biology, biochemistry and physiology. <i>International Journal of Biochemistry and Cell Biology</i> , 1996, 28, 1211-1222.	1.2	77
201	Novel Drugs and Current Therapeutic Approaches in the Treatment of Heart Failure. <i>Drugs</i> , 1996, 51, 347-358.	4.9	13
202	Captopril prevents vascular and fibrotic changes but not cardiac hypertrophy in aortic-banded rats. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 1996, 271, H906-H913.	1.5	9
203	Effects of Aldosterone and Spironolactone on the Isolated Perfused Rat Heart. <i>Pharmacology</i> , 1996, 53, 28-36.	0.9	18
204	Insulin-like growth factor-1 and myocyte growth: the danger of a dogma Part II. Induced myocardial growth: pathologic hypertrophy. <i>Cardiovascular Research</i> , 1996, 32, 484-495.	1.8	8
205	Evaluation of Angiotensin-Converting Enzyme Inhibitor in Congestive Heart Failure.. <i>Internal Medicine</i> , 1996, 35, 65-67.	0.3	0
206	Comparison of enalapril versus nifedipine to decrease left ventricular hypertrophy in systemic hypertension (the PRESERVE trial). <i>American Journal of Cardiology</i> , 1996, 78, 61-65.	0.7	139

#	ARTICLE	IF	CITATIONS
207	Effectiveness of Spironolactone Added to an Angiotensin-Converting Enzyme Inhibitor and a Loop Diuretic for Severe Chronic Congestive Heart Failure (The Randomized Aldactone Evaluation Study) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5</i> 902-907.	0.7	440
208	Diminished contractile reserve in patients with left ventricular hypertrophy and increased end-systolic stress during dobutamine stress echocardiography. <i>American Journal of Cardiology</i> , 1996, 78, 1029-1035.	0.7	16
209	Angiotensin-converting enzyme inhibition after acute myocardial infarction with special reference to the Fourth International Study of Infarct Survival (ISIS-4). <i>Progress in Cardiovascular Diseases</i> , 1996, 39, 201-206.	1.6	5
210	Angiotensin II and Cardiac Fibrosis. <i>Trends in Cardiovascular Medicine</i> , 1996, 6, 193-198.	2.3	31
211	Myocardial fiber and connective tissue architecture in the fish heart ventricle. <i>The Journal of Experimental Zoology</i> , 1996, 275, 112-124.	1.4	21
212	Effect of the renin-angiotensinaldosterone system on the cardiac interstium in heart failure. <i>Basic Research in Cardiology</i> , 1996, 91, 79-84.	2.5	61
213	Effect of prolonged inhibition of neutral endopeptidase on cardiac hypertrophy in rats with myocardial infarction. <i>Cardiovascular Drugs and Therapy</i> , 1996, 10, 593-598.	1.3	8
214	Cardioprotective effect of angiotensin-converting enzyme inhibitors in patients with coronary artery disease. <i>Cardiovascular Drugs and Therapy</i> , 1996, 10, 639-647.	1.3	12
215	Prevention of ventricular remodeling after myocardial infarction and in congestive heart failure. <i>Heart Failure Reviews</i> , 1996, 1, 115-129.	1.7	23
216	Regression of established ventricular remodeling: A therapeutic goal in ventricular dysfunction?. <i>Heart Failure Reviews</i> , 1996, 1, 131-137.	1.7	0
217	The healing wound: A case for extracellular matrix. <i>Heart Failure Reviews</i> , 1996, 1, 53-62.	1.7	1
218	Cardiac renin angiotensin system in hypertrophy and the progression to heart failure. <i>Heart Failure Reviews</i> , 1996, 1, 63-72.	1.7	3
219	Effects of angiotensin II and aldosterone on collagen gene expression and protein turnover in cardiac fibroblasts. <i>Molecular and Cellular Biochemistry</i> , 1996, 154, 171-178.	1.4	136
220	Angiotensin II signalling pathways in cardiac fibroblasts: Conventional versus novel mechanisms in mediating cardiac growth and function. <i>Molecular and Cellular Biochemistry</i> , 1996, 157, 15-21.	1.4	69
221	Alteration of extracellular matrix in dilated cardiomyopathic hamster heart. <i>Molecular and Cellular Biochemistry</i> , 1996, 156, 9-15.	1.4	15
222	The Importance of Different Atrioventricular Delay for Left Ventricular Filling in Sequential Pacing: Clinical Implications. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1996, 19, 1595-1604.	0.5	12
223	Vasoactive hormones and renal sclerosis. <i>Kidney International</i> , 1996, 49, 578-597.	2.6	180
224	ANALYSIS OF LINKAGE OF THE ACE LOCUS WITH MEASURES OF CARDIAC HYPERTROPHY IN THE SPONTANEOUSLY HYPERTENSIVE RAT. <i>Clinical and Experimental Pharmacology and Physiology</i> , 1996, 23, 597-599.	0.9	5

#	ARTICLE	IF	CITATIONS
226	Inflammatory cells and myocardial fibrosis: spatial and temporal distribution in renovascular hypertensive rats. <i>Cardiovascular Research</i> , 1996, 32, 1096-1107.	1.8	80
227	Investigative Concerns in Demonstrating Reduced Risk from Reversing Left Ventricular Hypertrophy. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 1996, 1, 17-22.	1.0	0
228	Collagen network remodelling and left ventricular function in constrictive pericarditis.. <i>Heart</i> , 1996, 75, 184-189.	1.2	14
229	Coronary haemodynamics in left ventricular hypertrophy.. <i>Heart</i> , 1996, 75, 369-376.	1.2	10
230	The Concept of Cardioreparation: Part 2. Medical Implications of Cardioreparation. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 1996, 3, 287-293.	3.1	2
231	Effects of Early Captopril Treatment and Its Removal on Plasma Angiotensin Converting Enzyme (ACE) Activity and Arginine Vasopressin in Hypertensive Rats (SHR) and Normotensive Rats (WKY). <i>Clinical and Experimental Hypertension</i> , 1996, 18, 201-226.	0.5	21
232	Hypertensive Left Ventricular Hypertrophy: Pathophysiology, Assessment and Treatment. <i>Blood Pressure</i> , 1996, 5, 5-15.	0.7	18
233	Triple Helix-forming Oligonucleotide Corresponding to the Polypyrimidine Sequence in the Rat $\hat{1}\pm 1$ (I) Collagen Promoter Specifically Inhibits Factor Binding and Transcription. <i>Journal of Biological Chemistry</i> , 1996, 271, 1805-1812.	1.6	56
234	Effects of incoordination on left ventricular force-velocity relation in aortic stenosis.. <i>Heart</i> , 1996, 76, 495-501.	1.2	10
235	Angiotensin II-induced myocardial fibrosis in rats: role of nitric oxide, prostaglandins and bradykinin. <i>Cardiovascular Research</i> , 1996, 31, 546-556.	1.8	35
236	Refractory Heart Failure: A Therapeutic Approach. <i>Journal of Intensive Care Medicine</i> , 1996, 11, 121-148.	1.3	5
237	Respective role of humoral factors and blood pressure in cardiac remodeling of DOCA hypertensive rats. <i>Cardiovascular Research</i> , 1996, 31, 287-295.	1.8	53
238	Compensated cardiac hypertrophy: arrhythmogenicity and the new myocardial phenotype. I. Fibrosis. <i>Cardiovascular Research</i> , 1997, 34, 439-444.	1.8	93
239	Mibefradil: A New Selective T-Channel Calcium Antagonist for Hypertension and Angina Pectoris. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 1997, 2, 321-330.	1.0	9
240	Evaluation of the Efficacy and Tolerability of Nitrendipine in Reducing Both Pressure and Left Ventricular Mass in Hypertensive Type 2 Diabetic Patients. <i>Diabetes Care</i> , 1997, 20, 1290-1292.	4.3	12
241	Cardiac nonmyocyte hyperplasia is modulated by angiotensin II and stretch. , 0, , .		0
242	Angiotensin-I-converting enzymeDDgenotype is a risk factor of coronary artery disease. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 1997, 57, 127-132.	0.6	17
243	Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion. <i>Cardiovascular Research</i> , 1997, 35, 138-147.	1.8	207

#	ARTICLE	IF	CITATIONS
244	Associations between circulating components of the renin-angiotensin-aldosterone system and left ventricular mass.. Heart, 1997, 77, 24-31.	1.2	101
245	Expression of angiotensin converting enzyme and chymase in human atria. Journal of Hypertension, 1997, 15, 935-943.	0.3	8
246	Angiotensin converting enzyme inhibitorâ€“calcium antagonist combination. Journal of Hypertension, 1997, 15, S109-S117.	0.3	14
247	Renin-angiotensin system and myocardial collagen matrix. Journal of Hypertension, 1997, 15, S13-S19.	0.3	57
248	Activation of angiotensin II-forming chymase in the cardiomyopathic hamster heart. Journal of Hypertension, 1997, 15, 431-440.	0.3	71
249	Reduction of left ventricular mass by antihypertensive treatment does not improve exercise performance in essential hypertension. Journal of Hypertension, 1997, 15, 309-317.	0.3	13
250	Influence of the angiotensin converting enzyme I/D gene polymorphisms on left ventricular diastolic filling in patients with essential hypertension. Journal of Hypertension, 1997, 15, 995-1000.	0.3	15
252	Chronic Therapy with Nipradilol, a .BETA.-Adrenergic Blocker, Attenuated Left Ventricular Remodeling Following Myocardial Infarction in Rats.. The Japanese Journal of Pharmacology, 1997, 74, 171-178.	1.2	2
253	Mibefradil (Ro 40-5967): the first selective T-type Ca ²⁺ channel blocker. Expert Opinion on Investigational Drugs, 1997, 6, 569-582.	1.9	32
254	Hypertensive cardiomegaly caused by an aldosterone-secreting adenoma in a newborn. Journal of Endocrinological Investigation, 1997, 20, 86-89.	1.8	15
256	Inhibition of nitric oxide synthase causes cardiac phenotypic modulation in rat. European Journal of Pharmacology, 1997, 322, 59-62.	1.7	7
257	Cardiac angiotensin II receptors: studies on functional coupling in Sprague-Dawley rats and TGR(α 1MHC-hAT1) transgenic rats. European Journal of Pharmacology, 1997, 330, 35-46.	1.7	13
258	Angiotensin-converting enzyme inhibitors in heart failure: Physicians' prescribing behavior. Journal of Cardiac Failure, 1997, 3, 295-302.	0.7	14
259	PDGF-AA, a Potent Mitogen for Cardiac Fibroblasts from Adult Rats. Journal of Molecular and Cellular Cardiology, 1997, 29, 357-368.	0.9	55
260	Differential Protein Expression and Subcellular Distribution of TGF β 1, β 2 and β 3 in Cardiomyocytes During Pressure Overload-induced Hypertrophy. Journal of Molecular and Cellular Cardiology, 1997, 29, 2213-2224.	0.9	58
262	Association Between Increased Plasma Levels of Aldosterone and Decreased Systemic Arterial Compliance in Subjects With Essential Hypertension. American Journal of Hypertension, 1997, 10, 1326-1334.	1.0	128
263	Myofibroblasts and local angiotensin II in rat cardiac tissue repair. International Journal of Biochemistry and Cell Biology, 1997, 29, 31-42.	1.2	65
264	Identification of negative and positive regulatory elements in the rat α 1(I) collagen gene promoter. International Journal of Biochemistry and Cell Biology, 1997, 29, 143-151.	1.2	11

#	ARTICLE	IF	CITATIONS
265	Time course of regression of left ventricular hypertrophy after successful parathyroidectomy. Surgery, 1997, 121, 157-161.	1.0	46
266	Endothelins and cardiac hypertrophy. Life Sciences, 1997, 61, 585-593.	2.0	36
267	Increased Survival After Long-Term Treatment With Mibefradil, a Selective T-Channel Calcium Antagonist, in Heart Failure. Journal of the American College of Cardiology, 1997, 29, 416-421.	1.2	71
268	Regulation of thrombospondin-1 production by angiotensin II in rat heart endothelial cells. Biochimica Et Biophysica Acta - Molecular Cell Research, 1997, 1357, 209-214.	1.9	25
270	Chronic Therapy with Nipradilol, a \hat{I}^2 -Adrenergic Blocker, Attenuated Left Ventricular Remodeling Following Myocardial Infarction in Rats. The Japanese Journal of Pharmacology, 1997, 74, 171-178.	1.2	0
271	Structure and function of myocardial fibrillar collagen. Technology and Health Care, 1997, 5, 95-113.	0.5	49
272	Contribution of angiotensin-converting enzyme to the cardiac metabolism of bradykinin: an interspecies study. American Journal of Physiology - Heart and Circulatory Physiology, 1997, 273, H2263-H2271.	1.5	24
273	Pressure-independent effects of AT1-receptor antagonism on cardiovascular remodeling in aortic-banded rats. American Journal of Physiology - Heart and Circulatory Physiology, 1997, 272, H2131-H2138.	1.5	13
274	Effects of ACE Inhibitors versus Calcium Antagonists on Left Ventricular Morphology and Function in Patients with Essential Hypertension.. Hypertension Research, 1997, 20, 7-10.	1.5	8
275	Left Ventricular Hypertrophy Is More Prominent in Patients with Primary Aldosteronism than in Patients with Other Types of Secondary Hypertension.. Hypertension Research, 1997, 20, 85-90.	1.5	148
276	Coronary circulation and left ventricular function in hypertension. Bailliere's Clinical Anaesthesiology, 1997, 11, 639-659.	0.2	0
277	Stereology of the myocardium in human foetuses. Early Human Development, 1997, 48, 249-259.	0.8	25
278	The integrated effects of angiotensin II. American Journal of Cardiology, 1997, 79, 9-11.	0.7	48
279	Detectable serum troponin I in patients with heart failure of nonmyocardial ischemic origin. American Journal of Cardiology, 1997, 80, 88-90.	0.7	99
280	Molecular and Cellular Mechanisms of Myocardial Failure. American Journal of Cardiology, 1997, 80, 15L-25L.	0.7	291
281	Effect of chronic colchicine administration on the myocardium of the aging spontaneously hypertensive rat. Molecular and Cellular Biochemistry, 1997, 166, 45-54.	1.4	15
282	T-type Ca ²⁺ channels and pharmacological blockade: potential pathophysiological relevance. Cardiovascular Drugs and Therapy, 1997, 11, 723-739.	1.3	115
283	Title is missing!. Heart Failure Reviews, 1997, 2, 107-116.	1.7	7

#	ARTICLE	IF	CITATIONS
284	Reversing effects of DDPH on cardiac hypertrophy and increased collagen content induced by partial narrowing of abdominal aorta. <i>Journal of Tongji Medical University</i> , 1997, 17, 147-150.	0.1	0
285	Structural analysis of arteriolar and myocardial remodelling in the subendocardial region of patients with hypertensive heart disease and hypertrophic cardiomyopathy. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 1997, 431, 265-273.	1.4	61
286	Mechanisms of mechanical load-induced atrial natriuretic peptide secretion: role of endothelin, nitric oxide, and angiotensin II. <i>Journal of Molecular Medicine</i> , 1997, 75, 876-885.	1.7	67
287	Cardiac ischaemia: possibilities for future drug therapy. <i>European Journal of Medicinal Chemistry</i> , 1997, 32, 687-707.	2.6	7
288	Evidence of functional and structural cardiac abnormalities in cirrhotic patients with and without ascites. <i>Hepatology</i> , 1997, 26, 1131-1137.	3.6	257
289	Myocyte Cell Loss in Ischemic Cardiomyopathy: Role of Apoptosis. <i>Heart Failure Reviews</i> , 1998, 3, 63-78.	1.7	1
290	Increased mRNA expression of cardiac renin-angiotensin system and collagen synthesis in spontaneously hypertensive rats. <i>Molecular and Cellular Biochemistry</i> , 1998, 178, 51-58.	1.4	24
291	Title is missing!. <i>Molecular and Cellular Biochemistry</i> , 1998, 186, 147-158.	1.4	28
292	Title is missing!. , 1998, 188, 225-233.		7
293	The effects of norepinephrine on myocardial biology: Implications for the therapy of heart failure. <i>Clinical Cardiology</i> , 1998, 21, 20-24.	0.7	55
294	ABSENCE OF DETECTABLE REGRESSION OF HUMAN HYPERTENSIVE LEFT VENTRICULAR HYPERTROPHY FOLLOWING DRUG TREATMENT FOR 1 YEAR. <i>Clinical and Experimental Pharmacology and Physiology</i> , 1998, 25, 208-215.	0.9	1
295	Effects of quinapril, losartan and hydralazine on cardiac hypertrophy and \hat{I}^2 -adrenergic neuroeffector mechanisms in transgenic (mREN2)27 rats. <i>British Journal of Pharmacology</i> , 1998, 123, 405-412.	2.7	25
296	Effect of atrial natriuretic peptide and cyclic GMP phosphodiesterase inhibition on collagen synthesis by adult cardiac fibroblasts. <i>British Journal of Pharmacology</i> , 1998, 124, 1455-1462.	2.7	62
297	Opposite associations of circulating aldosterone and atrial natriuretic peptide with left ventricular diastolic function in essential hypertension. <i>Journal of Human Hypertension</i> , 1998, 12, 195-202.	1.0	14
298	Plasma renin activity could be a useful predictor of left ventricular hypertrophy in essential hypertensives. <i>Journal of Human Hypertension</i> , 1998, 12, 455-461.	1.0	4
299	Diastolic heart failure: standard doppler approach and beyond. <i>American Journal of Cardiology</i> , 1998, 81, 115G-121G.	0.7	39
300	Systemic hypertension and coronary artery disease: the link. <i>American Journal of Cardiology</i> , 1998, 82, 2-7.	0.7	37
301	Effect of adrenomedullin on cAMP and cGMP levels in rat cardiac myocytes and nonmyocytes. <i>European Journal of Pharmacology</i> , 1998, 353, 337-344.	1.7	67

#	ARTICLE	IF	CITATIONS
302	Stress and strain as regulators of myocardial growth. Progress in Biophysics and Molecular Biology, 1998, 69, 559-572.	1.4	103
304	Human cardiac fibroblasts and receptors for angiotensin II and bradykinin: A potential role for bradykinin in the modulation of cardiac extracellular matrix. Basic Research in Cardiology, 1998, 93, s004-s007.	2.5	16
305	Mitogenic effect of PDGF-AA on cardiac fibroblasts. Basic Research in Cardiology, 1998, 93, s040-s043.	2.5	25
306	Stereology of the myocardium in hypertensive rats. Differences in relation to the time of inhibition of nitric oxide synthesis. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 1998, 433, 369.	1.4	14
310	Antiproliferative and antifibrotic effects of mimosine on adult cardiac fibroblasts Previously published in abstract form: Circulation 94(8) (1996) 355.1. Biochimica Et Biophysica Acta - Molecular Cell Research, 1998, 1448, 51-60.	1.9	38
311	Left ventricular filling profiles and angiotensin system activity in elite baseball players. International Journal of Cardiology, 1998, 67, 155-160.	0.8	8
312	The molecular and cellular pathophysiology of heart failure. Heart and Lung: Journal of Acute and Critical Care, 1998, 27, 3-19.	0.8	50
313	Maladaptive Remodeling of Cardiac Myocyte Shape Begins Long Before Failure in Hypertension. Hypertension, 1998, 32, 753-757.	1.3	66
314	Cardiac Fibroblasts. Cardiovascular Pathology, 1998, 7, 127-133.	0.7	38
315	Regulation of Myocardial Extracellular Matrix Components by Mechanical and Chemical Growth Factors. Cardiovascular Pathology, 1998, 7, 145-151.	0.7	23
316	The Physiological and Pharmacological Significance of Cardiovascular T-Type, Voltage-gated Calcium Channels. American Journal of Hypertension, 1998, 11, 80S-87S.	1.0	42
317	Increased myocardial ultrasonic reflectivity is associated with extreme hypertensive left ventricular hypertrophy A tissue characterization study in humans. American Journal of Hypertension, 1998, 11, 1442-1449.	1.0	19
318	Biomolecular changes in the aging myocardium The effect of enalapril. American Journal of Hypertension, 1998, 11, 1297-1304.	1.0	37
319	Effect of cilazapril on ventricular remodeling assessed by Doppler-echocardiographic assessment and cardiac gene expression. Cardiovascular Drugs and Therapy, 1998, 12, 57-70.	1.3	21
320	VENTRICULAR REMODELING. Cardiology Clinics, 1998, 16, 623-632.	0.9	50
321	Minoxidil accelerates heart failure development in rats with ascending aortic constriction. Canadian Journal of Physiology and Pharmacology, 1998, 76, 613-620.	0.7	7
322	Parasympathetic Neuropathy Associated with Left Ventricular Diastolic Dysfunction in Patients with Insulin-Dependent Diabetes Mellitus. Scandinavian Cardiovascular Journal, 1998, 32, 17-22.	0.4	25
323	Apoptosis. Circulation Research, 1998, 82, 1111-1129.	2.0	746

#	ARTICLE	IF	CITATIONS
324	Plasma brain natriuretic peptide is a biochemical marker for the prediction of progressive ventricular remodeling after acute myocardial infarction. <i>American Heart Journal</i> , 1998, 135, 21-28.	1.2	199
325	Neurohormonal activity and left ventricular geometry in patients with essential arterial hypertension. <i>American Heart Journal</i> , 1998, 135, 58-66.	1.2	74
326	MEDICAL THERAPY OF CHRONIC HEART FAILURE. <i>Cardiology Clinics</i> , 1998, 16, 711-725.	0.9	8
327	Increased Matrix Metalloproteinase Activity and Selective Upregulation in LV Myocardium From Patients With End-Stage Dilated Cardiomyopathy. <i>Circulation</i> , 1998, 97, 1708-1715.	1.6	436
328	Cell Type-Specific Angiotensin II-Evoked Signal Transduction Pathways. <i>Circulation Research</i> , 1998, 82, 337-345.	2.0	147
329	Synergistic Exacerbation of Diastolic Stiffness From Short-term Tachycardia-Induced Cardiodepression and Angiotensin II. <i>Circulation Research</i> , 1998, 82, 503-512.	2.0	32
330	Early Induction of Transforming Growth Factor- β^2 via Angiotensin II Type 1 Receptors Contributes to Cardiac Fibrosis Induced by Long-term Blockade of Nitric Oxide Synthesis in Rats. <i>Hypertension</i> , 1998, 32, 273-279.	1.3	190
331	Angiotensin II Type 1 Receptor-Induced Extracellular Signal-Regulated Protein Kinase Activation Is Mediated by Ca^{2+} /Calmodulin-Dependent Transactivation of Epidermal Growth Factor Receptor. <i>Circulation Research</i> , 1998, 82, 1338-1348.	2.0	184
332	Decreased Blood Pressure Variability at Rest in Patients With Primary Aldosteronism. <i>American Journal of Hypertension</i> , 1998, 11, 828-838.	1.0	10
333	Prolonged Captopril Therapy in Murine Viral Myocarditis. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 1998, 3, 43-49.	1.0	11
334	Pressure Overload Induces Cardiac Hypertrophy in Angiotensin II Type 1A Receptor Knockout Mice. <i>Circulation</i> , 1998, 97, 1952-1959.	1.6	239
335	Development of heart failure following isoproterenol administration in the rat: role of the renin-angiotensin system. <i>Cardiovascular Research</i> , 1998, 37, 91-100.	1.8	188
336	Expression of Functional Angiotensin-Converting Enzyme and AT1 Receptors in Cultured Human Cardiac Fibroblasts. <i>Circulation</i> , 1998, 98, 2553-2559.	1.6	57
337	Differential Effects of Angiotensin II on Cardiac Cell Proliferation and Intramyocardial Perivascular Fibrosis In Vivo. <i>Circulation</i> , 1998, 98, 2765-2773.	1.6	161
338	Regression of Left Ventricular Hypertrophy in Patients With Hypertension. <i>Circulation</i> , 1998, 98, 1987-1989.	1.6	36
339	Monitoring Vascular Sclerosis in Hypertension. <i>Circulation</i> , 1998, 98, 498-500.	1.6	13
340	Angiotensin II Type 2 Receptor Is Upregulated in Human Heart With Interstitial Fibrosis, and Cardiac Fibroblasts Are the Major Cell Type for Its Expression. <i>Circulation Research</i> , 1998, 83, 1035-1046.	2.0	223
341	Differential Activation of Cardiac c-Jun Amino-Terminal Kinase and Extracellular Signal-Regulated Kinase in Angiotensin II-Mediated Hypertension. <i>Circulation Research</i> , 1998, 83, 752-760.	2.0	87

#	ARTICLE	IF	CITATIONS
342	Differential Expression of Tissue Inhibitors of Metalloproteinases in the Failing Human Heart. <i>Circulation</i> , 1998, 98, 1728-1734.	1.6	352
344	Enhanced G α_q signaling: A common pathway mediates cardiac hypertrophy and apoptotic heart failure. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998, 95, 10140-10145.	3.3	498
345	How to diagnose diastolic heart failure. <i>European Heart Journal</i> , 1998, 19, 990-1003.	1.0	620
346	Stimulation of P2Y receptors activates c-fos gene expression and inhibits DNA synthesis in cultured cardiac fibroblasts. <i>Cardiovascular Research</i> , 1998, 37, 718-728.	1.8	30
347	Structural and Functional Properties of the Hypertrophied and Failing Heart. <i>Advances in Organ Biology</i> , 1998, 4, 3-45.	0.1	1
348	Altered Oxygen Availability and the Role of Nitric Oxide in the Development of Heart Failure. <i>Advances in Organ Biology</i> , 1998, 4, 171-192.	0.1	0
349	Pathologic fibrosis and connective tissue matrix in left ventricular hypertrophy due to chronic arterial hypertension in humans. <i>Journal of Hypertension</i> , 1998, 16, 1031-1041.	0.3	260
350	Biphasic Activation of the JAK/STAT Pathway by Angiotensin II in Rat Cardiomyocytes. <i>Circulation Research</i> , 1998, 82, 244-250.	2.0	105
351	Inhibitory Effect of Tranelast on Hypertrophic Collagen Production in the Spontaneously Hypertensive Rat Heart. <i>The Japanese Journal of Pharmacology</i> , 1998, 78, 161-167.	1.2	19
352	Shortening versus isometric contractions in isolated human failing and non-failing left ventricular myocardium: dependency of external work and force on muscle length, heart rate and inotropic stimulation. <i>Cardiovascular Research</i> , 1998, 37, 46-57.	1.8	43
353	Cardiac remodelling in experimental renal failure - an immunohistochemical study. <i>Nephrology Dialysis Transplantation</i> , 1998, 13, 1958-1966.	0.4	93
354	Role of the peripheral renin profile in predicting blood pressure control after bilateral nephrectomy in renal-transplant patients. <i>Nephrology Dialysis Transplantation</i> , 1998, 13, 2092-2097.	0.4	4
355	Regulation of extracellular matrix proteins in pressure-overload cardiac hypertrophy. <i>Journal of Hypertension</i> , 1998, 16, 1345-1355.	0.3	64
356	Modulatory effect of insulin on release of calcium from human fibroblasts by angiotensin II. <i>Journal of Hypertension</i> , 1998, 16, 487-493.	0.3	8
357	Prevention of salt-dependent cardiac remodeling and enhanced gene expression in stroke-prone hypertensive rats by the long-acting calcium channel blocker lacidipine. <i>Journal of Hypertension</i> , 1998, 16, 1515-1522.	0.3	19
358	Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients. <i>European Heart Journal</i> , 1998, 19, 1371-1376.	1.0	164
359	Effect of Manidipine Hydrochloride, a Calcium Antagonist, on Isoproterenol-Induced Left Ventricular Hypertrophy. <i>Japanese Circulation Journal</i> , 1998, 62, 47-52.	1.0	10
360	Long-Term Effects of Delapril Hydrochloride on Procollagen Type III Amino-Terminal Peptide, Left Ventricular Mass and Left Ventricular Function in Hypertensive Patients. <i>Japanese Circulation Journal</i> , 1998, 62, 900-902.	1.0	4

#	ARTICLE	IF	CITATIONS
361	Cytokine expression increases in nonmyocytes from rats with postinfarction heart failure. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 1998, 275, H250-H258.	1.5	69
362	Collagen Synthesis by Cultured Cardiac Fibroblasts Obtained from Cardiomyopathic Hamsters.. <i>International Heart Journal</i> , 1998, 39, 97-108.	0.6	4
363	Effects of growth hormone and IGF-I on cardiac hypertrophy and gene expression in mice. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 1998, 275, H393-H399.	1.5	27
364	Effects of ACE inhibition on cardiomyocyte apoptosis in dogs with heart failure. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 1998, 275, H626-H631.	1.5	70
365	Role of G1 phase cyclins and cyclin-dependent kinases during cardiomyocyte hypertrophic growth in rats. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 1998, 275, H814-H822.	1.5	62
366	Fibrosis, Myocyte Degeneration and Heart Failure in Chronic Experimental Aortic Regurgitation. <i>Cardiology</i> , 1998, 90, 101-109.	0.6	37
367	Efficient Inhibition of the Development of Cardiac Remodeling by a Long-Acting Calcium Antagonist Amlodipine. <i>Hypertension</i> , 1998, 31, 32-38.	1.3	30
369	Communication between myocytes and fibroblasts in cardiac remodeling in angiotensin chimeric mice. <i>Journal of Clinical Investigation</i> , 1999, 103, 1451-1458.	3.9	70
370	Cellular and molecular remodeling in a heart failure model treated with the β -blocker carteolol. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 1999, 276, H1678-H1690.	1.5	22
371	Stereology and Immunohistochemistry of the Myocardium in Experimental Hypertension: Long-Term and Low-Dosage Administration of Inhibitor of the Nitric Oxide Synthesis. <i>Pathobiology</i> , 1999, 67, 26-33.	1.9	31
372	Effects of AT1 receptor blockade after myocardial infarct on myocardial fibrosis, stiffness, and contractility. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 1999, 276, H873-H880.	1.5	26
373	Bradykinin metabolism in the postinfarcted rat heart: role of ACE and neutral endopeptidase 24.11. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 1999, 276, H1769-H1779.	1.5	27
374	Expression of FAS adjacent to fibrotic foci in the failing human heart is not associated with increased apoptosis. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 1999, 277, H445-H451.	1.5	14
375	Molecular Mechanisms of Myocardial Remodeling. <i>Physiological Reviews</i> , 1999, 79, 215-262.	13.1	1,451
376	Myocardial repair with long-term and low-dose administration of a nitric oxide synthesis inhibitor. Myofibroblasts, type III collagen and fibronectin. <i>Arquivos Brasileiros De Cardiologia</i> , 1999, 73, 87-96.	0.3	1
377	Novel approaches to retard ventricular remodeling in heart failure. <i>European Journal of Heart Failure</i> , 1999, 1, 17-23.	2.9	11
378	Chronic AT1 receptor blockade and angiotensin-converting enzyme (ACE) inhibition in (CHF 146) cardiomyopathic hamsters: effects on cardiac hypertrophy and survival. <i>Cardiovascular Research</i> , 1999, 43, 77-85.	1.8	28
379	Extracellular Matrix Gene Expression in the Left Ventricular Tissue of Spontaneously Hypertensive Rats. <i>Blood Pressure</i> , 1999, 8, 57-64.	0.7	26

#	ARTICLE	IF	CITATIONS
380	The Renin-Angiotensin System in Essential Hypertension: Associations with Cardiovascular Risk. <i>Blood Pressure</i> , 1999, 8, 70-78.	0.7	23
381	Cell Death in Acromegalic Cardiomyopathy. <i>Circulation</i> , 1999, 99, 1426-1434.	1.6	111
382	Regulation of cardiovascular collagen synthesis by mechanical load. <i>Cardiovascular Research</i> , 1999, 42, 27-44.	1.8	145
383	Promotion of Atrial Fibrillation by Heart Failure in Dogs. <i>Circulation</i> , 1999, 100, 87-95.	1.6	1,273
384	Angiotensin II-Induced Transactivation of Epidermal Growth Factor Receptor Regulates Fibronectin and Transforming Growth Factor- β Synthesis via Transcriptional and Posttranscriptional Mechanisms. <i>Circulation Research</i> , 1999, 84, 1073-1084.	2.0	119
385	Involvement of Cardiotrophin-1 in Cardiac Myocyte-Nonmyocyte Interactions During Hypertrophy of Rat Cardiac Myocytes In Vitro. <i>Circulation</i> , 1999, 100, 1116-1124.	1.6	117
386	Angiotensin II Type 1A Receptor Knockout Mice Display Less Left Ventricular Remodeling and Improved Survival After Myocardial Infarction. <i>Circulation</i> , 1999, 100, 2093-2099.	1.6	194
387	Myoarchitecture and connective tissue in hearts with tricuspid atresia. <i>Heart</i> , 1999, 81, 182-191.	1.2	60
388	Aldosterone and Spironolactone in Heart Failure. <i>New England Journal of Medicine</i> , 1999, 341, 753-755.	13.9	116
389	Calcineurin Plays a Critical Role in Pressure Overload-Induced Cardiac Hypertrophy. <i>Circulation</i> , 1999, 100, 2449-2454.	1.6	141
390	Lack of Association Between a Polymorphism of the Aldosterone Synthase Gene and Left Ventricular Structure. <i>Circulation</i> , 1999, 99, 2255-2260.	1.6	110
391	Low- and high-level transgenic expression of β 2-adrenergic receptors differentially affect cardiac hypertrophy and function in β 1-overexpressing mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1999, 96, 6400-6405.	3.3	226
392	Apoptosis in heart failure: Release of cytochrome c from mitochondria and activation of caspase-3 in human cardiomyopathy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1999, 96, 8144-8149.	3.3	553
393	Cardiac fibrosis and inflammation interaction with hemodynamic and hormonal factors. <i>Cardiovascular Research</i> , 1999, 41, 532-543.	1.8	189
394	Irbesartan Reduces QT Dispersion in Hypertensive Individuals. <i>Hypertension</i> , 1999, 33, 713-718.	1.3	52
395	Regression of left ventricular hypertrophy; what are appropriate therapeutic objectives?. <i>British Journal of Clinical Pharmacology</i> , 1999, 47, 125-130.	1.1	10
396	INHIBITION OF HUMAN CARDIAC FIBROBLAST MITOGENESIS BY BLOCKADE OF MITOGEN-ACTIVATED PROTEIN KINASE AND PHOSPHATIDYLINOSITOL 3-KINASE. <i>Clinical and Experimental Pharmacology and Physiology</i> , 1999, 26, 511-513.	0.9	16
397	Gene expression analysis by transcript profiling coupled to a gene database query. <i>Nature Biotechnology</i> , 1999, 17, 798-803.	9.4	172

#	ARTICLE	IF	CITATIONS
398	Mechanically Induced Potentials in Fibroblasts from Human Right Atrium. <i>Experimental Physiology</i> , 1999, 84, 347-356.	0.9	49
399	Value of ambulatory intra-arterial blood pressure monitoring in the long term prediction of left ventricular hypertrophy and carotid atherosclerosis in essential hypertension. <i>Journal of Human Hypertension</i> , 1999, 13, 111-116.	1.0	24
400	Early abnormalities in left ventricular diastolic function of sodium-sensitive hypertensive patients. <i>Journal of Human Hypertension</i> , 1999, 13, 711-716.	1.0	30
401	Role of Angiotensin II in Hypertension-Induced Cardiac Hypertrophy and Failure. <i>Heart Failure Reviews</i> , 1999, 3, 159-168.	1.7	2
402	Cardiac Remodeling: From Concepts to Therapeutics. <i>Heart Failure Reviews</i> , 1999, 4, 7-20.	1.7	1
403	Angiotensin peptides and inducible transcription factors. <i>Journal of Molecular Medicine</i> , 1999, 77, 339-357.	1.7	82
404	Ventricular remodeling and transforming growth factor-beta 1 mRNA expression after nontransmural myocardial infarction in rats: effects of angiotensin converting enzyme inhibition and angiotensin II type 1 receptor blockade. <i>Basic Research in Cardiology</i> , 1999, 94, 246-253.	2.5	39
405	Mechanisms of benefit in pacing of patients in heart failure. <i>Herzschrittmachertherapie Und Elektrophysiologie</i> , 1999, 10, 16-22.	0.3	1
406	Effects of reactive oxygen species on myofilament function in a rabbit coronary artery ligation model of heart failure. <i>Pflugers Archiv European Journal of Physiology</i> , 1999, 438, 289-298.	1.3	3
407	Functional, structural, and dynamic basis of electrical heterogeneity in healthy and diseased cardiac muscle implications for arrhythmogenesis and anti-arrhythmic drug therapy. , 1999, 84, 207-231.		75
408	Ambulatory blood pressure monitoring and echocardiographyâ€”Noninvasive techniques for evaluation of the hypertensive patient. <i>Progress in Cardiovascular Diseases</i> , 1999, 41, 397-440.	1.6	14
409	Cardiac angiotensin-converting enzyme activity in myocardial infarction. <i>American Journal of Cardiology</i> , 1999, 84, 774-778.	0.7	12
410	PREOPERATIVE EVALUATION OF HYPERTENSION. <i>Anesthesiology Clinics</i> , 1999, 17, 549-565.	1.4	1
411	Mechanism of Cardiac Fibrosis by Angiotensin. <i>Trends in Cardiovascular Medicine</i> , 1999, 9, 180-184.	2.3	16
412	Impact of Calcium Antagonists on the Cardiovascular System. <i>Drugs</i> , 1999, 57, 11-17.	4.9	5
413	The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure. <i>New England Journal of Medicine</i> , 1999, 341, 709-717.	13.9	8,093
414	Influence of felodipine on left ventricular hypertrophy and systolic function in orthotopic heart transplant recipients:. <i>Journal of Heart and Lung Transplantation</i> , 1999, 18, 1003-1013.	0.3	27
415	Distribution of Collagen Deposition in Cardiomyopathic Hamster Hearts Determined by Infrared Microscopy. <i>Cardiovascular Pathology</i> , 1999, 8, 41-47.	0.7	54

#	ARTICLE	IF	CITATIONS
416	Effects of Beta-Receptor Blockade and Angiotensin II Type I Receptor Antagonism in Isoproterenol - Induced Heart Failure in the Rat. <i>Cardiovascular Pathology</i> , 1999, 8, 315-323.	0.7	29
418	The infarcted myocardium Simply dead tissue, or a lively target for therapeutic interventions. <i>Cardiovascular Research</i> , 1999, 44, 232-241.	1.8	238
419	Recent insight into therapy of congestive heart failure: focus on ACE inhibition and angiotensin-II antagonism. <i>Journal of the American College of Cardiology</i> , 1999, 33, 1163-1173.	1.2	56
420	HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction—pharmacological approaches. <i>Journal of Cardiac Failure</i> , 1999, 5, 357-382.	0.7	306
421	Within-patient comparison of effects of different dosages of enalapril on functional capacity and neurohormone levels in patients with chronic heart failure. <i>American Heart Journal</i> , 1999, 138, 654-662.	1.2	46
422	Secondary prevention of myocardial infarction: Role of β^2 -adrenergic blockers and angiotensin-converting enzyme inhibitors. <i>American Heart Journal</i> , 1999, 137, S25-S34.	1.2	29
423	Extracellular Matrix Regulation in the Development of Syrian Cardiomyopathic Bio 14.6 and Bio 53.58 Hamsters. <i>Journal of Molecular and Cellular Cardiology</i> , 1999, 31, 1607-1615.	0.9	28
424	Expression of T-type Ca^{2+} Channels in Ventricular Cells from Hypertrophied Rat Hearts. <i>Journal of Molecular and Cellular Cardiology</i> , 1999, 31, 1617-1625.	0.9	149
425	Effects of Angiotensin Type-I Receptor Blockade on Pericardial Fibrosis. <i>Journal of Surgical Research</i> , 1999, 87, 101-107.	0.8	7
426	Alterations in Sarcoplasmic Reticulum and Angiotensin II Receptor Type 1 Gene Expression in Spontaneously Hypertensive Rat Hearts. <i>Japanese Circulation Journal</i> , 1999, 63, 367-372.	1.0	18
427	Contribution of non-cardiomyocyte apoptosis to cardiac remodelling that occurs in the transition from compensated hypertrophy to heart failure in spontaneously hypertensive rats. <i>Clinical Science</i> , 1999, 97, 239-246.	1.8	27
428	Contribution of non-cardiomyocyte apoptosis to cardiac remodelling that occurs in the transition from compensated hypertrophy to heart failure in spontaneously hypertensive rats. <i>Clinical Science</i> , 1999, 97, 239.	1.8	7
429	Myocardial diastolic impairment caused by left ventricular hypertrophy involves basal septum more than other walls. <i>Journal of Hypertension</i> , 1999, 17, 685-693.	0.3	49
430	Insertion/deletion angiotensin converting enzyme gene polymorphism affects the microvascular structure of the kidney in patients with nondiabetic renal disease. <i>Journal of Hypertension</i> , 1999, 17, 351-356.	0.3	14
431	Paracrine hypertrophic factors from cardiac non-myocyte cells downregulate the transient outward current density and $Kv4.2$ K^+ channel expression in cultured rat cardiomyocytes. <i>Cardiovascular Research</i> , 1999, 41, 157-165.	1.8	18
433	Fibrosis and hypertensive heart disease. <i>Current Opinion in Cardiology</i> , 2000, 15, 264-272.	0.8	265
434	Heart failure development in rats with ascending aortic constriction and angiotensin-converting enzyme inhibition. <i>British Journal of Pharmacology</i> , 2000, 130, 1671-1677.	2.7	19
435	Myocyte Death in Streptozotocin-Induced Diabetes in Rats Is Angiotensin II- Dependent. <i>Laboratory Investigation</i> , 2000, 80, 513-527.	1.7	287

#	ARTICLE	IF	CITATIONS
436	Angiotensin II-induced cardiomyocyte hypertrophy and cardiac fibrosis in stroke-prone spontaneously hypertensive rats. <i>Translational Research</i> , 2000, 135, 353-359.	2.4	29
437	Heart-hitting tales of salt and destruction. <i>Translational Research</i> , 2000, 136, 7-13.	2.4	9
438	Aldosterone, a New Appreciation of Its Role in Heart Failure. <i>Pharmacotherapy</i> , 2000, 20, 1107-1115.	1.2	8
439	Evolution and Pathophysiology of Chronic Systolic Heart Failure. <i>Pharmacotherapy</i> , 2000, 20, 349S-358S.	1.2	15
440	The Role of the Renin-Angiotensin-Aldosterone System in the Management of Heart Failure. <i>Pharmacotherapy</i> , 2000, 20, 368S-378S.	1.2	8
441	HFSA Guidelines for Management of Patients With Heart Failure Caused by Left Ventricular Systolic Dysfunction—Pharmacological Approaches. <i>Pharmacotherapy</i> , 2000, 20, 495-522.	1.2	72
442	Role of Å Blockers in Congestive Heart Failure. <i>Congestive Heart Failure</i> , 2000, 6, 299-312.	2.0	3
443	Impact of aldosterone on left ventricular structure and function in young normotensive and mildly hypertensive subjects. <i>American Journal of Cardiology</i> , 2000, 85, 1199-1206.	0.7	56
444	Control of cardiomyocyte gene expression as drug target. <i>Molecular and Cellular Biochemistry</i> , 2000, 212, 135-142.	1.4	8
445	Extracellular matrix and growth factors during heart growth. <i>Heart Failure Reviews</i> , 2000, 5, 119-130.	1.7	96
446	The extracellular matrix and the cytoskeleton in heart hypertrophy and failure. <i>Heart Failure Reviews</i> , 2000, 5, 239-250.	1.7	71
447	Influence of the chronic nitric oxide synthesis inhibition on cardiomyocytes number. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2000, 437, 667-674.	1.4	24
448	Normalization of left ventricular dysfunction in systemic hypertension. <i>Clinical Cardiology</i> , 2000, 23, 443-448.	0.7	8
449	Left ventricular myocardial remodeling and contractile state in chronic aortic regurgitation. <i>Clinical Cardiology</i> , 2000, 23, 608-614.	0.7	32
450	Beta-blockers and spironolactone in heart failure. <i>Current Cardiology Reports</i> , 2000, 2, 87-89.	1.3	1
451	Diastolic heart failure. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2000, 2, 439-450.	0.4	14
453	Aldosterone and Myocardial Fibrosis in Heart Failure. <i>Herz</i> , 2000, 25, 299-306.	0.4	107
454	Differential effects of pressure or volume overload on myocardial MMP levels and inhibitory control. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2000, 278, H151-H161.	1.5	102

#	ARTICLE	IF	CITATIONS
455	Effects of exercise training on cardiac function, gene expression, and apoptosis in rats. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2000, 279, H2994-H3002.	1.5	105
456	Expression and localization of angiotensin subtype receptor proteins in the hypertensive rat heart. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2000, 278, R781-R789.	0.9	17
457	The Regression of Left Ventricular Hypertrophy by Imidapril and the Reduction of Serum Procollagen Type III Amino-Terminal Peptide in Hypertensive Patients.. <i>Hypertension Research</i> , 2000, 23, 317-322.	1.5	16
458	Type 2 angiotensin II receptor is downregulated in cardiomyocytes of patients with heart failure. <i>Cardiovascular Research</i> , 2000, 46, 73-81.	1.8	31
460	Time-Course Changes in Left Ventricular Geometry and Function during the Development of Hypertension in Dahl Salt-Sensitive Rats.. <i>Hypertension Research</i> , 2000, 23, 613-623.	1.5	33
461	Role of mechanical factors in modulating cardiac fibroblast function and extracellular matrix synthesis. <i>Cardiovascular Research</i> , 2000, 46, 257-263.	1.8	338
462	Testosterone Increases Blood Pressure and Cardiovascular and Renal Pathology in Spontaneously Hypertensive Rats. <i>Blood Pressure</i> , 2000, 9, 227-238.	0.7	15
463	Impaired Endothelium-Dependent Regulation of Ventricular Relaxation in Pressure-Overload Cardiac Hypertrophy. <i>Circulation</i> , 2000, 101, 1854-1860.	1.6	52
464	Repair of Coronary Arterioles After Treatment With Perindopril in Hypertensive Heart Disease. <i>Hypertension</i> , 2000, 36, 220-225.	1.3	227
465	Left ventricular dysfunction: causes, natural history, and hopes for reversal. <i>British Heart Journal</i> , 2000, 84, 15i-17.	2.2	20
466	Cardiac fibrosis in mice lacking brain natriuretic peptide. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000, 97, 4239-4244.	3.3	558
467	Is there a cirrhotic cardiomyopathy?. <i>American Journal of Gastroenterology</i> , 2000, 95, 3026-3028.	0.2	33
468	Inhibitory Effect of Angiotensin II Type 2 Receptor on Coronary Arterial Remodeling After Aortic Banding in Mice. <i>Circulation</i> , 2000, 102, 1684-1689.	1.6	112
469	Myocardial matrix degradation and metalloproteinase activation in the failing heart: a potential therapeutic target. <i>Cardiovascular Research</i> , 2000, 46, 225-238.	1.8	185
470	Arrhythmogenic mechanisms in left ventricular hypertrophy. <i>Europace</i> , 2000, 2, 216-223.	0.7	69
471	Treatment of Familial Hyperaldosteronism Type I: Only Partial Suppression of Adrenocorticotropin Required to Correct Hypertension. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 3313-3318.	1.8	81
472	Renin-angiotensin-aldosterone system and myocardial fibrosis. <i>Cardiovascular Research</i> , 2000, 47, 1-3.	1.8	105
473	Angiotensin II binding and extracellular matrix remodelling in a rat model of myocardial infarction. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2000, 1, 369-378.	1.0	5

#	ARTICLE	IF	CITATIONS
474	Recruitable ACE and tissue repair in the infarcted heart. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2000, 1, 295-303.	1.0	30
475	Hypertensive heart disease. A complex syndrome or a hypertensive 'cardiomyopathy'?. European Heart Journal, 2000, 21, 1653-1665.	1.0	107
476	Lisinopril-Mediated Regression of Myocardial Fibrosis in Patients With Hypertensive Heart Disease. Circulation, 2000, 102, 1388-1393.	1.6	591
477	Targeting Pathological Remodeling. Circulation, 2000, 102, 1342-1345.	1.6	117
478	Spirolactone in the Treatment of Congestive Heart Failure. Annals of Pharmacotherapy, 2000, 34, 1336-1340.	0.9	5
479	Aldosterone mediates angiotensin II-stimulated rat vascular smooth muscle cell proliferation. Journal of Endocrinology, 2000, 165, 533-536.	1.2	58
480	Left Ventricular Hypertrophy. Circulation, 2000, 102, 470-479.	1.6	971
481	Î²-Blockade Prevents Sustained Metalloproteinase Activation and Diastolic Stiffening Induced by Angiotensin II Combined With Evolving Cardiac Dysfunction. Circulation Research, 2000, 86, 807-815.	2.0	90
482	Endothelin-1 Stimulates Cardiac Fibroblast Proliferation Through Activation of Protein Kinase C. Journal of Molecular and Cellular Cardiology, 2000, 32, 565-576.	0.9	113
483	Outside-in Signalling of Fibronectin Stimulates Cardiomyocyte Hypertrophy in Cultured Neonatal Rat Ventricular Myocytes. Journal of Molecular and Cellular Cardiology, 2000, 32, 765-776.	0.9	62
484	Induction of Cardiac Fibrosis by Aldosterone. Journal of Molecular and Cellular Cardiology, 2000, 32, 865-879.	0.9	227
485	Induction of Cardiac Fibrosis by Transforming Growth Factor-Î²1. Molecular Genetics and Metabolism, 2000, 71, 418-435.	0.5	424
486	Association between elevated brain natriuretic peptide levels and the development of left ventricular hypertrophy in patients with hypertension. American Journal of Medicine, 2000, 108, 627-633.	0.6	29
487	The implications for cardiac recovery of left ventricular assist device support on myocardial collagen content. American Journal of Surgery, 2000, 180, 498-502.	0.9	56
488	Hypertensive cardiovascular damage in patients with primary autonomic failure. Lancet, The, 2000, 355, 725-726.	6.3	141
489	Prognostic value of left ventricular hypertrophy and geometry in patients with a first, uncomplicated myocardial infarction. International Journal of Cardiology, 2000, 74, 177-183.	0.8	31
490	Left ventricular remodelling and dysfunction. International Journal of Cardiology, 2000, 72, 143-150.	0.8	25
491	Molecular characterization of myocardial fibrosis during hypothyroidism: evidence for negative regulation of the pro-Î±1(I) collagen gene expression by thyroid hormone receptor. Molecular and Cellular Endocrinology, 2000, 162, 45-55.	1.6	62

#	ARTICLE	IF	CITATIONS
492	The kallikrein-kininogen-kinin system: lessons from the quantification of endogenous kinins. <i>Peptides</i> , 2000, 21, 1903-1940.	1.2	119
493	Effects of acute and chronic angiotensin receptor blockade on myocardial vascular blood volume and perfusion in a pig model of coronary microembolization. <i>American Journal of Hypertension</i> , 2000, 13, 827-837.	1.0	12
494	Myocardial fibrosis in DOCA-salt hypertensive rats: effect of endothelin ETA receptor antagonism. <i>American Journal of Hypertension</i> , 2000, 13, S243.	1.0	1
495	Cardiac troponin I as diagnostic and prognostic marker in severe heart failure. <i>Journal of Heart and Lung Transplantation</i> , 2000, 19, 644-652.	0.3	172
496	Reversibility and Pathohistological Basis of Left Ventricular Remodeling in Hibernating Myocardium. <i>Cardiovascular Pathology</i> , 2000, 9, 323-335.	0.7	19
497	CONNECTIVE TISSUE AND THE HEART. <i>Cardiology Clinics</i> , 2000, 18, 435-442.	0.9	139
498	Angiotensin II, adhesion, and cardiac fibrosis. <i>Cardiovascular Research</i> , 2000, 46, 264-268.	1.8	206
500	Echocardiographic predictors of clinical outcome in patients with left ventricular dysfunction enrolled in the SOLVD registry and trials: significance of left ventricular hypertrophy—A list of participating hospitals, central agencies and personnel appears in reference 26.. <i>Journal of the American College of Cardiology</i> , 2000, 35, 1237-1244.	1.2	239
501	Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. <i>Journal of the American College of Cardiology</i> , 2000, 35, 1669-1677.	1.2	548
502	Spironolactone inhibits the transcardiac extraction of aldosterone in patients with congestive heart failure. <i>Journal of the American College of Cardiology</i> , 2000, 36, 838-844.	1.2	79
503	Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death. <i>Journal of the American College of Cardiology</i> , 2000, 35, 36-44.	1.2	365
504	Effects of long-term therapy with bosentan on the progression of left ventricular dysfunction and remodeling in dogs with heart failure. <i>Journal of the American College of Cardiology</i> , 2000, 35, 222-229.	1.2	42
505	Cardiac remodeling—concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. <i>Journal of the American College of Cardiology</i> , 2000, 35, 569-582.	1.2	2,171
507	Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats. <i>Journal of the American College of Cardiology</i> , 2001, 37, 662-667.	1.2	145
508	Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. <i>Journal of the American College of Cardiology</i> , 2001, 37, 1228-1233.	1.2	322
509	Activation of the cardiac renin-angiotensin system and increased myocardial collagen expression in human aortic valve disease. <i>Journal of the American College of Cardiology</i> , 2001, 37, 1443-1449.	1.2	149
510	A remarkable medical story: benefits of angiotensin-converting enzyme inhibitors in cardiac patients. <i>Journal of the American College of Cardiology</i> , 2001, 37, 1757-1764.	1.2	71
511	Intravenous atrial natriuretic peptide prevents left ventricular remodeling in patients with first anterior acute myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2001, 37, 1820-1826.	1.2	161

#	ARTICLE	IF	CITATIONS
512	Relation of thallium uptake to morphologic features of chronic ischemic heart disease: evidence for myocardial remodeling in noninfarcted myocardium. <i>Journal of the American College of Cardiology</i> , 2001, 38, 84-90.	1.2	18
513	Relationship between transcatheter extraction of aldosterone and left ventricular remodeling in patients with first acute myocardial infarction: extracting aldosterone through the heart promotes ventricular remodeling after acute myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2001, 38, 1375-1382.	1.2	71
514	Long-term administration of amlodipine prevents decompensation to diastolic heart failure in hypertensive rats. <i>Journal of the American College of Cardiology</i> , 2001, 38, 1539-1545.	1.2	50
515	Aldosterone in Congestive Heart Failure. <i>New England Journal of Medicine</i> , 2001, 345, 1689-1697.	13.9	675
516	ANGIOTENSIN RECEPTOR BLOCKERS AND ALDOSTERONE ANTAGONISTS IN CHRONIC HEART FAILURE. <i>Cardiology Clinics</i> , 2001, 19, 195-202.	0.9	16
517	Diastolic Dysfunction in Arterial Hypertension. <i>Journal of Clinical Hypertension</i> , 2001, 3, 22-27.	1.0	31
518	Extracellular Matrix Proteins in Cardiac Fibroblasts Derived from Rat Hearts with Chronic Pressure Overload: Effects of Beta-receptor Blockade. <i>Journal of Molecular and Cellular Cardiology</i> , 2001, 33, 487-501.	0.9	65
519	Stage-specific Differential Activation of Mitogen-activated Protein Kinases in Hypertrophied and Failing Rat Hearts. <i>Journal of Molecular and Cellular Cardiology</i> , 2001, 33, 733-744.	0.9	42
520	β_2 -Adrenergic Stimulation of Rat Cardiac Fibroblasts Promotes Protein Synthesis via the Activation of Phosphatidylinositol 3-kinase. <i>Journal of Molecular and Cellular Cardiology</i> , 2001, 33, 1091-1106.	0.9	36
521	Pathophysiology of chronic heart failure. <i>American Journal of Medicine</i> , 2001, 110, 37-46.	0.6	197
522	Spirolactone and captopril attenuates isoproterenol-induced cardiac remodeling in rats. <i>Pharmacological Research</i> , 2001, 44, 311-315.	3.1	29
523	Histological remodeling in an ovine heart failure model resembles human ischemic cardiomyopathy. <i>Cardiovascular Pathology</i> , 2001, 10, 19-27.	0.7	20
524	Aldosterone inhibition and heart failure: Too good to be true?. <i>American Heart Journal</i> , 2001, 141, 1-2.	1.2	42
525	Aldosterone inhibition limits collagen synthesis and progressive left ventricular enlargement after anterior myocardial infarction. <i>American Heart Journal</i> , 2001, 141, 41-46.	1.2	89
526	Regression of left ventricular remodeling in chronic heart failure: Comparative and combined effects of captopril and carvedilol. <i>American Heart Journal</i> , 2001, 142, 704-713.	1.2	45
527	The combination ace-inhibitors plus canrenone in patients with anterior myocardial infarction: safety and tolerability study. <i>International Journal of Cardiology</i> , 2001, 77, 119-127.	0.8	6
528	Left ventricular hypertrophy and angiotensin II antagonists. <i>American Journal of Hypertension</i> , 2001, 14, 174-182.	1.0	69
529	Familial hyperaldosteronism. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2001, 78, 215-229.	1.2	92

#	ARTICLE	IF	CITATIONS
531	Aldosterone Induces Angiotensin-Converting-Enzyme Gene Expression in Cultured Neonatal Rat Cardiocytes. <i>Circulation</i> , 2001, 104, 137-139.	1.6	202
532	Effects of Antihypertensive Agents on the Left Ventricle. <i>American Journal of Cardiovascular Drugs</i> , 2001, 1, 263-279.	1.0	20
533	Myocardial remodelling and matrix metalloproteinases in heart failure: turmoil within the interstitium. <i>Annals of Medicine</i> , 2001, 33, 623-634.	1.5	49
534	Glucocorticoid regulation of angiotensin-converting enzyme in primary culture of adult cardiac fibroblasts. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2001, 280, R25-R32.	0.9	28
535	Relative Wall Thickness Is an Independent Predictor of Left Ventricular Systolic and Diastolic Dysfunctions in Essential Hypertension.. <i>Hypertension Research</i> , 2001, 24, 493-499.	1.5	48
536	Coronary Capillary Remodeling in Non-Insulin-Dependent Diabetic Rats: Amelioration by Inhibition of Angiotensin Converting Enzyme and Its Potential Clinical Implications.. <i>Hypertension Research</i> , 2001, 24, 75-81.	1.5	14
537	Catecholamines stimulate interleukin-6 synthesis in rat cardiac fibroblasts. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2001, 281, H14-H21.	1.5	72
538	Endothelial function during stimulation of renin-angiotensin system by low-sodium diet in humans. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2001, 280, H2248-H2254.	1.5	6
539	Vitamin C and quinapril abrogate LVH and endothelial dysfunction in aortic-banded guinea pigs. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2001, 281, H1704-H1710.	1.5	31
540	Ventricular production of natriuretic peptides and ventricular structural remodeling in hypertensive heart failure. <i>Journal of Hypertension</i> , 2001, 19, 1905-1912.	0.3	42
541	Effect of Telmisartan on Angiotensin II-Mediated Collagen Gel Contraction by Adult Rat Cardiac Fibroblasts. <i>Journal of Cardiovascular Pharmacology</i> , 2001, 38, 39-48.	0.8	12
542	Regression of left ventricular hypertrophy in human hypertension with irbesartan. <i>Journal of Hypertension</i> , 2001, 19, 1167-1176.	0.3	148
543	Arterial hypertension and cardiac arrhythmias. <i>Journal of Hypertension</i> , 2001, 19, 167-177.	0.3	55
544	Effects of angiotensin II subtype 1 receptor blockade on cardiac fibrosis and sarcoplasmic reticulum Ca ²⁺ handling in hypertensive transgenic rats overexpressing the Ren2 gene. <i>Journal of Hypertension</i> , 2001, 19, 1465-1472.	0.3	15
545	Histopathologic findings in explanted heart tissue from patients with end-stage idiopathic dilated cardiomyopathy. <i>Transplant International</i> , 2001, 14, 299-306.	0.8	94
546	Recent developments in microvascular angina. <i>Current Atherosclerosis Reports</i> , 2001, 3, 149-155.	2.0	4
547	Diastolic function in hypertension. <i>Current Cardiology Reports</i> , 2001, 3, 485-497.	1.3	7
548	Semiquantitative analysis of collagen types in the hypertrophied left ventricle. <i>Journal of Anatomy</i> , 2001, 198, 83-92.	0.9	15

#	ARTICLE	IF	CITATIONS
549	New Perspectives On The Role Of Aldosterone Excess In Cardiovascular Disease. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2001, 28, 783-791.	0.9	58
550	Angiotensin II type1 receptor regulation and differential trophic effects on rat cardiac myofibroblasts after acute myocardial infarction. <i>Journal of Cellular Physiology</i> , 2001, 187, 326-335.	2.0	21
551	New treasures from old? EPHEUS. Eplerenome Post-AHI Heart Failure Efficacy and Survival Study. , 2001, 15, 11-13.		8
552	Effects of losartan on the collagen degradative enzymes in hypertrophic and congestive types of cardiomyopathic hamsters. <i>Molecular and Cellular Biochemistry</i> , 2001, 224, 19-27.	1.4	23
553	ACE-inhibition plus mineralocorticoid antagonism versus ACE-inhibition alone in patients with anterior myocardial infarction. <i>Cardiovascular Drugs and Therapy</i> , 2001, 15, 309-314.	1.3	7
554	Neurohormones, cytokines and programmed cell death in heart failure: a new paradigm for the remodeling heart. <i>Cardiovascular Drugs and Therapy</i> , 2001, 15, 529-537.	1.3	5
556	Influence of aldosterone on collagen synthesis and proliferation of rat cardiac fibroblasts. <i>British Journal of Pharmacology</i> , 2001, 134, 224-232.	2.7	36
557	Polymorphisms of the renin-angiotensin system in patients with multifocal renal arterial fibromuscular dysplasia. <i>Journal of Human Hypertension</i> , 2001, 15, 185-190.	1.0	48
558	Histopathologic findings in explanted heart tissue from patients with end-stage idiopathic dilated cardiomyopathy. <i>Transplant International</i> , 2001, 14, 299-306.	0.8	62
559	The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data. <i>American Journal of Cardiology</i> , 2001, 88, 1-20.	0.7	202
560	Electrical and structural remodeling of the failing ventricle. , 2001, 92, 213-230.		87
561	Age-associated changes in cardiac matrix and integrins. <i>Mechanisms of Ageing and Development</i> , 2001, 122, 1739-1756.	2.2	107
562	Effects of cilnidipine on nitric oxide and endothelin-1 expression and extracellular signal-regulated kinase in hypertensive rats. <i>European Journal of Pharmacology</i> , 2001, 422, 149-157.	1.7	29
563	Left ventricular diastolic heart failure with normal left ventricular systolic function in older persons. <i>Translational Research</i> , 2001, 137, 316-323.	2.4	17
564	Heart biometry and allometry in rats submitted to nitric oxide synthesis blockade and treatment with antihypertensive drugs. <i>Annals of Anatomy</i> , 2001, 183, 171-176.	1.0	5
565	Optimal Use of Spironolactone for Treatment of Heart Failure. <i>Congestive Heart Failure</i> , 2001, 7, 315-318.	2.0	1
566	Effects of Combination of ACE Inhibitor and Angiotensin Receptor Blocker on Cardiac Remodeling, Cardiac Function, and Survival in Rat Heart Failure. <i>Circulation</i> , 2001, 103, 148-154.	1.6	143
567	The Endothelin-Aldosterone Axis and Cardiovascular Diseases. <i>Journal of Cardiovascular Pharmacology</i> , 2001, 38, S49-S52.	0.8	31

#	ARTICLE	IF	CITATIONS
568	Myocardial Fibrosis in DOCA-Salt Hypertensive Rats. <i>Circulation</i> , 2001, 103, 319-324.	1.6	148
569	Angiotensin II Type 2 Receptor Is Essential for Left Ventricular Hypertrophy and Cardiac Fibrosis in Chronic Angiotensin II-Induced Hypertension. <i>Circulation</i> , 2001, 104, 346-351.	1.6	277
570	Successful Long-Term Treatment of Refractory Cushing's Disease with High-Dose Mifepristone (RU) Tj ETQq0 0.0 rgBT /Overlock 10	1.8	167
571	Ongoing clinical trials in systemic hypertension. <i>Expert Opinion on Investigational Drugs</i> , 2001, 10, 2031-2037.	1.9	2
572	Use of a Biological Peptide Pump to Study Chronic Peptide Hormone Action in Transgenic Mice. <i>Journal of Biological Chemistry</i> , 2001, 276, 44012-44017.	1.6	75
573	Review: Aldosterone-induced vasculopathy: a new reversible cause of cardiac death. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2001, 2, 211-214.	1.0	12
574	Nitric Oxide Attenuates the Expression of Transforming Growth Factor- β 3 mRNA in Rat Cardiac Fibroblasts via Destabilization. <i>Hypertension</i> , 2001, 38, 261-266.	1.3	34
575	Cardioreparation in Hypertensive Heart Disease. <i>Hypertension</i> , 2001, 38, 588-591.	1.3	60
576	Overexpression of 12-Lipoxygenase Causes Cardiac Fibroblast Cell Growth. <i>Circulation Research</i> , 2001, 88, 70-76.	2.0	40
577	Fibrinogen and Preclinical Echocardiographic Target Organ Damage. <i>Hypertension</i> , 2001, 38, 1068-1074.	1.3	39
578	Expression and Distribution of NOS1 and NOS3 in the Myocardium of Angiotensin II-Infused Rats. <i>Hypertension</i> , 2001, 37, 1423-1428.	1.3	30
579	Review: Diagnosis and management of primary aldosteronism. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2001, 2, 156-169.	1.0	156
580	Cardiac Troponin I Levels in Patients with Left Heart Failure and Cor Pulmonale. <i>Angiology</i> , 2001, 52, 317-322.	0.8	6
581	Aldosterone Production Is Activated in Failing Ventricle in Humans. <i>Circulation</i> , 2001, 103, 72-77.	1.6	327
582	Reduction in Myocardial Collagen Cross-Linking Parallels Left Ventricular Dilatation in Rat Models of Systolic Chamber Dysfunction. <i>Circulation</i> , 2001, 103, 155-160.	1.6	175
583	Brain natriuretic peptide appears to act locally as an antifibrotic factor in the heart. <i>Canadian Journal of Physiology and Pharmacology</i> , 2001, 79, 723-729.	0.7	78
584	Primary Diastolic Heart Failure. <i>The American Journal of Geriatric Cardiology</i> , 2002, 11, 178-189.	0.7	12
585	Rapid Effects of Aldosterone and Spironolactone in the Isolated Working Rat Heart. <i>Hypertension</i> , 2002, 40, 130-135.	1.3	56

#	ARTICLE	IF	CITATIONS
586	New Concepts in Diastolic Dysfunction and Diastolic Heart Failure: Part II. <i>Circulation</i> , 2002, 105, 1503-1508.	1.6	696
587	Reduced Myocardial and Systemic Arginine Uptake in Heart Failure. <i>Circulation Research</i> , 2002, 91, 1198-1203.	2.0	31
588	Increased Carotid Wall Elastic Modulus and Fibronectin in Aldosterone-Salt-Treated Rats. <i>Circulation</i> , 2002, 106, 2848-2853.	1.6	221
589	Left ventricular hypertrophy: a new approach for fibrosis inhibition. <i>Journal of Hypertension</i> , 2002, 20, 611-613.	0.3	5
590	Expression of Aldosterone Synthase Gene in Failing Human Heart: Quantitative Analysis Using Modified Real-Time Polymerase Chain Reaction. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 3936-3940.	1.8	96
591	Is angiotensin II a proliferative factor of cardiac fibroblasts?. <i>Cardiovascular Research</i> , 2002, 53, 304-312.	1.8	103
592	Effects of Long-Term Monotherapy With Eplerenone, a Novel Aldosterone Blocker, on Progression of Left Ventricular Dysfunction and Remodeling in Dogs With Heart Failure. <i>Circulation</i> , 2002, 106, 2967-2972.	1.6	198
593	Mechanisms of cytokine induced NO-mediated cardiac fibroblast apoptosis. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2002, 283, H1958-H1967.	1.5	42
594	AT 1 Receptor Blockade Reduces Cardiac Calcineurin Activity in Hypertensive Rats. <i>Hypertension</i> , 2002, 40, 168-174.	1.3	104
595	Guanylyl Cyclase-A Inhibits Angiotensin II Type 1A Receptor-Mediated Cardiac Remodeling, an Endogenous Protective Mechanism in the Heart. <i>Circulation</i> , 2002, 106, 1722-1728.	1.6	92
596	N-Acetyl-Ser-Asp-Lys-Pro Inhibits Phosphorylation of Smad2 in Cardiac Fibroblasts. <i>Hypertension</i> , 2002, 40, 155-161.	1.3	58
597	Aldosterone Is Produced From Ventricles in Patients With Essential Hypertension. <i>Hypertension</i> , 2002, 39, 958-962.	1.3	72
598	Perindopril Effect on Uncoupling Protein and Energy Metabolism in Failing Rat Hearts. <i>Hypertension</i> , 2002, 40, 251-255.	1.3	34
599	Lack of rapid aldosterone effects on forearm resistance vasculature in health. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2002, 3, 123-125.	1.0	36
600	Hyperhomocysteinemia leads to adverse cardiac remodeling in hypertensive rats. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2002, 283, H2567-H2574.	1.5	71
601	Systemic and Regional Hemodynamic and Cardiac Remodeling Effects of Candesartan in Dilated Cardiomyopathic Hamsters With Advanced Congestive Heart Failure. <i>Journal of Cardiovascular Pharmacology</i> , 2002, 40, 189-200.	0.8	4
602	Inhibition of left ventricular fibrosis by tranilast in rats with renovascular hypertension. <i>Journal of Hypertension</i> , 2002, 20, 745-751.	0.3	37
603	Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension. <i>Journal of Hypertension</i> , 2002, 20, 2293-2300.	0.3	105

#	ARTICLE	IF	CITATIONS
604	Effects of the calcineurin dependent signaling pathway inhibition by cyclosporin A on early and late cardiac remodeling following myocardial infarction. <i>European Journal of Heart Failure</i> , 2002, 4, 713-718.	2.9	27
605	Elevated serum markers of collagen degradation in patients with mild to moderate dilated cardiomyopathy. <i>European Journal of Heart Failure</i> , 2002, 4, 439-444.	2.9	101
606	Simultaneous angiotensin converting enzyme inhibition moderates ventricular dysfunction caused by doxorubicin. <i>European Journal of Heart Failure</i> , 2002, 4, 583-586.	2.9	56
607	Aldosterone synthase (CYP11B2) expression and myocardial fibrosis in the failing human heart. <i>Clinical Science</i> , 2002, 102, 381-386.	1.8	64
608	Aldosterone synthase (CYP11B2) expression and myocardial fibrosis in the failing human heart. <i>Clinical Science</i> , 2002, 102, 381.	1.8	35
609	Beneficial Effects of Angiotensin-Converting Enzyme Inhibition in Adriamycin-Induced Cardiomyopathy in Hamsters. <i>The Japanese Journal of Pharmacology</i> , 2002, 88, 183-188.	1.2	44
610	Inhibition of Angiotensin-Converting Enzyme Reduces Susceptibility of Hypertrophied Rat Myocardium to Ventricular Fibrillation.. <i>Circulation Journal</i> , 2002, 66, 1045-1053.	0.7	9
611	Candesartan Cilexetil Improves Left Ventricular Function, Left Ventricular Hypertrophy, and Endothelial Function in Patients With Hypertensive Heart Disease.. <i>Circulation Journal</i> , 2002, 66, 993-999.	0.7	27
612	Molecular and Cellular Mechanisms of Mechanical Stress-Induced Cardiac Hypertrophy.. <i>Endocrine Journal</i> , 2002, 49, 1-13.	0.7	22
613	Regression of cardiomyocyte hypertrophy in SHR following chronic inhibition of the Na ⁺ /H ⁺ exchanger. <i>Cardiovascular Research</i> , 2002, 53, 862-868.	1.8	82
615	Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure. <i>Journal of the American College of Cardiology</i> , 2002, 40, 304-310.	1.2	160
616	Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study. <i>Journal of the American College of Cardiology</i> , 2002, 40, 970-975.	1.2	228
617	Beneficial neurohormonal profile of spironolactone in severe congestive heart failure. <i>Journal of the American College of Cardiology</i> , 2002, 40, 1596-1601.	1.2	180
621	Should ??-Blockers be Used for the Treatment of Pediatric Patients with Chronic Heart Failure?. <i>Paediatric Drugs</i> , 2002, 4, 771-778.	1.3	25
622	Clinical implications of aldosterone blockade. <i>American Heart Journal</i> , 2002, 144, S12-S18.	1.2	28
623	Differential integrin expression by cardiac fibroblasts from hypertensive and exercise-trained rat hearts. <i>Cardiovascular Pathology</i> , 2002, 11, 78-87.	0.7	65
624	Effects of early treatment with growth hormone on infarct size, survival, and cardiac gene expression after acute myocardial infarction. <i>Growth Hormone and IGF Research</i> , 2002, 12, 208-215.	0.5	28
625	Echocardiographic comparison of left ventricular structure and function in hypertensive patients with primary aldosteronism and essential hypertension. <i>American Journal of Hypertension</i> , 2002, 15, 340-345.	1.0	31

#	ARTICLE	IF	CITATIONS
626	Early onset of chondroitin sulfate and osteopontin expression in angiotensin ii-dependent left ventricular hypertrophy1. American Journal of Hypertension, 2002, 15, 644-652.	1.0	52
627	Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. American Journal of Hypertension, 2002, 15, 709-716.	1.0	343
628	Advances in our understanding of aging: role of the renin-angiotensin system. Current Opinion in Pharmacology, 2002, 2, 189-194.	1.7	56
629	New Concepts in Diastolic Dysfunction and Diastolic Heart Failure: Part I. Circulation, 2002, 105, 1387-1393.	1.6	1,078
630	Temocapril treatment ameliorates autoimmune myocarditis associated with enhanced cardiomyocyte thioredoxin expression. Cardiovascular Research, 2002, 55, 320-328.	1.8	19
631	An analysis of electrocardiographic criteria for determining left ventricular hypertrophy. Arquivos Brasileiros De Cardiologia, 2002, 78, 72-82.	0.3	13
632	Quantitative analysis of cardiac lesions in chronic canine chagasic cardiomyopathy. Revista Do Instituto De Medicina Tropical De Sao Paulo, 2002, 44, 273-278.	0.5	27
633	Influence of Plasma Aldosterone on Left Ventricular Geometry and Diastolic Function in Treated Essential Hypertension. Hypertension Research, 2002, 25, 49-56.	1.5	34
634	Celiprolol inhibits mitogen-activated protein kinase and endothelin-1 and transforming growth factor- β 1 gene in rats. European Journal of Pharmacology, 2002, 457, 85-93.	1.7	3
635	Relation of aldosterone "escape" despite angiotensin-converting enzyme inhibitor administration to impaired exercise capacity in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. American Journal of Cardiology, 2002, 89, 403-407.	0.7	72
636	Crumbling of left ventricular hypertrophy as a surrogate end point (the Losartan for Intervention) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 3 1133-1134.	0.7	9
637	Impact of Aldosterone on Vascular Pathophysiology. Congestive Heart Failure, 2002, 8, 18-22.	2.0	29
638	Matrix Metalloproteinase Disruption of the Extracellular Matrix and Cardiac Dysfunction. Trends in Cardiovascular Medicine, 2002, 12, 97-101.	2.3	99
639	Low doses of 2,3,7,8-tetrachlorodibenzo- p -dioxin increase transforming growth factor β 2 and cause myocardial fibrosis in marmosets (Callithrix jacchus). Archives of Toxicology, 2002, 76, 360-366.	1.9	45
640	Cardiac Fibrosis as a Cause of Diastolic Dysfunction. Herz, 2002, 27, 92-98.	0.4	225
641	Combination of Therapeutic Apheresis and Therapeutic Ventricular Assistance for End-Stage Heart Failure Patients. Therapeutic Apheresis and Dialysis, 2002, 6, 247-254.	0.4	1
642	Evidence for modulation of pericryptal sheath myofibroblasts in rat descending colon by Transforming Growth Factor β 2 and Angiotensin II.. BMC Gastroenterology, 2002, 2, 4.	0.8	12
643	Hypertension-Related Intermyocyte Junction Remodelling is Associated with a Higher Incidence of Low-K+ -Induced Lethal Arrhythmias in Isolated Rat Heart. Experimental Physiology, 2002, 87, 195-205.	0.9	28

#	ARTICLE	IF	CITATIONS
644	Noninvasive magnetic resonance imaging assessment of myocardial changes and the effects of angiotensin-converting enzyme inhibition in diabetic rats. <i>Journal of Physiology</i> , 2002, 538, 541-553.	1.3	33
645	Elevated mean arterial pressure in the ovariectomized rat was normalized by ETA receptor antagonist therapy: absence of cardiac hypertrophy and fibrosis. <i>British Journal of Pharmacology</i> , 2002, 136, 685-692.	2.7	19
646	Studies of prevention, treatment and mechanisms of heart failure in the aging spontaneously hypertensive rat. <i>Heart Failure Reviews</i> , 2002, 7, 71-88.	1.7	54
647	Aldosterone receptor blockade in the management of heart failure. <i>Heart Failure Reviews</i> , 2002, 7, 205-219.	1.7	5
648	Pathophysiologic and therapeutic importance of tissue ACE: a consensus report. <i>Cardiovascular Drugs and Therapy</i> , 2002, 16, 149-160.	1.3	118
650	Interaction of Xenobiotics with Myocardial Signal Transduction Pathways. <i>Cardiovascular Toxicology</i> , 2002, 2, 01-24.	1.1	2
651	Temocapril treatment ameliorates autoimmune myocarditis associated with enhanced cardiomyocyte thioredoxin expression. <i>Molecular and Cellular Biochemistry</i> , 2003, 248, 185-192.	1.4	10
652	Title is missing!. <i>Molecular and Cellular Biochemistry</i> , 2003, 251, 77-82.	1.4	7
653	Pharmacological modulation of cardiovascular remodeling: a guide to heart failure therapy. <i>Cardiovascular Drugs and Therapy</i> , 2003, 17, 349-360.	1.3	39
654	Postinfarction Remodeling of the Heart: Types of Pathomorphological Changes in the Right Ventricle. <i>Bulletin of Experimental Biology and Medicine</i> , 2003, 136, 291-295.	0.3	2
655	Expression of the translational repressor NAT1 in experimental models of cardiac hypertrophy. <i>Molecular and Cellular Biochemistry</i> , 2003, 245, 183-190.	1.4	11
656	The effects of spironolactone monotherapy on blood pressure and myocardial remodeling in spontaneously hypertensive rats: A stereological study. <i>Journal of Biomedical Science</i> , 2003, 10, 50-57.	2.6	13
657	A Neuroendocrine-Immune Interface. <i>Herz</i> , 2003, 28, 692-701.	0.4	12
658	Effects of ACE Inhibition versus Non-ACE Inhibitor Antihypertensive Treatment on Myocardial Fibrosis in Patients with Arterial Hypertension. <i>Herz</i> , 2003, 28, 744-753.	0.4	43
659	Endothelial Cell Swelling by Aldosterone. <i>Journal of Membrane Biology</i> , 2003, 196, 163-172.	1.0	92
660	Taurine transporter in primary cultured neonatal rat heart cells: a comparison between cardiac myocytes and nonmyocytes. <i>Biochemical Pharmacology</i> , 2003, 65, 1181-1187.	2.0	15
661	Fourier transform infrared evaluation of microscopic scarring in the cardiomyopathic heart: Effect of chronic AT1 suppression. <i>Analytical Biochemistry</i> , 2003, 316, 232-242.	1.1	59
662	Measured haplotype analysis of the aldosterone synthase gene and heart size. <i>European Journal of Human Genetics</i> , 2003, 11, 395-401.	1.4	19

#	ARTICLE	IF	CITATIONS
663	Blood pressure and left ventricular geometric pattern determine diastolic function in hypertensive myocardial hypertrophy. <i>Journal of Human Hypertension</i> , 2003, 17, 841-849.	1.0	29
664	Doppler tissue imaging reveals systolic dysfunction in patients with hypertension and apparent ?isolated? diastolic dysfunction. <i>Journal of the American Society of Echocardiography</i> , 2003, 16, 724-731.	1.2	101
665	Effect of spironolactone on cardiac sympathetic nerve activity and left ventricular remodeling in patients with dilated cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2003, 41, 574-581.	1.2	141
666	Diuretic use, progressive heart failure, and death in patients in the studies of left ventricular dysfunction (SOLVD). <i>Journal of the American College of Cardiology</i> , 2003, 42, 705-708.	1.2	315
668	Aldosterone Receptor Antagonists for Hypertension. <i>Drugs</i> , 2003, 63, 1963-1972.	4.9	12
669	Prescription patterns of diuretics in chronic heart failure: A contemporary background as a clue to their role in treatment. <i>Journal of Cardiac Failure</i> , 2003, 9, 210-218.	0.7	25
670	Primary aldosteronism. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2003, 17, 591-605.	2.2	55
671	Aldosterone receptor antagonists: Biology and novel therapeutical applications. <i>Journal of Endocrinological Investigation</i> , 2003, 26, 788-798.	1.8	4
672	Modeling Total Heart Function. <i>Annual Review of Biomedical Engineering</i> , 2003, 5, 147-177.	5.7	250
673	Chronic inhibition of Rho kinase blunts the process of left ventricular hypertrophy leading to cardiac contractile dysfunction in hypertension-induced heart failure. <i>Journal of Molecular and Cellular Cardiology</i> , 2003, 35, 59-70.	0.9	97
674	Cardiac dysfunction in portal hypertension among patients with cirrhosis and non-cirrhotic portal fibrosis. <i>Journal of Hepatology</i> , 2003, 39, 315-319.	1.8	47
675	Type 2 diabetes, cardiovascular risk, and the link to insulin resistance. <i>Clinical Therapeutics</i> , 2003, 25, B4-B31.	1.1	54
676	Studies on apoptosis and fibrosis in skeletal musculature: a comparison of heart failure patients with and without cardiac cachexia. <i>International Journal of Cardiology</i> , 2003, 90, 107-113.	0.8	46
677	RAS and connective tissue in the heart. <i>International Journal of Biochemistry and Cell Biology</i> , 2003, 35, 919-931.	1.2	34
678	Primary aldosteronism: from genesis to genetics. <i>Trends in Endocrinology and Metabolism</i> , 2003, 14, 310-317.	3.1	46
680	Cardioprotective Role of AT2 Receptor in Postinfarction Left Ventricular Remodeling. <i>Hypertension</i> , 2003, 41, 814-818.	1.3	79
681	Aldosterone Regulates Vascular Reactivity. <i>Circulation</i> , 2003, 108, 2400-2406.	1.6	163
682	Regression of Hypertensive Myocardial Fibrosis by Na ⁺ /H ⁺ Exchange Inhibition. <i>Hypertension</i> , 2003, 41, 373-377.	1.3	62

#	ARTICLE	IF	CITATIONS
683	Aortic Distensibility Independently Affects Exercise Tolerance in Patients With Dilated Cardiomyopathy. <i>Circulation</i> , 2003, 107, 1603-1608.	1.6	74
684	Myocardial Ultrasonic Backscatter in Hypertension. <i>Hypertension</i> , 2003, 41, 230-236.	1.3	78
685	Effects of Eplerenone, Enalapril, and Eplerenone/Enalapril in Patients With Essential Hypertension and Left Ventricular Hypertrophy. <i>Circulation</i> , 2003, 108, 1831-1838.	1.6	605
686	Protein Kinase C β Negatively Regulates Systolic and Diastolic Function in Pathological Hypertrophy. <i>Circulation Research</i> , 2003, 93, 1111-1119.	2.0	114
687	Aldosterone Blockade in Patients With Acute Myocardial Infarction. <i>Circulation</i> , 2003, 107, 2525-2527.	1.6	13
688	Working heart function in diabetes is not improved by spironolactone treatment. <i>Canadian Journal of Physiology and Pharmacology</i> , 2003, 81, 493-496.	0.7	6
689	Immediate Administration of Mineralocorticoid Receptor Antagonist Spironolactone Prevents Post-Infarct Left Ventricular Remodeling Associated With Suppression of a Marker of Myocardial Collagen Synthesis in Patients With First Anterior Acute Myocardial Infarction. <i>Circulation</i> , 2003, 107, 2559-2565.	1.6	295
690	Heart Failure: The frequent, forgotten, and often fatal complication of diabetes. <i>Diabetes Care</i> , 2003, 26, 2433-2441.	4.3	387
691	Effects of the Selective Aldosterone Blocker Eplerenone Versus the Calcium Antagonist Amlodipine in Systolic Hypertension. <i>Hypertension</i> , 2003, 41, 1021-1026.	1.3	273
692	Differential activation of matrix metalloproteinases in heart failure with and without ventricular dilatation. <i>Cardiovascular Research</i> , 2003, 57, 766-774.	1.8	70
693	Inhibitory Effect of Natriuretic Peptides on Aldosterone Synthase Gene Expression in Cultured Neonatal Rat Cardiocytes. <i>Circulation</i> , 2003, 107, 807-810.	1.6	81
694	Gene Expression Profile Revealed Different Effects of Angiotensin II Receptor Blockade and Angiotensin-Converting Enzyme Inhibitor on Heart Failure. <i>Journal of Cardiovascular Pharmacology</i> , 2003, 42, S1-S6.	0.8	5
695	Sub-Depressor Dose of Angiotensin Type-1 Receptor Blocker Inhibits Transforming Growth Factor- β 2-Mediated Perivascular Fibrosis in Hypertensive Rat Hearts. <i>Journal of Cardiovascular Pharmacology</i> , 2003, 42, S61-S65.	0.8	16
696	Mechanisms of cardiovascular risk reduction with ramipril: insights from HOPE and HOPE substudies. <i>European Heart Journal Supplements</i> , 2003, 5, A43-A48.	0.0	25
697	Comparative Effects of Perindopril with Enalapril in Rats with Dilated Cardiomyopathy. <i>Journal of Cardiovascular Pharmacology</i> , 2003, 42, S105-109.	0.8	9
698	Effects of Arginine Vasopressin on Growth of Rat Cardiac Fibroblasts: Role of V1 Receptor. <i>Journal of Cardiovascular Pharmacology</i> , 2003, 42, 132-135.	0.8	28
699	Combined Effects of Low-dose Oral Spironolactone and Captopril Therapy in a Rat Model of Spontaneous Hypertension and Heart Failure. <i>Journal of Cardiovascular Pharmacology</i> , 2003, 41, 830-837.	0.8	37
700	Inhibition of Matrix Metalloproteinases Prevents Cardiac Hypertrophy Induced by β -Adrenergic Stimulation in Rats. <i>Journal of Cardiovascular Pharmacology</i> , 2003, 42, 174-181.	0.8	42

#	ARTICLE	IF	CITATIONS
701	Cardiac Angiotensin II Type 2 Receptor Activates the Kinin/NO System and Inhibits Fibrosis. <i>Hypertension</i> , 2003, 41, 99-107.	1.3	169
702	Epidemiology, Pathophysiology, Prognosis, and Treatment of Systolic and Diastolic Heart Failure in Elderly Patients. <i>Heart Disease (Hagerstown, Md)</i> , 2003, 5, 279-294.	1.3	29
703	Hyperhomocysteinemia leads to pathological ventricular hypertrophy in normotensive rats. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2003, 285, H679-H686.	1.5	106
704	Association between Altered Circadian Blood Pressure Profile and Cardiac End-Organ Damage in Patients with Renovascular Hypertension. <i>Cardiology</i> , 2003, 100, 114-119.	0.6	23
705	Kallikrein gene delivery attenuates cardiac remodeling and promotes neovascularization in spontaneously hypertensive rats. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2003, 285, H1479-H1488.	1.5	44
706	Effects of Torasemide on Left Ventricular Function and Neurohumoral Factors in Patients With Chronic Heart Failure. <i>Circulation Journal</i> , 2003, 67, 384-390.	0.7	64
707	Beneficial Effects of Angiotensin-Converting Enzyme Inhibition on Sarcoplasmic Reticulum Function in the Failing Heart of the Dahl Rat. <i>Circulation Journal</i> , 2003, 67, 705-711.	0.7	26
708	Angiotensin II modulates nitric oxide-induced cardiac fibroblast apoptosis by activation of AKT/PKB. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2003, 285, H1105-H1112.	1.5	49
709	Remodeling of the Myocardium and Potential Targets in the Collagen Degradation and Synthesis Pathways. <i>Current Drug Targets Cardiovascular & Haematological Disorders</i> , 2003, 3, 1-30.	2.0	175
710	Enalapril alters the formation of the collagen matrix in spontaneously hypertensive rats. <i>Arquivos Brasileiros De Cardiologia</i> , 2003, 81, 69-72, 64-8.	0.3	0
711	Biã³psia endomiocãrdica prediz a recuperaã§Ã£o da funã§Ã£o ventricular apã³s cirurgia de revascularizaã§Ã£o do miocãrdio. <i>Arquivos Brasileiros De Cardiologia</i> , 2004, 83, 379-84; 373-8.	0.3	0
712	Morphometric and Serum Biochemical Analysis of Myocardial Fibrosis in Patients with Valvular Heart Disease. <i>Sunhwan'gi</i> , 2004, 34, 230.	0.3	0
713	The Influence of Aldosterone on the Development of Left Ventricular Geometry and Hypertrophy in Patients With Essential Hypertension. <i>International Heart Journal</i> , 2004, 45, 807-821.	0.6	14
714	Improved Systolic Ventricular Function With Normal Myocardial Mechanics in Compensated Cardiac Hypertrophy. <i>International Heart Journal</i> , 2004, 45, 647-656.	0.6	38
715	Additive Beneficial Effects of the Combination of a Calcium Channel Blocker and an Angiotensin Blocker on a Hypertensive Rat-Heart Failure Model. <i>Hypertension Research</i> , 2004, 27, 771-779.	1.5	33
716	Ventricular Nonmyocytes Inhibit Doxorubicin-Induced Myocyte Apoptosis: Involvement of Endogenous Endothelin-1 as a Paracrine Factor. <i>Endocrinology</i> , 2004, 145, 2458-2466.	1.4	19
717	Association of a ~344/T/C aldosterone synthase polymorphism (CYP11B2) with left ventricular structure and humoral parameters in young normotensive men. <i>Blood Pressure</i> , 2004, 13, 158-163.	0.7	13
718	Diastolic Dysfunction in the Elderlyã€”The Interstitial Issue. <i>The American Journal of Geriatric Cardiology</i> , 2004, 13, 29-38.	0.7	59

#	ARTICLE	IF	CITATIONS
720	Effect of Aldosterone Antagonism on Myocardial Dysfunction in Hypertensive Patients With Diastolic Heart Failure. <i>Circulation</i> , 2004, 110, 558-565.	1.6	276
721	Surrogate Markers for Cardiovascular Disease: Structural Markers. <i>Circulation</i> , 2004, 109, IV-22-IV-30.	1.6	175
722	Relations of Serum Aldosterone to Cardiac Structure. <i>Hypertension</i> , 2004, 43, 957-962.	1.3	128
723	TGF- β 1 and angiotensin networking in cardiac remodeling. <i>Cardiovascular Research</i> , 2004, 63, 423-432.	1.8	605
724	Serum cardiac troponin T in patients hospitalized with heart failure is associated with left ventricular hypertrophy and systolic dysfunction. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2004, 64, 667-676.	0.6	41
725	Treatment of the Patient With Diabetes Mellitus and Risk of Nephropathy. <i>Archives of Internal Medicine</i> , 2004, 164, 125.	4.3	19
727	Comparative Effects of Quinapril with Enalapril in Rats with Heart Failure. <i>Pharmacology</i> , 2004, 71, 157-161.	0.9	4
728	Cardiac tissue remodeling and renin-angiotensin system in hypertrophic heart. <i>Biogenic Amines</i> , 2004, 18, 451-462.	0.3	0
729	Overexpression of Brain Natriuretic Peptide Facilitates Neutrophil Infiltration and Cardiac Matrix Metalloproteinase-9 Expression After Acute Myocardial Infarction. <i>Circulation</i> , 2004, 110, 3306-3312.	1.6	95
730	Candesartan Prevents Myocardial Fibrosis during Progression of Congestive Heart Failure. <i>Journal of Cardiovascular Pharmacology</i> , 2004, 43, 860-867.	0.8	9
731	Angiotensin II Regulation of Collagen Type I Expression in Cardiac Fibroblasts. <i>Hypertension</i> , 2004, 44, 655-661.	1.3	141
732	Pressure-Independent Effects of Angiotensin II on Hypertensive Myocardial Fibrosis. <i>Hypertension</i> , 2004, 43, 499-503.	1.3	105
733	Combined angiotensin receptor blocker and ACE inhibitor on myocardial fibrosis and left ventricular stiffness in dogs with heart failure. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2004, 287, H2487-H2492.	1.5	24
734	Role of Osteopontin in Cardiac Fibrosis and Remodeling in Angiotensin II-Induced Cardiac Hypertrophy. <i>Hypertension</i> , 2004, 43, 1195-1201.	1.3	165
735	Androgen Contributes to Gender-Related Cardiac Hypertrophy and Fibrosis in Mice Lacking the Gene Encoding Guanylyl Cyclase-A. <i>Endocrinology</i> , 2004, 145, 951-958.	1.4	75
736	Adrenomedullin Administration Immediately After Myocardial Infarction Ameliorates Progression of Heart Failure in Rats. <i>Circulation</i> , 2004, 110, 426-431.	1.6	72
737	HYPERHOMOCYSTEINAEMIA-INDUCED ATRIAL REMODELLING IN HYPERTENSIVE RATS. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2004, 31, 331-337.	0.9	7
738	Meta-Analysis of effectiveness or lack thereof of Angiotensin-Converting enzyme inhibitors for prevention of heart failure in patients with systemic hypertension. <i>American Journal of Cardiology</i> , 2004, 93, 240-243.	0.7	28

#	ARTICLE	IF	CITATIONS
740	Cardioprotective Action of Perindopril versus Candesartan in Renovascular Hypertensive Rats. <i>Cardiovascular Drugs and Therapy</i> , 2004, 18, 353-362.	1.3	22
743	Evolving concepts in left ventricular systolic and diastolic remodeling: Implications for therapy. <i>Current Cardiology Reports</i> , 2004, 6, 200-204.	1.3	1
744	Antihypertensive drugs and the heart. <i>Current Cardiology Reports</i> , 2004, 6, 409-415.	1.3	2
745	Aldosterone-receptor antagonism and end-stage renal disease. <i>Current Hypertension Reports</i> , 2004, 6, 327-330.	1.5	19
746	Prevention and reversal of LV remodeling with neurohormonal inhibitors. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2004, 6, 313-325.	0.4	5
747	Activity of Angiotensinâ€Converting Enzyme After Treatment with Lâ€Arginine in Renovascular Hypertension. <i>Clinical and Experimental Hypertension</i> , 2004, 26, 569-579.	0.5	18
748	Reversal of Left Ventricular Hypertrophy. <i>American Journal of Cardiovascular Drugs</i> , 2004, 4, 369-378.	1.0	9
749	Left Ventricular Diastolic Dysfunction and Diastolic Heart Failure. <i>Annual Review of Medicine</i> , 2004, 55, 373-394.	5.0	256
750	Fibrosis in hypertensive heart disease: role of the renin-angiotensin-aldosterone system. <i>Medical Clinics of North America</i> , 2004, 88, 83-97.	1.1	83
751	Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure. <i>Journal of the American College of Cardiology</i> , 2004, 43, 2022-2027.	1.2	206
752	Furosemide and the progression of left ventricular dysfunction in experimental heart failure. <i>Journal of the American College of Cardiology</i> , 2004, 44, 1301-1307.	1.2	140
753	Losartan improves regional left ventricular systolic and diastolic function in patients with hypertension: accurate evaluation using a newly developed color-coded tissue doppler imaging technique. <i>Journal of Cardiac Failure</i> , 2004, 10, 412-420.	0.7	15
754	Independent and additional prognostic value of aminoterminal propeptide of type III procollagen circulating levels in patients with chronic heart failure. <i>Journal of Cardiac Failure</i> , 2004, 10, 403-411.	0.7	91
755	Eplerenone in the treatment of chronic heart failure. <i>Expert Review of Cardiovascular Therapy</i> , 2004, 2, 315-320.	0.6	2
756	Cardiac remodeling in systemic hypertension. <i>Medical Clinics of North America</i> , 2004, 88, 115-130.	1.1	56
757	Role of mast cells and their mediators in failing myocardium under mechanical ventricular support. <i>Journal of Heart and Lung Transplantation</i> , 2004, 23, 709-715.	0.3	56
758	Commentary 1. Evidence-based Cardiovascular Medicine, 2004, 8, 18-19.	0.0	1
759	Quantitative analysis of the cardiac fibroblast transcriptomeâ€™implications for NO/cGMP signaling. <i>Genomics</i> , 2004, 83, 577-587.	1.3	21

#	ARTICLE	IF	CITATIONS
760	PPAR α activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats. <i>Journal of Molecular and Cellular Cardiology</i> , 2004, 36, 295-304.	0.9	163
761	Differential response of human cardiac fibroblasts to angiotensin I and angiotensin II. <i>Peptides</i> , 2004, 25, 1031-1033.	1.2	3
762	Anesthesiology: perioperative medicine or "when the anesthetic is a diuretic". <i>Journal of Clinical Anesthesia</i> , 2004, 16, 130-137.	0.7	1
763	Applying standard therapies to new targets: the use of ACE inhibitors and B-blockers for heart failure in adults with congenital heart disease. <i>International Journal of Cardiology</i> , 2004, 97, 25-33.	0.8	48
764	Salacia oblonga improves cardiac fibrosis and inhibits postprandial hyperglycemia in obese Zucker rats. <i>Life Sciences</i> , 2004, 75, 1735-1746.	2.0	60
765	Aldosterone-induced vasculopathy. <i>Molecular and Cellular Endocrinology</i> , 2004, 217, 239-241.	1.6	34
766	Evolving role of aldosterone blockers alone and in combination with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in hypertension management: a review of mechanistic and clinical data. <i>American Heart Journal</i> , 2004, 147, 564-572.	1.2	23
767	Mice lacking osteopontin exhibit increased left ventricular dilation and reduced fibrosis after aldosterone infusion. <i>American Journal of Hypertension</i> , 2004, 17, 188-193.	1.0	66
768	A modification of the staining technique of reticular fibres for image analysis of the cardiac collagen network. <i>Cardiovascular Pathology</i> , 2004, 13, 213-220.	0.7	8
769	The fibrous matrix of ventricular myocardium in hypoplastic left heart syndrome: a quantitative and qualitative analysis. <i>Annals of Thoracic Surgery</i> , 2004, 77, 36-40.	0.7	24
770	Diabetic Cardiomyopathy: Evidence, Mechanisms, and Therapeutic Implications. <i>Endocrine Reviews</i> , 2004, 25, 543-567.	8.9	793
771	Transforming Growth Factor β 2 Receptor Endoglin Is Expressed in Cardiac Fibroblasts and Modulates Profibrogenic Actions of Angiotensin II. <i>Circulation Research</i> , 2004, 95, 1167-1173.	2.0	132
772	Dietary Copper Restriction-Induced Changes in Myocardial Gene Expression and the Effect of Copper Repletion. <i>Experimental Biology and Medicine</i> , 2004, 229, 616-622.	1.1	37
773	Aldosterone antagonism and congestive heart failure: a new look at an old therapy. <i>Current Opinion in Cardiology</i> , 2004, 19, 301-308.	0.8	14
774	The Aldosterone:Renin Ratio in Screening for Primary Aldosteronism. , 2004, 14, 267-276.		36
775	Plasminogen activator inhibitor-1 and transforming growth factor- β 1 in carotid glomus and autonomic ganglia from spontaneously hypertensive rats. <i>Journal of Hypertension</i> , 2004, 22, 1351-1359.	0.3	9
776	Relationship between left ventricular mass and the ACE D/I polymorphism varies according to sodium intake. <i>Journal of Hypertension</i> , 2004, 22, 287-295.	0.3	25
777	The role of the AT1 receptor in the cardiovascular continuum. <i>European Heart Journal Supplements</i> , 2004, 6, h3-h9.	0.0	8

#	ARTICLE	IF	CITATIONS
778	Polymorphism in gene coding for ACE determines different development of myocardial fibrosis in rats. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2004, 286, H498-H506.	1.5	30
780	Cardiac transcriptional response to acute and chronic angiotensin II treatments. <i>Physiological Genomics</i> , 2004, 18, 152-166.	1.0	67
781	Retinoic Acid Supplementation Attenuates Ventricular Remodeling after Myocardial Infarction in Rats. <i>Journal of Nutrition</i> , 2005, 135, 2326-2328.	1.3	42
782	Angiotensin type-2 receptors and cardiovascular function: are angiotensin type-2 receptors protective?. <i>Current Opinion in Cardiology</i> , 2005, 20, 264-269.	0.8	24
783	Irbesartan and atenolol improve diastolic function in patients with hypertensive left ventricular hypertrophy. <i>Journal of Hypertension</i> , 2005, 23, 633-640.	0.3	20
784	Angiotensin II-induced over-activation of p47phox in fibroblasts from hypertensives: which role in the enhanced ERK1/2 responsiveness to angiotensin II?. <i>Journal of Hypertension</i> , 2005, 23, 793-800.	0.3	17
785	Gene variants of aldosterone synthase and hypertension. <i>Journal of Hypertension</i> , 2005, 23, 1957-1959.	0.3	11
786	Collagen deposition in myocardium after inhibition of fibrinolytic activity. <i>Blood Coagulation and Fibrinolysis</i> , 2005, 16, 25-30.	0.5	6
787	Beneficial effect of simvastatin and pravastatin treatment on adverse cardiac remodelling and glomeruli loss in spontaneously hypertensive rats. <i>Clinical Science</i> , 2005, 108, 349-355.	1.8	43
788	Long-Term Effect of Spironolactone on Cardiac Structure as Assessed by Analysis of Ultrasonic Radio-Frequency Signals in Patients With Ventricular Hypertrophy. <i>Circulation Journal</i> , 2005, 69, 1394-1400.	0.7	5
789	Effects of trans α -resveratrol on hypertension-induced cardiac hypertrophy using the partially nephrectomized rat model. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2005, 32, 1049-1054.	0.9	51
790	Antagonists of Aldosterone and Proteinuria in Patients With CKD: An Uncontrolled Pilot Study. <i>American Journal of Kidney Diseases</i> , 2005, 46, 45-51.	2.1	128
791	Longitudinal Left Ventricular Myocardial Dysfunction Assessed by 2D Colour Tissue Doppler Imaging in a Dog with Systemic Hypertension and Severe Arteriosclerosis. <i>Transboundary and Emerging Diseases</i> , 2005, 52, 83-87.	0.6	17
792	Effects of early perturbation of the renin-angiotensin system on cardiovascular remodeling in spontaneously hypertensive rats. <i>Vascular Pharmacology</i> , 2005, 42, 93-98.	1.0	18
793	Role of interleukin-6 in cardiomyocyte/cardiac fibroblast interactions during myocyte hypertrophy and fibroblast proliferation. <i>Journal of Cellular Physiology</i> , 2005, 204, 428-436.	2.0	115
795	Clinical modifiers for heart failure following myocardial infarction. <i>Current Heart Failure Reports</i> , 2005, 2, 165-173.	1.3	2
796	Current treatment options for CHF management: Focus on the renin-angiotensin-aldosterone system. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2005, 7, 3-13.	0.4	3
797	Aldosterone receptor antagonists: Biology and novel therapeutic applications. <i>Current Hypertension Reports</i> , 2005, 7, 206-211.	1.5	8

#	ARTICLE	IF	CITATIONS
798	Cardioprotection by Aldosterone Receptor Antagonism in Heart Failure: 1. The Role of Aldosterone in Heart Failure. <i>Human Physiology</i> , 2005, 31, 706-714.	0.1	4
799	Effects of angiotensin-II receptor blocker candesartan cilexetil in rats with dilated cardiomyopathy. <i>Molecular and Cellular Biochemistry</i> , 2005, 269, 137-142.	1.4	13
800	Simvastatin Regulates Myocardial Cytokine Expression and Improves Ventricular Remodeling in Rats after Acute Myocardial Infarction. <i>Cardiovascular Drugs and Therapy</i> , 2005, 19, 13-21.	1.3	52
801	Oxytalan elastic and collagen fibers during the repair process in experimental nitric oxide inhibition. <i>Clinics</i> , 2005, 60, 85-92.	0.6	6
802	Mineralocorticoid Receptor Antagonism Ameliorates Left Ventricular Diastolic Dysfunction and Myocardial Fibrosis in Mildly Symptomatic Patients With Idiopathic Dilated Cardiomyopathy. <i>Circulation</i> , 2005, 112, 2940-2945.	1.6	236
803	Modulation of Cardiovascular Remodeling with Statins: Fact or Fiction?. <i>Current Vascular Pharmacology</i> , 2005, 3, 69-79.	0.8	24
804	Antihypertensive Therapy: Role of Aldosterone Antagonists. <i>Current Pharmaceutical Design</i> , 2005, 11, 2235-2242.	0.9	8
805	Marked attenuation of production of collagen type I from cardiac fibroblasts by dehydroepiandrosterone. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2005, 288, E1222-E1228.	1.8	26
806	Effects of spironolactone and eprosartan on cardiac remodeling and angiotensin-converting enzyme isoforms in rats with experimental heart failure. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2005, 289, H1351-H1358.	1.5	79
807	Emerging evidence for the role of cardiotrophin-1 in cardiac repair in the infarcted heart. <i>Cardiovascular Research</i> , 2005, 65, 782-792.	1.8	74
808	Myocardial osteopontin expression is associated with collagen fibrillogenesis in human dilated cardiomyopathy. <i>European Journal of Heart Failure</i> , 2005, 7, 755-762.	2.9	49
809	Calcineurinâ€“Nuclear Factor of Activated T Cells Pathwayâ€“Dependent Cardiac Remodeling in Mice Deficient in Guanylyl Cyclase A, a Receptor for Atrial and Brain Natriuretic Peptides. <i>Circulation</i> , 2005, 111, 3095-3104.	1.6	77
810	Somatostatin receptor subtype expression in the human heart: differential expression by myocytes and fibroblasts. <i>Journal of Endocrinology</i> , 2005, 187, 379-386.	1.2	44
811	Reduced Left Ventricular Functional Reserve in Hypertensive Patients With Preserved Function at Rest. <i>Hypertension</i> , 2005, 45, 619-624.	1.3	17
812	Reduced cardiac expression of plasminogen activator inhibitor 1 and transforming growth factor β 1 in obese Zucker rats by perindopril. <i>Heart</i> , 2005, 91, 80-86.	1.2	38
813	Effects of eplerenone on transcriptional factors and mRNA expression related to cardiac remodelling after myocardial infarction. <i>Heart</i> , 2005, 91, 1595-1600.	1.2	31
814	Matrix Proteinâ€“Specific Regulation of Cx43 Expression in Cardiac Myocytes Subjected to Mechanical Load. <i>Circulation Research</i> , 2005, 96, 558-566.	2.0	51
815	Aldosterone, Normotension, and Diastolic Dysfunction. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 5500-5501.	1.8	2

#	ARTICLE	IF	CITATIONS
817	Aldosterone Blunts Human Baroreflex Sensitivity by a Nongenomic Mechanism. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2005, 113, 252-256.	0.6	17
818	Evidence for Abnormal Left Ventricular Structure and Function in Normotensive Individuals with Familial Hyperaldosteronism Type I. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 5070-5076.	1.8	230
819	Involvement of the NF- κ B/Matrix Metalloproteinase Pathway in Cardiac Fibrosis of Mice Lacking Guanylyl Cyclase/Natriuretic Peptide Receptor A. <i>Journal of Biological Chemistry</i> , 2005, 280, 19230-19242.	1.6	87
820	Beneficial Cardiovascular Actions of Eplerenone in the Spontaneously Hypertensive Rat. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2005, 10, 197-203.	1.0	10
821	Effects of trans-resveratrol on hypertension-induced cardiac hypertrophy using the partially nephrectomized rat model. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2005, 32, 1049-1054.	0.9	55
822	Relaxin Reverses Cardiac and Renal Fibrosis in Spontaneously Hypertensive Rats. <i>Hypertension</i> , 2005, 46, 412-418.	1.3	175
823	Effects of Eplerenone, a Selective Aldosterone Blocker, on the Progression of Left Ventricular Dysfunction and Remodeling in Rats with Dilated Cardiomyopathy. <i>Pharmacology</i> , 2005, 73, 81-88.	0.9	26
824	Spirolactone improves lung diffusion in chronic heart failure. <i>European Heart Journal</i> , 2005, 26, 159-164.	1.0	66
825	11 β -Hydroxysteroid dehydrogenase type 2 activity is associated with left ventricular mass in essential hypertension. <i>European Heart Journal</i> , 2005, 26, 498-504.	1.0	21
826	Role and Optimal Dosing of Angiotensin-Converting Enzyme Inhibitor Therapy. <i>Heart Failure Clinics</i> , 2005, 1, 25-37.	1.0	0
827	The mitral L wave: A marker of pseudonormal filling and predictor of heart failure in patients with left ventricular hypertrophy. <i>Journal of the American Society of Echocardiography</i> , 2005, 18, 336-341.	1.2	46
828	The Architecture of the Heart: Myocyte Organization and the Cardiac Extracellular Matrix. , 2005, , 3-21.		13
829	Induction of Cardiac Hypertrophy by a Controlled Reproducible Sutureless Aortocaval Shunt in the Mouse. <i>Journal of Investigative Surgery</i> , 2005, 18, 325-334.	0.6	9
830	The role of endothelin-1 in myocarditis and inflammatory cardiomyopathy: old lessons and new insights. <i>Canadian Journal of Physiology and Pharmacology</i> , 2005, 83, 47-62.	0.7	18
831	Targeting Hypertensive Myocardial Fibrosis. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2005, 12, 225-230.	1.0	0
832	Structural and functional characterisation of cardiac fibroblasts. <i>Cardiovascular Research</i> , 2005, 65, 40-51.	1.8	782
833	Effects of ACE inhibition during fetal development on cardiac microvasculature in adult spontaneously hypertensive rats. <i>International Journal of Cardiology</i> , 2005, 101, 237-242.	0.8	4
834	Increased circulating big endothelin-1, endothelin-1 and atrial natriuretic peptide in infants and children with heart failure secondary to congenital heart disease. <i>International Journal of Cardiology</i> , 2005, 104, 15-20.	0.8	14

#	ARTICLE	IF	CITATIONS
835	Prostacyclin protects against elevated blood pressure and cardiac fibrosis. <i>Cell Metabolism</i> , 2005, 2, 201-207.	7.2	141
836	Prevention of cardiac remodeling after myocardial infarction in transgenic rats deficient in brain angiotensinogen. <i>Journal of Molecular and Cellular Cardiology</i> , 2005, 39, 521-529.	0.9	45
837	Angiotensin II, angiotensin II antagonists and spironolactone and their modulation of cardiac repolarization. <i>Trends in Pharmacological Sciences</i> , 2005, 26, 155-161.	4.0	36
838	Effects of canrenoate plus angiotensin-converting enzyme inhibitors versus angiotensin-converting enzyme inhibitors alone on systolic and diastolic function in patients with acute anterior myocardial infarction. <i>American Heart Journal</i> , 2005, 150, 919.e1-919.e8.	1.2	25
839	Heart failure after long-term supra-ventricular aortic constriction in rats. <i>American Journal of Hypertension</i> , 2005, 18, 202-212.	1.0	46
840	Hypertensive Heart Disease. <i>Hypertension Research</i> , 2005, 28, 191-202.	1.5	146
841	Diastolic Dysfunction in Hypertensive Hearts: Roles of Perivascular Inflammation and Reactive Myocardial Fibrosis. <i>Hypertension Research</i> , 2005, 28, 483-490.	1.5	151
842	Plasma Monitoring of the Myocardial Specific Tissue Inhibitor of Metalloproteinase-4 After Alcohol Septal Ablation in Hypertrophic Obstructive Cardiomyopathy. <i>Journal of Cardiac Failure</i> , 2005, 11, 124-130.	0.7	16
843	Targets for Pharmacological Modulation of Cardiac Fibrosis. , 2005, , 275-310.		1
845	Renin Angiotensin Aldosterone System and Cardiac Extracellular Matrix. , 2005, , 167-180.		0
846	Matrix Metalloproteinases and Myocardial Remodeling. , 2005, , 181-196.		0
847	Metabolic Derangements in the Insulin-Resistant Heart. <i>Journal of the Cardiometabolic Syndrome</i> , 2006, 1, 102-106.	1.7	13
848	Cellular and Molecular Basis of Remodeling in Valvular Heart Diseases. <i>Heart Failure Clinics</i> , 2006, 2, 415-424.	1.0	13
849	Section 7: Heart Failure in Patients With Left Ventricular Systolic Dysfunction. <i>Journal of Cardiac Failure</i> , 2006, 12, e38-e57.	0.7	21
850	Diuretic Use, Progressive Heart Failure, and Death in Patients in the DIG Study. <i>Journal of Cardiac Failure</i> , 2006, 12, 327-332.	0.7	86
851	Cardiac fibroblasts: friend or foe?. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2006, 291, H1015-H1026.	1.5	367
852	Chronic angiotensin-(1 ⁷) prevents cardiac fibrosis in DOCA-salt model of hypertension. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2006, 290, H2417-H2423.	1.5	182
853	Role of Aldosterone in Left Ventricular Hypertrophy in Hypertension. <i>American Journal of Hypertension</i> , 2006, 19, 13-18.	1.0	115

#	ARTICLE	IF	CITATIONS
854	Cardiac Consequences of Aldosterone Excess In Human Hypertension. American Journal of Hypertension, 2006, 19, 10-12.	1.0	22
855	Tissue Velocity Echocardiography Shows Early Improvement in Diastolic Function With Irbesartan and Atenolol Therapy in Patients With Hypertensive Left Ventricular Hypertrophy Results From the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA). American Journal of Hypertension, 2006, 19, 927-936.	1.0	45
856	Rationale and design: The VALsartan In Diastolic Dysfunction (VALIDD) Trial: Evolving the management of diastolic dysfunction in hypertension. American Heart Journal, 2006, 152, 246-252.	1.2	22
857	Aortic stiffness correlates with an increased extracellular matrix turnover in patients with dilated cardiomyopathy. American Heart Journal, 2006, 152, 93.e1-93.e6.	1.2	23
858	Expression of procollagen C-proteinase enhancer-1 in the remodeling rat heart is stimulated by aldosterone. International Journal of Biochemistry and Cell Biology, 2006, 38, 358-365.	1.2	38
859	Effect of long-term hyperhomocysteinemia on myocardial structure and function in hypertensive rats. Cardiovascular Pathology, 2006, 15, 75-82.	0.7	49
860	Equine endometrial fibrosis correlates with 11 β -HSD2, TGF- β 1 and ACE activities. Molecular and Cellular Endocrinology, 2006, 248, 104-108.	1.6	13
861	Reverse left ventricular remodeling by intermittent dobutamine infusions and amiodarone in end-stage heart failure due to idiopathic dilated cardiomyopathy. International Journal of Cardiology, 2006, 108, 237-243.	0.8	9
862	O papel do acúmulo de colágeno no interstício miocárdico na sobrevida dos pacientes com cardiomiopatia dilatada idiopática e chagásica. Arquivos Brasileiros De Cardiologia, 2006, 87, 757-762.	0.3	9
863	Beneficial Effects of Angiotensin II AT1 Blocker on Cardiovascular Adverse Remodeling Due to Nitric Oxide Synthesis Blockade. International Journal of Morphology, 2006, 24, 309.	0.1	3
865	Aldosterone Antagonism in the Pharmacological Management of Chronic Heart Failure. , 0, , 82-103.		0
866	Management of Diastolic Dysfunction. , 0, , 250-265.		0
867	Efficacy of Low-Dose Continuous Infusion of α -Human Atrial Natriuretic Peptide (hANP) During Cardiac Surgery Possibility of Postoperative Left Ventricular Remodeling Effect. Circulation Journal, 2006, 70, 1426-1431.	0.7	33
868	Effect of Obstructive Sleep Apnea on Aortic Elastic Parameters. Circulation Journal, 2006, 70, 737-743.	0.7	31
869	Effects of Spironolactone During an Angiotensin II Receptor Blocker Treatment on the Left Ventricular Mass Reduction in Hypertensive Patients With Concentric Left Ventricular Hypertrophy. Circulation Journal, 2006, 70, 995-1000.	0.7	38
870	Epidemiology, Pathophysiology, Prognosis, and Treatment of Systolic and Diastolic Heart Failure. Cardiology in Review, 2006, 14, 108-124.	0.6	100
871	Combined Effects of Low-Dose Spironolactone and Captopril Therapy in a Rat Model of Genetic Hypertrophic Cardiomyopathy. Journal of Cardiovascular Pharmacology, 2006, 48, 265-273.	0.8	31
872	Effect of Intermittent Administration of Sustained Release Isosorbide Dinitrate (sr-ISDN) in Rats with Pressure-Overload Heart. Journal of Veterinary Medical Science, 2006, 68, 213-217.	0.3	2

#	ARTICLE	IF	CITATIONS
873	Eplerenone: A Selective Aldosterone Receptor Antagonist (SARA). <i>Cardiovascular Drug Reviews</i> , 2001, 19, 185-200.	4.4	95
874	The Possible Role of Caspase-3 in Pathological and Physiological Cardiac Hypertrophy in Rats. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2006, 99, 418-424.	1.2	36
875	All-trans retinoic acid inhibited angiotensin II-induced increase in cell growth and collagen secretion of neonatal cardiac fibroblasts ¹ . <i>Acta Pharmacologica Sinica</i> , 2006, 27, 423-429.	2.8	18
876	Angiotensin II Type 1 Receptor Blocker Prevents Atrial Structural Remodeling in Rats with Hypertension Induced by Chronic Nitric Oxide Inhibition. <i>Hypertension Research</i> , 2006, 29, 277-284.	1.5	64
877	Plasma Aldosterone in Hypertensive Patients on Chronic Hemodialysis: Distribution, Determinants and Impact on Survival. <i>Hypertension Research</i> , 2006, 29, 597-604.	1.5	17
878	Pressure Overload-Induced Transient Oxidative Stress Mediates Perivascular Inflammation and Cardiac Fibrosis through Angiotensin II. <i>Hypertension Research</i> , 2006, 29, 711-718.	1.5	103
879	Role of transforming growth factor- β^2 in the progression of heart failure. <i>Cellular and Molecular Life Sciences</i> , 2006, 63, 2584-2596.	2.4	129
880	Aldosterone breakthrough during ras blockade: A role for endothelins and their antagonists?. <i>Current Hypertension Reports</i> , 2006, 8, 262-268.	1.5	21
881	What is the Optimal Angiotensin-Converting Enzyme Inhibitor Dose in Heart Failure?. <i>Congestive Heart Failure</i> , 2006, 12, 213-218.	2.0	4
882	Relation of Loop Diuretic Dose to Mortality in Advanced Heart Failure. <i>American Journal of Cardiology</i> , 2006, 97, 1759-1764.	0.7	350
883	Relation of Arterial Stiffness to Left Ventricular Diastolic Function and Cardiovascular Risk Prediction in Patients ≥ 65 Years of Age. <i>American Journal of Cardiology</i> , 2006, 98, 1387-1392.	0.7	123
884	ACE2: A novel therapeutic target for cardiovascular diseases. <i>Progress in Biophysics and Molecular Biology</i> , 2006, 91, 163-198.	1.4	81
885	BNP-induced activation of cGMP in human cardiac fibroblasts: Interactions with fibronectin and natriuretic peptide receptors. <i>Journal of Cellular Physiology</i> , 2006, 209, 943-949.	2.0	55
886	Growth Hormone Replacement Attenuates Diastolic Dysfunction and Cardiac Angiotensin II Expression in Senescent Rats. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2006, 61, 28-35.	1.7	69
887	Differential Role of Rho-Kinase in Pathological and Physiological Cardiac Hypertrophy in Rats. <i>Pharmacology</i> , 2006, 78, 91-97.	0.9	26
888	Selective matrix metalloproteinase inhibition attenuates progression of left ventricular dysfunction and remodeling in dogs with chronic heart failure. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2006, 290, H2522-H2527.	1.5	35
889	Age-related changes in cardiac structure and function in Fischer 344 \times Brown Norway hybrid rats. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2006, 290, H304-H311.	1.5	78
890	Subcellular Remodeling as a Viable Target for the Treatment of Congestive Heart Failure. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2006, 11, 31-45.	1.0	51

#	ARTICLE	IF	CITATIONS
891	Myocardial dysfunction with increased ventricular compliance in volume overload hypertrophy. <i>European Journal of Heart Failure</i> , 2006, 8, 784-789.	2.9	12
892	Cardiac myofibroblasts differentiated in 3D culture exhibit distinct changes in collagen I production, processing, and matrix deposition. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2006, 291, H2924-H2932.	1.5	54
893	Type VI collagen induces cardiac myofibroblast differentiation: implications for postinfarction remodeling. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2006, 290, H323-H330.	1.5	138
894	Activation of AMP-Activated Protein Kinase Enhances Angiotensin II-Induced Proliferation in Cardiac Fibroblasts. <i>Hypertension</i> , 2006, 47, 265-270.	1.3	29
896	Aldosterone Blockade Over and Above ACE-Inhibitors in Patients with Coronary Artery Disease but without Heart Failure. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2006, 7, 20-30.	1.0	12
897	The Resurgence of Aldosterone in Hypertension and Cardiovascular Disease. <i>Current Hypertension Reviews</i> , 2006, 2, 21-32.	0.5	1
898	Aldosterone and the Pathogenesis of Hypertension. <i>Current Hypertension Reviews</i> , 2006, 2, 113-122.	0.5	2
899	Perivascular Inflammation and Hypertensive Cardiovascular Remodeling. <i>Current Hypertension Reviews</i> , 2006, 2, 263-269.	0.5	3
900	Metabolic Derangements in the Insulin-Resistant Heart. <i>The American Journal of Geriatric Cardiology</i> , 2006, 15, 102-106.	0.7	7
901	LOX-1 deletion alters signals of myocardial remodeling immediately after ischemia-reperfusion. <i>Cardiovascular Research</i> , 2007, 76, 292-302.	1.8	54
902	Sodium-Hydrogen Exchanger, Cardiac Overload, and Myocardial Hypertrophy. <i>Circulation</i> , 2007, 115, 1090-1100.	1.6	145
903	Globular Adiponectin Activates Nuclear Factor- κ B and Activating Protein-1 and Enhances Angiotensin II-Induced Proliferation in Cardiac Fibroblasts. <i>Diabetes</i> , 2007, 56, 804-808.	0.3	67
904	Aldosterone promotes proximal tubular cell apoptosis: role of oxidative stress. <i>American Journal of Physiology - Renal Physiology</i> , 2007, 293, F1065-F1071.	1.3	67
905	Cardiac response to pressure overload in 129S1/SvImJ and C57BL/6J mice: temporal- and background-dependent development of concentric left ventricular hypertrophy. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2007, 292, H2119-H2130.	1.5	117
906	Rapid effects of aldosterone on clonal human vascular smooth muscle cells. <i>American Journal of Physiology - Cell Physiology</i> , 2007, 292, C788-C794.	2.1	56
907	Increased Cx43 and Angiogenesis in Exercised Mouse Hearts. <i>International Journal of Sports Medicine</i> , 2007, 28, 749-755.	0.8	36
908	Elevated cardiac tissue level of aldosterone and mineralocorticoid receptor in diastolic heart failure: beneficial effects of mineralocorticoid receptor blocker. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2007, 292, R946-R954.	0.9	98
909	Anabolic steroids induce cardiac renin-angiotensin system and impair the beneficial effects of aerobic training in rats. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2007, 293, H3575-H3583.	1.5	95

#	ARTICLE	IF	CITATIONS
910	From Anreps Phenomenon to Myocardial Hypertrophy: Role of the Na ⁺ /H ⁺ Exchanger. <i>Current Cardiology Reviews</i> , 2007, 3, 149-164.	0.6	7
911	Lessons from EuroHeart Failure Survey. <i>European Heart Journal</i> , 2007, 28, 1037-1037.	1.0	2
912	Drug Insight: aldosterone-receptor antagonists in heart failure—the journey continues. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2007, 4, 368-378.	3.3	17
913	Reduction of QTc Dispersion by the Angiotensin II Receptor Blocker Valsartan May Be Related to Its Anti-Oxidative Stress Effect in Patients with Essential Hypertension. <i>Hypertension Research</i> , 2007, 30, 307-313.	1.5	29
914	Prehypertensive Renin-Angiotensin-Aldosterone System Blockade in Spontaneously Hypertensive Rats Ameliorates the Loss of Long-Term Vascular Function. <i>Hypertension Research</i> , 2007, 30, 853-861.	1.5	17
915	Inhibition of NF- κ B improves left ventricular remodeling and cardiac dysfunction after myocardial infarction. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2007, 292, H530-H538.	1.5	105
916	Mounting Evidence That Fibrosis Generates a Major Mechanism for Atrial Fibrillation. <i>Circulation Research</i> , 2007, 101, 743-745.	2.0	53
917	Activation of protective and damaging components of the cardiac renin-angiotensin system after myocardial infarction in experimental diabetes. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2007, 8, 66-73.	1.0	4
918	Additive Effects of Spironolactone and Candesartan on Cardiac Sympathetic Nerve Activity and Left Ventricular Remodeling in Patients with Congestive Heart Failure. <i>Journal of Nuclear Medicine</i> , 2007, 48, 1993-2000.	2.8	45
919	Drospirenone and its antialdosterone properties. <i>Climacteric</i> , 2007, 10, 11-18.	1.1	71
920	Plasma Osteoprotegerin Levels in the General Population. <i>Hypertension</i> , 2007, 49, 1392-1398.	1.3	74
921	Is There an Unrecognized Epidemic of Primary Aldosteronism? (Con). <i>Hypertension</i> , 2007, 50, 454-458.	1.3	48
922	Role of Subcellular Remodeling in Cardiac Dysfunction due to Congestive Heart Failure. <i>Medical Principles and Practice</i> , 2007, 16, 81-89.	1.1	17
923	p21 ^{waf1/cip1/sdi1} as a Central Regulator of Inducible Smooth Muscle Actin Expression and Differentiation of Cardiac Fibroblasts to Myofibroblasts. <i>Molecular Biology of the Cell</i> , 2007, 18, 4837-4846.	0.9	40
924	Effect of Long-term Administration of a Prostacyclin Analogue (Beraprost Sodium) on Myocardial Fibrosis in Dahl Rats. <i>Journal of Veterinary Medical Science</i> , 2007, 69, 1271-1276.	0.3	12
925	Efficacy of Continuous Low-Dose hANP Administration in Patients Undergoing Emergent Coronary Artery Bypass Grafting for Acute Coronary Syndrome. <i>Circulation Journal</i> , 2007, 71, 1401-1407.	0.7	43
926	Diacylglycerol Kinase .XI. Attenuates Pressure Overload-Induced Cardiac Hypertrophy. <i>Circulation Journal</i> , 2007, 71, 276-282.	0.7	39
927	Left Ventricular Hypertrophy and Geometry in Untreated Essential Hypertension is Associated With Blood Levels of Aldosterone and Procollagen Type III Amino-Terminal Peptide. <i>Circulation Journal</i> , 2007, 71, 716-721.	0.7	37

#	ARTICLE	IF	CITATIONS
928	Errata. Journal of Hypertension, 2007, 25, 1524.	0.3	40
929	Novel therapies blocking the renin-angiotensin-aldosterone system in the management of hypertension and related disorders. Journal of Hypertension, 2007, 25, 25-35.	0.3	47
930	Echocardiographic left ventricular hypertrophy in hypertension: marker for future events or mediator of events?. Current Opinion in Cardiology, 2007, 22, 329-334.	0.8	66
931	Angiotensin Receptor Blockers in Chronic Heart Failure: Clinical Implications and Molecular Mechanisms. Current Cardiology Reviews, 2007, 3, 296-303.	0.6	0
932	Transient prehypertensive treatment in spontaneously hypertensive rats: a comparison of spironolactone and losartan regarding long-term blood pressure and target organ damage. Journal of Hypertension, 2007, 25, 2504-2511.	0.3	22
933	Aldosterone Antagonism Fails to Attenuate Age-Associated Left Ventricular Fibrosis. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2007, 62, 382-388.	1.7	4
934	Eplerenone Attenuates Myocardial Fibrosis in the Angiotensin II-Induced Hypertensive Mouse: Involvement of Tenascin-C Induced by Aldosterone-Mediated Inflammation. Journal of Cardiovascular Pharmacology, 2007, 49, 261-268.	0.8	78
935	The involvement of transforming growth factor- β 1 secretion in Urotensin II-induced collagen synthesis in neonatal cardiac fibroblasts. Regulatory Peptides, 2007, 140, 88-93.	1.9	31
936	Renin-Angiotensin System Blockade: Therapeutic Implications Beyond Blood Pressure Control. Journal of Clinical Hypertension, 2007, 9, 2-3.	1.0	1
937	Clinical and echocardiographic correlates of plasma procollagen type III amino-terminal peptide levels in the community. American Heart Journal, 2007, 154, 291-297.	1.2	39
938	Effects of ACE Inhibition and β -Blockade on Plasminogen Activator Inhibitor-1 and Transforming Growth Factor- β 1 in Carotid Glomus and Autonomic Ganglia in Hypertensive Rats. American Journal of Hypertension, 2007, 20, 326-334.	1.0	4
939	Arginine vasopressin increases iNOS-NO system activity in cardiac fibroblasts through NF- κ B activation and its relation with myocardial fibrosis. Life Sciences, 2007, 81, 327-335.	2.0	39
940	Thyroid hormone induces myocardial matrix degradation by activating matrix metalloproteinase-1. Matrix Biology, 2007, 26, 269-279.	1.5	52
941	VALIDD should not invalidate angiotensin-receptor blockers. Lancet, The, 2007, 369, 2053-2054.	6.3	5
942	Infant vitamin A supplementation: consensus and controversy. Lancet, The, 2007, 369, 2054-2056.	6.3	3
943	Aldosterone Induces Elastin Production in Cardiac Fibroblasts through Activation of Insulin-Like Growth Factor-I Receptors in a Mineralocorticoid Receptor-Independent Manner. American Journal of Pathology, 2007, 171, 809-819.	1.9	36
944	Velocity vector imaging in assessing myocardial systolic function of hypertensive patients with left ventricular hypertrophy. Canadian Journal of Cardiology, 2007, 23, 957-961.	0.8	50
945	Genetic Forms of Primary Aldosteronism. High Blood Pressure and Cardiovascular Prevention, 2007, 14, 75-81.	1.0	4

#	ARTICLE	IF	CITATIONS
946	Spironolactone Reduced Arrhythmia and Maintained Magnesium Homeostasis in Patients With Congestive Heart Failure. <i>Journal of Cardiac Failure</i> , 2007, 13, 170-177.	0.7	84
947	Angiotensin II Antagonist in Paroxysmal Atrial Fibrillation (ANTIPAF) Trial. <i>Clinical Drug Investigation</i> , 2007, 27, 697-705.	1.1	34
948	Aldosterone antagonists in heart failure. <i>British Journal of Cardiac Nursing</i> , 2007, 2, 342-350.	0.0	4
950	Inhibitors of Steroidal Cytochrome P450 Enzymes as Targets for Drug Development. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2007, 2, 31-58.	0.8	48
951	Cardiac-specific overexpression of diacylglycerol kinase β attenuates left ventricular remodeling and improves survival after myocardial infarction. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2007, 292, H1105-H1112.	1.5	29
952	Pomegranate flower: a unique traditional antidiabetic medicine with dual PPAR- α activator properties. <i>Diabetes, Obesity and Metabolism</i> , 2007, 10, 070216060939001-???	2.2	80
953	Endogenous corticosteroid biosynthesis in subjects after bilateral adrenalectomy. <i>Clinical Endocrinology</i> , 2007, 66, 659-665.	1.2	10
954	Statins: a perspective for left ventricular hypertrophy treatment. <i>European Journal of Clinical Investigation</i> , 2007, 37, 681-691.	1.7	34
955	The renin-angiotensin system and angiotensin convertin enzyme (ACE) inhibitors.. <i>Anaesthesia</i> , 1994, 49, 613-622.	1.8	17
956	Matrine Induces Apoptosis in Angiotensin II-Stimulated Hyperplasia of Cardiac Fibroblasts: Effects on Bcl-2/Bax Expression and Caspase-3 Activation. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2007, 101, 1-8.	1.2	54
957	The Role of Cardiac Tissue Alignment in Modulating Electrical Function. <i>Journal of Cardiovascular Electrophysiology</i> , 2007, 18, 1323-1329.	0.8	71
958	Association of β -Blocker Dose with Serum Procollagen Concentrations and Cardiac Response to Spironolactone in Patients with Heart Failure. <i>Pharmacotherapy</i> , 2007, 27, 801-812.	1.2	5
959	Markers of Cardiac Collagen Turnover Are Similar in Patients With Mild and More Severe Symptoms of Heart Failure. <i>Congestive Heart Failure</i> , 2007, 13, 275-279.	2.0	6
960	Treatment of Heart Failure with Normal Left Ventricular Ejection Fraction. <i>Comprehensive Therapy</i> , 2007, 33, 223-230.	0.2	2
961	Endocardial endothelial cells stimulate proliferation and collagen synthesis of cardiac fibroblasts. <i>Cell Biochemistry and Biophysics</i> , 2007, 47, 65-72.	0.9	22
962	Effect of Long-term Monotherapy with the Aldosterone Receptor Blocker Eplerenone on Cytoskeletal Proteins and Matrix Metalloproteinases in Dogs with Heart Failure. <i>Cardiovascular Drugs and Therapy</i> , 2007, 21, 415-422.	1.3	22
963	Optimal use of diuretics in patients with heart failure. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2007, 9, 332-342.	0.4	10
964	Adaptations in autonomic function during exercise training in heart failure. <i>Heart Failure Reviews</i> , 2008, 13, 51-60.	1.7	86

#	ARTICLE	IF	CITATIONS
965	Relationship between early diastolic strain rate imaging and left ventricular geometric patterns in hypertensive patients. <i>Heart and Vessels</i> , 2008, 23, 271-278.	0.5	20
967	Rational use of diuretics in acute decompensated heart failure. <i>Current Heart Failure Reports</i> , 2008, 5, 153-162.	1.3	15
968	Angiotensin-(1-7) as an antihypertensive, antifibrotic target. <i>Current Hypertension Reports</i> , 2008, 10, 227-232.	1.5	37
969	Interleukin-18 stimulates fibronectin expression in primary human cardiac fibroblasts via PI3K-dependent NF- κ B activation. <i>Journal of Cellular Physiology</i> , 2008, 215, 697-707.	2.0	65
970	Extracellular matrix profiles in the progression to heart failure. <i>Acta Physiologica</i> , 2008, 194, 3-21.	1.8	83
971	The IL-33/ST2 pathway: therapeutic target and novel biomarker. <i>Nature Reviews Drug Discovery</i> , 2008, 7, 827-840.	21.5	634
972	Pharmacotherapy for Heart Failure with Left Ventricular Dysfunction: Beyond Angiotensin-Converting Enzyme Inhibitors and β -Blockers. <i>Pharmacotherapy</i> , 2008, 28, 920-931.	1.2	3
973	Insertion/deletion (I/D) polymorphism at the locus for angiotensin converting enzyme and myocardial infarction. <i>Clinical Genetics</i> , 1993, 44, 292-297.	1.0	97
974	Comparative effects of torasemide and furosemide in rats with heart failure. <i>Biochemical Pharmacology</i> , 2008, 75, 649-659.	2.0	44
975	Torasemide, a long-acting loop diuretic, reduces the progression of myocarditis to dilated cardiomyopathy. <i>European Journal of Pharmacology</i> , 2008, 581, 121-131.	1.7	31
976	Fluvastatin decreases cardiac fibrosis possibly through regulation of TGF- β 1/Smad 7 expression in the spontaneously hypertensive rats. <i>European Journal of Pharmacology</i> , 2008, 587, 196-203.	1.7	38
977	Sudden Cardiac Death and the Role of Medical Therapy. <i>Progress in Cardiovascular Diseases</i> , 2008, 50, 420-438.	1.6	29
978	Rationale for and Design of the CREATIVE-AF Trial. <i>Clinical Drug Investigation</i> , 2008, 28, 565-572.	1.1	1
979	Noninvasive Imaging of Angiotensin Receptors After Myocardial Infarction. <i>JACC: Cardiovascular Imaging</i> , 2008, 1, 354-362.	2.3	71
980	Prognostic Implications of Left Ventricular Mass and Geometry Following Myocardial Infarction. <i>JACC: Cardiovascular Imaging</i> , 2008, 1, 582-591.	2.3	227
982	Role and Optimal Dosing of Angiotensin-Converting Enzyme Inhibitors in Heart Failure. <i>Cardiology Clinics</i> , 2008, 26, 1-14.	0.9	20
983	Reduced isoproterenol-induced renin-angiotensin changes and extracellular matrix deposition in hearts of TGR(A1 α 7)3292 rats. <i>Journal of the American Society of Hypertension</i> , 2008, 2, 341-348.	2.3	24
984	Arterial Hypertension and Cardiac Damage. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2008, 15, 141-170.	1.0	10

#	ARTICLE	IF	CITATIONS
985	Hypertension and Valvular Heart Disease. , 2008, , 233-246.		1
986	Review: Atrial fibrillation and renin-angiotensin system. Therapeutic Advances in Cardiovascular Disease, 2008, 2, 215-223.	1.0	13
987	A Lifetime of Aldosterone Excess: Long-Term Consequences of Altered Regulation of Aldosterone Production for Cardiovascular Function. Endocrine Reviews, 2008, 29, 133-154.	8.9	165
988	Influence of diabetes on the maintenance of sinus rhythm after a successful direct current cardioversion in patients with atrial fibrillation. QJM - Monthly Journal of the Association of Physicians, 2008, 101, 181-187.	0.2	18
989	The Aging Cardiomyocyte: A Mini-Review. Gerontology, 2008, 54, 24-31.	1.4	94
991	Myocardial collagen metabolism in failing hearts before and during cardiac resynchronization therapy. European Journal of Heart Failure, 2008, 10, 878-883.	2.9	28
992	All-trans retinoic acid prevents development of cardiac remodeling in aortic banded rats by inhibiting the renin-angiotensin system. American Journal of Physiology - Heart and Circulatory Physiology, 2008, 294, H633-H644.	1.5	73
993	Blood pressure versus direct mineralocorticoid effects on kidney inflammation and fibrosis in DOCA-salt hypertension. Nephrology Dialysis Transplantation, 2008, 23, 3456-3463.	0.4	41
994	Pharmacological Intervention for Prevention of Left Ventricular Remodeling and Improving Prognosis in Myocardial Infarction. Circulation, 2008, 118, 2710-2718.	1.6	53
995	The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart, 2008, 94, 573-580.	1.2	170
996	Myocardial Protection Against Pressure Overload in Mice Lacking Bach1, a Transcriptional Repressor of Heme Oxygenase-1. Hypertension, 2008, 51, 1570-1577.	1.3	70
997	Management of Volume Overload in Acute Heart Failure: Diuretics and Ultrafiltration. , 2008, , 503-518.		1
998	Early expression of monocyte chemoattractant protein-1 correlates with the onset of isoproterenol-induced cardiac fibrosis in rats with distinct angiotensin-converting enzyme polymorphism. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2008, 9, 154-162.	1.0	10
999	Subcellular remodelling may induce cardiac dysfunction in congestive heart failure. Cardiovascular Research, 2008, 81, 429-438.	1.8	86
1000	Cardiac Patch Engineering. , 2008, , 542-551.		0
1001	Rapidly Reversible Myocardial Edema in Patients with Acromegaly: Assessment with Ultrafast T2 Mapping in a Single-Breath-Hold MRI Sequence. American Journal of Roentgenology, 2008, 190, 1576-1582.	1.0	40
1002	Diacylglycerol Kinase .ZETA.Rescues G.ALPHA.q-Induced Heart Failure in Transgenic Mice. Circulation Journal, 2008, 72, 309-317.	0.7	23
1003	Role of the Insulin-Like Growth Factor 1 (IGF1)/Phosphoinositide-3-Kinase (PI3K) Pathway Mediating Physiological Cardiac Hypertrophy. Novartis Foundation Symposium, 2008, , 90-117.	1.2	24

#	ARTICLE	IF	CITATIONS
1004	Hypertensive Left Ventricular Hypertrophy Regression: Does It Matter?. <i>Current Hypertension Reviews</i> , 2008, 4, 275-288.	0.5	1
1005	Heart failure in the elderly. <i>Aging Health</i> , 2008, 4, 137-155.	0.3	1
1006	Aortic stiffness for the detection of preclinical left ventricular diastolic dysfunction: pulse wave velocity versus pulse pressure. <i>Journal of Hypertension</i> , 2008, 26, 758-764.	0.3	80
1007	Inhibition of cardiovascular cell proliferation by angiotensin receptor blockers: are all molecules the same?. <i>Journal of Hypertension</i> , 2008, 26, 973-980.	0.3	32
1008	ANGIOTENSIN II AND MYOCARDIAL INFARCTION. <i>Rational Pharmacotherapy in Cardiology</i> , 2008, 4, 105-110.	0.3	2
1009	Cardiac resynchronization therapy in chronic heart failure. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2008, 69, 392-398.	0.2	1
1010	Early signals after stretch leading to cardiac hypertrophy. Key role of NHE-1. <i>Frontiers in Bioscience - Landmark</i> , 2008, Volume, 7096.	3.0	27
1011	Role of Neurohormones. , 2008, , 345-366.		0
1012	Correlação do colágeno intersticial miocárdico do septo do ventrículo direito com a função ventricular em pacientes com cardiomiopatia isquêmica. <i>Arquivos Brasileiros De Cardiologia</i> , 2009, 92, 54-62.	0.3	3
1014	Aldosterone Stimulates Elastogenesis in Cardiac Fibroblasts via Mineralocorticoid Receptor-independent Action Involving the Consecutive Activation of G13, c-Src, the Insulin-like Growth Factor-I Receptor, and Phosphatidylinositol 3-Kinase/Akt. <i>Journal of Biological Chemistry</i> , 2009, 284, 16633-16647.	1.6	43
1015	Blocking aldosterone in heart failure. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2009, 3, 379-385.	1.0	23
1016	Beneficial effects of delayed ivabradine treatment on cardiac anatomical and electrical remodeling in rat severe chronic heart failure. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2009, 296, H435-H441.	1.5	81
1017	Update in Primary Aldosteronism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 3623-3630.	1.8	93
1018	Sodium tanshinone IIA sulfonate attenuates angiotensin II-induced collagen type I expression in cardiac fibroblasts in vitro. <i>Experimental and Molecular Medicine</i> , 2009, 41, 508.	3.2	44
1019	Excess of Glucocorticoid Induces Cardiac Dysfunction via Activating Angiotensin II Pathway. <i>Cellular Physiology and Biochemistry</i> , 2009, 24, 1-10.	1.1	42
1020	Pediatric Myocardial Stunning Underscores the Cardiac Toxicity of Conventional Hemodialysis Treatments. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 790-797.	2.2	91
1021	Long-Term Low-Dose Spironolactone Therapy Is Safe in Oligoanuric Hemodialysis Patients. <i>Cardiology</i> , 2009, 114, 32-38.	0.6	48
1022	Decorin Gene Delivery Inhibits Cardiac Fibrosis in Spontaneously Hypertensive Rats by Modulation of Transforming Growth Factor- β /Smad and p38 Mitogen-Activated Protein Kinase Signaling Pathways. <i>Human Gene Therapy</i> , 2009, 20, 1190-1200.	1.4	83

#	ARTICLE	IF	CITATIONS
1023	Homocysteine and Heart Failure: An Overview. Recent Patents on Cardiovascular Drug Discovery, 2009, 4, 15-21.	1.5	33
1024	Desynchronization: A Novel Model to Induce Heart Failure. Thoracic and Cardiovascular Surgeon, 2009, 57, 441-448.	0.4	4
1025	Impact of type 1 diabetes on cardiac fibroblast activation: enhanced cell cycle progression and reduced myofibroblast content in diabetic myocardium. American Journal of Physiology - Endocrinology and Metabolism, 2009, 297, E1147-E1153.	1.8	17
1026	Aldosterone status associated with insulin resistance in patients with heart failure--data from the ALOFT study. Heart, 2009, 95, 1920-1924.	1.2	29
1027	Human embryonic stem cells and cardiac repair. Transplantation Reviews, 2009, 23, 53-68.	1.2	60
1028	Adiponectin induces interleukin-6 production and activates STAT3 in adult mouse cardiac fibroblasts. Biology of the Cell, 2009, 101, 263-272.	0.7	33
1029	Multiple Ca ²⁺ signaling pathways regulate intracellular Ca ²⁺ activity in human cardiac fibroblasts. Journal of Cellular Physiology, 2010, 223, 68-75.	2.0	56
1030	The Influence of Naturally Occurring Differences in Birthweight on Ventricular Cardiomyocyte Number in Sheep. Anatomical Record, 2009, 292, 29-37.	0.8	33
1031	Therapeutic approaches to diastolic dysfunction. Current Hypertension Reports, 2009, 11, 283-291.	1.5	17
1032	Aldosterone and cardiovascular risk. Current Hypertension Reports, 2009, 11, 450-455.	1.5	21
1033	Molecular imaging of ventricular remodeling. Journal of Nuclear Cardiology, 2009, 16, 456-465.	1.4	0
1034	Cardiac Fibroblasts Regulate Myocardial Proliferation through β 1 Integrin Signaling. Developmental Cell, 2009, 16, 233-244.	3.1	515
1035	Left ventricular hypertrophy induced by overnutrition early in life. Nutrition, Metabolism and Cardiovascular Diseases, 2009, 19, 805-810.	1.1	36
1036	Contrast-enhanced magnetic resonance imaging identifies focal regions of intramyocardial fibrosis in patients with severe aortic valve disease: Correlation with quantitative histopathology. American Heart Journal, 2009, 157, 361-368.	1.2	45
1037	Effect of Spironolactone on Left Ventricular Mass and Aortic Stiffness in Early-Stage Chronic Kidney Disease. Journal of the American College of Cardiology, 2009, 54, 505-512.	1.2	256
1038	Molecular Imaging for Efficacy of Pharmacologic Intervention in Myocardial Remodeling. JACC: Cardiovascular Imaging, 2009, 2, 187-198.	2.3	59
1039	Acute effects of digoxin on plasma aldosterone and cortisol in monkeys. Metabolism: Clinical and Experimental, 2009, 58, 55-61.	1.5	9
1040	Diuretics in Heart Failure. Drugs, 2009, 69, 2451-2461.	4.9	6

#	ARTICLE	IF	CITATIONS
1041	Extracellular Matrix Remodelling in Myocardial Hypertrophy and Failure. High Blood Pressure and Cardiovascular Prevention, 2009, 16, 195-199.	1.0	5
1043	Diastolic Dysfunction as a Link Between Hypertension and Heart Failure. Medical Clinics of North America, 2009, 93, 647-664.	1.1	44
1044	Statin treatment reduces glomerular inflammation and podocyte damage in rat deoxycorticosterone-acetate-salt hypertension. Journal of Hypertension, 2009, 27, 376-385.	0.3	28
1045	Additional salutary effects of the combination of exercise training and an angiotensin-converting enzyme inhibitor on the left ventricular function of spontaneously hypertensive rats. Journal of Hypertension, 2009, 27, 1309-1316.	0.3	5
1046	Cross-sectional relations of multiple biomarkers representing distinct biological pathways to plasma markers of collagen metabolism in the community. Journal of Hypertension, 2009, 27, 1317-1324.	0.3	10
1047	Beneficial effects of telmisartan on left ventricular structure and function in patients with hypertension determined by two-dimensional strain imaging. Journal of Hypertension, 2009, 27, 1892-1899.	0.3	29
1049	Mechanisms of Remodelling A Question of Life (Stem Cell Production) and Death (Myocyte Apoptosis). Circulation Journal, 2009, 73, 1973-1982.	0.7	38
1050	Beneficial Effects of Torasemide on Systolic Wall Stress and Sympathetic Nervous Activity in Asymptomatic or Mildly Symptomatic Patients With Heart Failure: Comparison With Azosemide. Journal of Cardiovascular Pharmacology, 2009, 53, 468-473.	0.8	25
1051	Associations between cardiac target organ damage and microvascular dysfunction: the role of blood pressure. Journal of Hypertension, 2010, 28, 952-958.	0.3	29
1052	Adherence to Aldosterone-Blocking Agents in Patients with Heart Failure. American Journal of Therapeutics, 2010, 17, 446-454.	0.5	11
1053	Stromal Cell Biology - A Way to Understand the Evolution of Cardiovascular Diseases -. Circulation Journal, 2010, 74, 1042-1050.	0.7	12
1054	Proteasome inhibitors and cardiac cell growth. Cardiovascular Research, 2010, 85, 321-329.	1.8	53
1055	Clinical practice. European Journal of Pediatrics, 2010, 169, 403-410.	1.3	14
1056	Molecular distinction between physiological and pathological cardiac hypertrophy: Experimental findings and therapeutic strategies. , 2010, 128, 191-227.		694
1057	Peripheral benzodiazepine receptor ligand Ro5-4864 inhibits isoprenaline-induced cardiac hypertrophy in rats. European Journal of Pharmacology, 2010, 644, 146-153.	1.7	16
1058	Effects of polydatin on attenuating ventricular remodeling in isoproterenol-induced mouse and pressure-overload rat models. FÅ-toterapÅ-Åç, 2010, 81, 953-960.	1.1	42
1059	Bâ€type natriuretic peptide and extracellular matrix protein interactions in human cardiac fibroblasts. Journal of Cellular Physiology, 2010, 225, 251-255.	2.0	15
1060	Reninâ€angiotensinâ€aldosterone system blockade for cardiovascular diseases: current status. British Journal of Pharmacology, 2010, 160, 1273-1292.	2.7	277

#	ARTICLE	IF	CITATIONS
1061	AT1-receptor mediated vascular damage in myocardium, kidneys and liver in rats. <i>Pesquisa Veterinaria Brasileira</i> , 2010, 30, 605-611.	0.5	0
1062	Primary aldosteronism: an update. <i>Expert Review of Endocrinology and Metabolism</i> , 2010, 5, 389-402.	1.2	0
1063	Angiotensin-Converting Enzyme 2 Suppresses Pathological Hypertrophy, Myocardial Fibrosis, and Cardiac Dysfunction. <i>Circulation</i> , 2010, 122, 717-728.	1.6	383
1064	Decreased cardiac Ang-(1-7) is associated with salt-induced cardiac remodeling and dysfunction. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2010, 4, 17-25.	1.0	18
1065	Tissue Vitamin A Insufficiency Results in Adverse Ventricular Remodeling after Experimental Myocardial Infarction. <i>Cellular Physiology and Biochemistry</i> , 2010, 26, 523-530.	1.1	36
1066	Aldosterone and Angiogenesis. <i>American Journal of Hypertension</i> , 2010, 23, 940-940.	1.0	2
1067	Protein Kinases as Drug Development Targets for Heart Disease Therapy. <i>Pharmaceuticals</i> , 2010, 3, 2111-2145.	1.7	30
1068	The Impact of Vascular Endothelial Growth Factor and Basic Fibroblast Growth Factor on Cardiac Fibroblasts Grown under Altered Gravity Conditions. <i>Cellular Physiology and Biochemistry</i> , 2010, 26, 1011-1022.	1.1	9
1069	Beneficial effects of olmesartan, an angiotensin II receptor type 1 antagonist, in rats with dilated cardiomyopathy. <i>Experimental Biology and Medicine</i> , 2010, 235, 1338-1346.	1.1	21
1070	Effect of sodium houthuyfonate on inhibiting ventricular remodeling induced by abdominal aortic banding in rats. <i>Canadian Journal of Physiology and Pharmacology</i> , 2010, 88, 693-701.	0.7	18
1071	Association of Serum Osteoprotegerin With Left Ventricular Mass in African American Adults With Hypertension. <i>American Journal of Hypertension</i> , 2010, 23, 767-774.	1.0	18
1072	Tafazzin knockdown causes hypertrophy of neonatal ventricular myocytes. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2010, 299, H210-H216.	1.5	27
1073	Familial Hyperaldosteronism III. <i>Hormone and Metabolic Research</i> , 2010, 42, 424-428.	0.7	31
1074	Effects of Visfatin on Proliferation and Collagen Synthesis in Rat Cardiac Fibroblasts. <i>Hormone and Metabolic Research</i> , 2010, 42, 507-513.	0.7	39
1075	Quantification of Diffuse Myocardial Fibrosis and Its Association With Myocardial Dysfunction in Congenital Heart Disease. <i>Circulation: Cardiovascular Imaging</i> , 2010, 3, 727-734.	1.3	237
1076	The Soluble Interleukin 6 Receptor Takes Its Place in the Pantheon of Interleukin 6 Signaling Proteins. <i>Hypertension</i> , 2010, 56, 193-195.	1.3	8
1077	Novel therapeutic targets for hypertension. <i>Nature Reviews Cardiology</i> , 2010, 7, 431-441.	6.1	101
1078	Tissue ACE inhibition improves microcirculation in remote myocardium after coronary stenosis: MR imaging study in rats. <i>Microvascular Research</i> , 2010, 80, 484-490.	1.1	14

#	ARTICLE	IF	CITATIONS
1079	Modulation of impact of high fat diet in pathological and physiological left ventricular cardiac hypertrophy by fluvastatin. <i>Biomedicine and Pharmacotherapy</i> , 2010, 64, 147-153.	2.5	7
1080	Effect of telmisartan on QT interval variability and autonomic control in hypertensive patients with left ventricular hypertrophy. <i>Biomedicine and Pharmacotherapy</i> , 2010, 64, 516-520.	2.5	22
1081	Impaired Kidney Function and Atrial Fibrillation in Elderly Subjects. <i>Journal of Cardiac Failure</i> , 2010, 16, 55-60.	0.7	42
1083	Silencing MR-1 attenuates inflammatory damage in mice heart induced by AngII. <i>Biochemical and Biophysical Research Communications</i> , 2010, 391, 1573-1578.	1.0	13
1084	Treatment of primary aldosteronism. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2010, 24, 923-932.	2.2	24
1085	Extracellular matrix remodeling in atrial fibrosis: Mechanisms and implications in atrial fibrillation. <i>Journal of Molecular and Cellular Cardiology</i> , 2010, 48, 461-467.	0.9	123
1086	Spironolactone use at discharge was associated with improved survival in hospitalized patients with systolic heart failure. <i>American Heart Journal</i> , 2010, 160, 1156-1162.	1.2	49
1087	Efficacy of Spironolactone on Survival in Dogs with Naturally Occurring Mitral Regurgitation Caused by Myxomatous Mitral Valve Disease. <i>Journal of Veterinary Internal Medicine</i> , 2010, 24, 331-341.	0.6	93
1088	Capillary Supply to the Sinus Node in Subjects with Long-Term Atrial Fibrillation. <i>Annals of Thoracic Surgery</i> , 2010, 89, 38-43.	0.7	16
1089	Invited Commentary. <i>Annals of Thoracic Surgery</i> , 2010, 89, 43.	0.7	1
1090	Rapid vascular effects of steroids – a question of balance?. <i>Canadian Journal of Cardiology</i> , 2010, 26, 22A-26A.	0.8	16
1091	Pathophysiology of heart failure. , 2010, , 55-57.		2
1092	Mechanosensitivity of the Heart. , 2010, , .		9
1093	Late Gadolinium-Enhancement Cardiac Magnetic Resonance Identifies Postinfarction Myocardial Fibrosis and the Border Zone at the Near Cellular Level in Ex Vivo Rat Heart. <i>Circulation: Cardiovascular Imaging</i> , 2010, 3, 743-752.	1.3	156
1094	Fibroblasts Support Functional Integration of Purified Embryonic Stem Cell-Derived Cardiomyocytes into Avital Myocardial Tissue. <i>Stem Cells and Development</i> , 2011, 20, 821-830.	1.1	12
1095	Renin-Angiotensin-Aldosterone Blockade for Cardiovascular Disease Prevention. <i>Cardiology Clinics</i> , 2011, 29, 137-156.	0.9	40
1096	Protective effects of aliskiren in doxorubicin-induced acute cardiomyopathy in rats. <i>Human and Experimental Toxicology</i> , 2011, 30, 102-109.	1.1	26
1097	Urotensin-2 promotes collagen synthesis via ERK1/2-dependent and ERK1/2-independent TGF- β 1 in neonatal cardiac fibroblasts. <i>Cell Biology International</i> , 2011, 35, 93-98.	1.4	22

#	ARTICLE	IF	CITATIONS
1098	Assessment of Myocardial Fibrosis With Cardiovascular Magnetic Resonance. <i>Journal of the American College of Cardiology</i> , 2011, 57, 891-903.	1.2	802
1099	Familial or Genetic Primary Aldosteronism and Gordon Syndrome. <i>Endocrinology and Metabolism Clinics of North America</i> , 2011, 40, 343-368.	1.2	25
1100	Heart Rate and Rhythm. , 2011, , .		8
1101	Control of the Mesenchymal-Derived Cell Phenotype by Ski and Meox2: A Putative Mechanism for Postdevelopmental Phenoconversion. , 2011, , 29-42.		0
1102	Furosemide in chronic advanced heart failure: Intimate friend or cunning foe?. <i>International Journal of Cardiology</i> , 2011, 151, 108-109.	0.8	0
1103	Malnutrition, anemia and renal dysfunction in patients with Chagasic cardiomyopathy. <i>International Journal of Cardiology</i> , 2011, 151, 109-110.	0.8	3
1104	Prevention of Angiotensin II-Mediated Renal Oxidative Stress, Inflammation, and Fibrosis by Angiotensin-Converting Enzyme 2. <i>Hypertension</i> , 2011, 57, 314-322.	1.3	200
1105	Aldosterone Antagonists in Heart Failure. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2011, 16, 150-159.	1.0	13
1106	Alterations in Ventricular Structure. , 2011, , 232-253.		1
1107	Alterations in Ventricular Function. , 2011, , 213-231.		2
1108	Management of Volume Overload in Heart Failure. , 2011, , 650-658.		1
1109	Cyclophilin A: A Mediator of Cardiovascular Pathology. <i>Journal of the Korean Society of Hypertension</i> , 2011, 17, 133.	0.2	2
1110	Heart structure and function in patients with generalized autoimmune diseases: echocardiography with tissue Doppler study. <i>Acta Cardiologica</i> , 2011, 66, 159-165.	0.3	30
1111	Role of plasma aldosterone concentration in regression of left-ventricular mass following antihypertensive medication. <i>Journal of Hypertension</i> , 2011, 29, 357-363.	0.3	18
1112	Anabolic Steroid Associated to Physical Training Induces Deleterious Cardiac Effects. <i>Medicine and Science in Sports and Exercise</i> , 2011, 43, 1836-1848.	0.2	28
1113	Aldosterone as a modulator of immunity. <i>Journal of Hypertension</i> , 2011, 29, 1684-1692.	0.3	57
1114	Spirolactone use at discharge was associated with improved survival in hospitalized patients with systolic heart failure. <i>Yearbook of Cardiology</i> , 2011, 2011, 325-328.	0.0	0
1116	Spirolactone use at discharge was associated with improved survival in hospitalized patients with systolic heart failure. <i>Yearbook of Medicine</i> , 2011, 2011, 399-402.	0.1	0

#	ARTICLE	IF	CITATIONS
1117	Spironolactone Decreases Isoproterenol-Induced Ventricular Fibrosis and Matrix Metalloproteinase-2 in Rats. <i>Biological and Pharmaceutical Bulletin</i> , 2011, 34, 61-65.	0.6	15
1118	Mineralocorticoid antagonism: a novel way to treat sarcopenia and physical impairment in older people?. <i>Clinical Endocrinology</i> , 2011, 75, 725-729.	1.2	34
1119	Unraveling the mechanisms underlying the rapid vascular effects of steroids: sorting out the receptors and the pathways. <i>British Journal of Pharmacology</i> , 2011, 163, 1163-1169.	2.7	35
1120	Left Ventricular Function in Hypertension: New Insight by Speckle Tracking Echocardiography. <i>Echocardiography</i> , 2011, 28, 649-657.	0.3	120
1121	Mitochondrial cyclophilin-D as a potential therapeutic target for post-myocardial infarction heart failure. <i>Journal of Cellular and Molecular Medicine</i> , 2011, 15, 2443-2451.	1.6	58
1122	Assessment of Myocardial Ischemia with Cardiovascular Magnetic Resonance. <i>Progress in Cardiovascular Diseases</i> , 2011, 54, 191-203.	1.6	22
1123	Prevalence of Left Ventricular Systolic Dysfunction in Adults With Repaired Tetralogy of Fallot. <i>American Journal of Cardiology</i> , 2011, 107, 1215-1220.	0.7	148
1124	MicroRNA Involvement in Immune Activation During Heart Failure. <i>Cardiovascular Drugs and Therapy</i> , 2011, 25, 161-170.	1.3	31
1125	Intradialytic hypotension. <i>Pediatric Nephrology</i> , 2011, 26, 867-879.	0.9	35
1126	Recombinant Human Angiotensin-Converting Enzyme 2 as a New Renin-Angiotensin System Peptidase for Heart Failure Therapy. <i>Current Heart Failure Reports</i> , 2011, 8, 176-183.	1.3	62
1127	Myocardial extravascular extracellular volume fraction measurement by gadolinium cardiovascular magnetic resonance in humans: slow infusion versus bolus. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2011, 13, 16.	1.6	198
1128	Assessment of cardiac dynamics during stress echocardiography by the peak power output-to-left ventricular mass ratio. <i>Future Cardiology</i> , 2011, 7, 347-356.	0.5	9
1130	Mineralocorticoid receptor antagonists for heart failure. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 2801-2815.	0.9	7
1131	Cardiac Dimensions Are Largely Determined by Dietary Salt in Patients with Primary Aldosteronism: Results of a Case-Control Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 2813-2820.	1.8	72
1132	MicroRNAs 29 are involved in the improvement of ventricular compliance promoted by aerobic exercise training in rats. <i>Physiological Genomics</i> , 2011, 43, 665-673.	1.0	157
1133	Therapeutic perspectives in hypertension: novel means for renin-angiotensin-aldosterone system modulation and emerging device-based approaches. <i>European Heart Journal</i> , 2011, 32, 2739-2747.	1.0	96
1134	Excess of glucocorticoid induces myocardial remodeling and alteration of calcium signaling in cardiomyocytes. <i>Journal of Endocrinology</i> , 2011, 209, 105-114.	1.2	37
1135	Suppression of aldosterone mediates regression of left ventricular hypertrophy in patients with hypertension. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2011, 12, 483-490.	1.0	18

#	ARTICLE	IF	CITATIONS
1136	Long-Term Antihypertensive Effect of Angiotensin-Converting Enzyme Inhibitory Peptide LAP. <i>Kidney and Blood Pressure Research</i> , 2011, 34, 358-364.	0.9	4
1137	Factors influencing left ventricular mass regression in patients with primary aldosteronism post adrenalectomy. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2011, 12, 48-53.	1.0	30
1138	Effects of spironolactone on cardiac sympathetic nerve activity and left ventricular remodelling after reperfusion therapy in patients with first ST-segment elevation myocardial infarction. <i>Heart</i> , 2011, 97, 817-822.	1.2	11
1139	Influence of Taurine on Cardiac Remodeling Induced by Tobacco Smoke Exposure. <i>Cellular Physiology and Biochemistry</i> , 2011, 27, 291-298.	1.1	15
1140	Prognostic Implications of Diuretic Dose in Chronic Heart Failure. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2011, 16, 185-191.	1.0	13
1141	Unilateral adrenalectomy improves urinary protein excretion but does not abolish its relationship to sodium excretion in patients with aldosterone-producing adenoma. <i>Journal of Human Hypertension</i> , 2011, 25, 592-599.	1.0	11
1142	Angiotensin III Stimulates Aldosterone Secretion from Adrenal Gland Partially via Angiotensin II Type 2 Receptor But Not Angiotensin II Type 1 Receptor. <i>Endocrinology</i> , 2011, 152, 1582-1588.	1.4	67
1143	CCR2 mediates the uptake of bone marrow-derived fibroblast precursors in angiotensin II-induced cardiac fibrosis. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2011, 301, H538-H547.	1.5	78
1144	Mineralocorticoid receptor blockade improves diastolic function independent of blood pressure reduction in a transgenic model of RAAS overexpression. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2011, 300, H1484-H1491.	1.5	62
1145	Chronic Antagonism of the Mineralocorticoid Receptor Ameliorates Hypertension and End Organ Damage in a Rodent Model of Salt-Sensitive Hypertension. <i>Clinical and Experimental Hypertension</i> , 2011, 33, 538-547.	0.5	11
1146	Vulnerable Myocardial Interstitium in Patients With Isolated Left Ventricular Hypertrophy and Sudden Cardiac Death: A Postmortem Histological Evaluation. <i>Journal of the American Heart Association</i> , 2012, 1, e001511.	1.6	49
1147	Agonist-Induced Hypertrophy and Diastolic Dysfunction Are Associated With Selective Reduction in Glucose Oxidation. <i>Circulation: Heart Failure</i> , 2012, 5, 493-503.	1.6	136
1148	Cardiac Micro-Computed Tomography Imaging of the Aging Coronary Vasculature. <i>Circulation: Cardiovascular Imaging</i> , 2012, 5, 518-524.	1.3	29
1149	Troponin T and Plasma Collagen Peptides in Heart Failure. <i>Circulation: Heart Failure</i> , 2012, 5, 394-397.	1.6	4
1150	How Cardiomyocytes Make the Heart Old. <i>Current Pharmaceutical Biotechnology</i> , 2012, 13, 2515-2521.	0.9	4
1151	Eplerenone for the treatment of cardiovascular disorders. <i>Expert Review of Cardiovascular Therapy</i> , 2012, 10, 831-838.	0.6	3
1152	Inhibition of Signal Transducer and Activator of Transcription 3 (STAT3) Attenuates Interleukin-6 (IL-6)-induced Collagen Synthesis and Resultant Hypertrophy in Rat Heart. <i>Journal of Biological Chemistry</i> , 2012, 287, 2666-2677.	1.6	115
1153	Quantifying Cardiac Hemodynamic Stress and Cardiomyocyte Damage in Ischemic and Nonischemic Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2012, 5, 17-24.	1.6	18

#	ARTICLE	IF	CITATIONS
1154	Associations among serum N-terminal procollagen type III concentration, urinary aldosterone-to-creatinine ratio, and ventricular remodeling in dogs with myxomatous mitral valve disease. <i>American Journal of Veterinary Research</i> , 2012, 73, 1765-1774.	0.3	13
1155	Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. <i>European Heart Journal</i> , 2012, 33, 2782-2795.	1.0	148
1156	The role of angiotensin receptor blockers in reducing the risk of cardiovascular disease. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2012, 13, 317-327.	1.0	8
1157	Left ventricle remodeling in men with moderate to severe volume-dependent hypertension. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2012, 13, 426-434.	1.0	8
1158	Left ventricular structure and function in black normotensive type 2 diabetes mellitus patients. <i>Annals of African Medicine</i> , 2012, 11, 84.	0.2	9
1159	Association Between Extracellular Matrix Expansion Quantified by Cardiovascular Magnetic Resonance and Short-Term Mortality. <i>Circulation</i> , 2012, 126, 1206-1216.	1.6	422
1160	Triggers and Anatomical Substrates in the Genesis and Perpetuation of Atrial Fibrillation. <i>Current Cardiology Reviews</i> , 2012, 8, 310-326.	0.6	58
1161	Novel Anti-arrhythmic Medications in the Treatment of Atrial Fibrillation. <i>Current Cardiology Reviews</i> , 2012, 8, 302-309.	0.6	13
1162	Influence of diabetes on efficacy of aliskiren, losartan or both on left ventricular mass regression. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2012, 13, 265-272.	1.0	3
1163	Repopulation of the Heart with New Cardiomyocytes. , 2012, , 105-217.		2
1164	Hypertensive left ventricular hypertrophy. <i>Journal of Hypertension</i> , 2012, 30, 2039-2046.	0.3	24
1165	Artemisinin Attenuates Post-Infarct Myocardial Remodeling by Down-Regulating the NF- κ B Pathway. <i>Tohoku Journal of Experimental Medicine</i> , 2012, 227, 161-170.	0.5	24
1166	Structural Remodeling and Mechanical Function in Heart Failure. <i>Microscopy and Microanalysis</i> , 2012, 18, 50-67.	0.2	38
1167	Loop Diuretic Use at Discharge Is Associated With Adverse Outcomes in Hospitalized Patients With Heart Failure. <i>Circulation Journal</i> , 2012, 76, 1920-1927.	0.7	50
1168	Testosterone improves cardiac function and alters angiotensin II receptors in isoproterenol-induced heart failure. <i>Archives of Cardiovascular Diseases</i> , 2012, 105, 68-76.	0.7	38
1169	Current treatment options in (peri)myocarditis and inflammatory cardiomyopathy. <i>Herz</i> , 2012, 37, 644-656.	0.4	68
1170	Cardiac resynchronization therapy is certainly cardiac therapy, but how much resynchronization and how much atrioventricular delay optimization?. <i>Heart Failure Reviews</i> , 2012, 17, 727-736.	1.7	14
1171	Effect of spironolactone on ventricular arrhythmias in patients with left ventricular systolic dysfunction and implantable cardioverter defibrillators. <i>Indian Heart Journal</i> , 2012, 64, 123-127.	0.2	3

#	ARTICLE	IF	CITATIONS
1172	Manipulating angiotensin metabolism with angiotensin converting enzyme 2 (ACE2) in heart failure. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2012, 9, e141-e148.	0.5	4
1173	Cardioprotective Effects Mediated by Angiotensin II Type 1 Receptor Blockade and Enhancing Angiotensin 1-7 in Experimental Heart Failure in Angiotensin-Converting Enzyme 2 ^{-/-} Null Mice. <i>Hypertension</i> , 2012, 59, 1195-1203.	1.3	97
1174	Myocardial Tissue Characterization Using Magnetic Resonance Noncontrast T1 Mapping in Hypertrophic and Dilated Cardiomyopathy. <i>Circulation: Cardiovascular Imaging</i> , 2012, 5, 726-733.	1.3	286
1175	Cardiac Microinjury Measured by Troponin T Predicts Collagen Metabolism in Adults Aged ≥ 65 Years With Heart Failure. <i>Circulation: Heart Failure</i> , 2012, 5, 406-413.	1.6	12
1176	Influence of AIN-93 diet on mortality and cardiac remodeling after myocardial infarction in rats. <i>International Journal of Cardiology</i> , 2012, 156, 265-269.	0.8	12
1177	Myocardial delayed enhancement in paucisymptomatic nonischemic dilated cardiomyopathy. <i>International Journal of Cardiology</i> , 2012, 157, 43-47.	0.8	51
1178	Efficacy of ACE inhibitors in chronic heart failure with preserved ejection fraction $\geq 40\%$: A meta analysis of 7 prospective clinical studies. <i>International Journal of Cardiology</i> , 2012, 155, 33-38.	0.8	47
1179	Mast cells and metabolic syndrome. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2012, 1822, 14-20.	1.8	78
1180	Altered melusin pathways involved in cardiac remodeling following acute myocardial infarction. <i>Cardiovascular Pathology</i> , 2012, 21, 105-111.	0.7	15
1181	Expanding Role of Mineralocorticoid Receptor Antagonists in the Treatment of Heart Failure. <i>Pharmacotherapy</i> , 2012, 32, 827-837.	1.2	8
1183	Artificial microRNA interference targeting AT1a receptors in paraventricular nucleus attenuates hypertension in rats. <i>Gene Therapy</i> , 2012, 19, 810-817.	2.3	63
1184	Early Activation of Intracellular Signals after Myocardial Stretch: Anrep Effect, Myocardial Hypertrophy and Heart Failure. , 2012, , 327-365.		1
1185	Cell Lineages, Growth and Repair of the Mouse Heart. <i>Results and Problems in Cell Differentiation</i> , 2012, 55, 263-289.	0.2	11
1186	Molecular Imaging of Human ACE-1 Expression in Transgenic Rats. <i>JACC: Cardiovascular Imaging</i> , 2012, 5, 409-418.	2.3	39
1187	Plasma metalloproteinase-9 and restrictive filling pattern as major predictors of outcome in patients with ischemic cardiomyopathy. <i>European Journal of Internal Medicine</i> , 2012, 23, 616-620.	1.0	5
1188	A potential role for integrin signaling in mechanoelectrical feedback. <i>Progress in Biophysics and Molecular Biology</i> , 2012, 110, 196-203.	1.4	43
1189	Pharmacologic management of myxomatous mitral valve disease in dogs. <i>Journal of Veterinary Cardiology</i> , 2012, 14, 165-184.	0.3	42
1190	Biomarkers. <i>Heart Failure Clinics</i> , 2012, 8, 207-224.	1.0	7

#	ARTICLE	IF	CITATIONS
1191	The Epidemiology and Pathophysiology of Heart Failure. <i>Medical Clinics of North America</i> , 2012, 96, 881-890.	1.1	35
1192	Pressure Overload. <i>Heart Failure Clinics</i> , 2012, 8, 21-32.	1.0	39
1193	Ischemia-Reperfusion Injury Leads to Distinct Temporal Cardiac Remodeling in Normal versus Diabetic Mice. <i>PLoS ONE</i> , 2012, 7, e30450.	1.1	33
1194	CD-NP: A Novel Engineered Dual Guanylyl Cyclase Activator with Anti-Fibrotic Actions in the Heart. <i>PLoS ONE</i> , 2012, 7, e52422.	1.1	54
1195	White Blood Cell Transcriptome Correlates With Renal Function in Acute Heart Failure. <i>International Heart Journal</i> , 2012, 53, 117-124.	0.5	3
1196	Arrhythmogenic Implications of Fibroblast-Myocyte Interactions. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2012, 5, 442-452.	2.1	170
1197	Implications of protease activation in cardiac dysfunction and development of genetic cardiomyopathy in hamsters. <i>Canadian Journal of Physiology and Pharmacology</i> , 2012, 90, 995-1004.	0.7	14
1198	Diabetic cardiomyopathy: understanding the molecular and cellular basis to progress in diagnosis and treatment. <i>Heart Failure Reviews</i> , 2012, 17, 325-344.	1.7	287
1199	Role of ACE2 in diastolic and systolic heart failure. <i>Heart Failure Reviews</i> , 2012, 17, 683-691.	1.7	63
1200	Cardiac remodeling and subcellular defects in heart failure due to myocardial infarction and aging. <i>Heart Failure Reviews</i> , 2012, 17, 671-681.	1.7	59
1202	Moderate cardiac-selective overexpression of angiotensin II type 2 receptor protects cardiac functions from ischaemic injury. <i>Experimental Physiology</i> , 2012, 97, 89-101.	0.9	55
1203	Relation of Renal Function to Risk for Incident Atrial Fibrillation in Women. <i>American Journal of Cardiology</i> , 2012, 109, 538-542.	0.7	27
1204	Diastolic dysfunction and heart failure with a preserved ejection fraction: Relevance in critical illness and anaesthesia. <i>Journal of the Saudi Heart Association</i> , 2012, 24, 99-121.	0.2	10
1205	Local renin-angiotensin systems in the genitourinary tract. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2012, 385, 13-26.	1.4	10
1206	Echo-Doppler Assessment of the Biophysical Properties of the Aorta in Children With Chronic Kidney Disease. <i>Pediatric Cardiology</i> , 2013, 34, 1218-1225.	0.6	4
1207	Impact of aldosterone-producing adenoma on cardiac structures in echocardiography. <i>Journal of Echocardiography</i> , 2013, 11, 123-129.	0.4	8
1208	Management of Neurogenic Orthostatic Hypotension in Patients with Autonomic Failure. <i>Drugs</i> , 2013, 73, 1267-1279.	4.9	28
1209	Translational Approach to Heart Failure. , 2013, , .		3

#	ARTICLE	IF	CITATIONS
1210	Inhibition of Platelet Activation by Clopidogrel Prevents Hypertension-Induced Cardiac Inflammation and Fibrosis. <i>Cardiovascular Drugs and Therapy</i> , 2013, 27, 521-530.	1.3	60
1211	Heart Failure with Normal Left Ventricular Ejection Fraction: Basic Principles and Clinical Diagnostics. , 2013, , 25-61.		2
1212	Systemic right ventricles rarely show myocardial scars in cardiac magnetic resonance delayed-enhancement imaging. <i>Clinical Research in Cardiology</i> , 2013, 102, 337-344.	1.5	18
1213	Fibroblast growth factor-23: what we know, what we don't know, and what we need to know. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 2228-2236.	0.4	92
1214	Deficiency of senescence marker protein 30 exacerbates angiotensin II-induced cardiac remodelling. <i>Cardiovascular Research</i> , 2013, 99, 461-470.	1.8	20
1215	Eplerenone in systemic right ventricle: Double blind randomized clinical trial. The evedes study. <i>International Journal of Cardiology</i> , 2013, 168, 5167-5173.	0.8	60
1216	NF- κ B mediated miR-26a regulation in cardiac fibrosis. <i>Journal of Cellular Physiology</i> , 2013, 228, 1433-1442.	2.0	119
1217	Update on diastolic heart failure or heart failure with preserved ejection fraction in the older adults. <i>Annals of Medicine</i> , 2013, 45, 37-50.	1.5	56
1218	3,3'-Diindolymethane ameliorates adriamycin-induced cardiac fibrosis via activation of a BRCA1-dependent anti-oxidant pathway. <i>Pharmacological Research</i> , 2013, 70, 139-146.	3.1	21
1219	Surgical Treatment for Advanced Heart Failure. , 2013, , .		5
1220	Spironolactone Improves the Arrhythmogenic Substrate in Heart Failure by Preventing Ventricular Electrical Activation Delays Associated with Myocardial Interstitial Fibrosis and Inflammation. <i>Journal of Cardiovascular Electrophysiology</i> , 2013, 24, 806-812.	0.8	14
1221	Myocardial Fibrosis as a Key Determinant of Left Ventricular Remodeling in Idiopathic Dilated Cardiomyopathy. <i>Circulation: Cardiovascular Imaging</i> , 2013, 6, 790-799.	1.3	132
1222	Comprehensive Validation of Cardiovascular Magnetic Resonance Techniques for the Assessment of Myocardial Extracellular Volume. <i>Circulation: Cardiovascular Imaging</i> , 2013, 6, 373-383.	1.3	324
1223	Measurement of Viscoelastic Properties of In Vivo Swine Myocardium Using Lamb Wave Dispersion Ultrasound Vibrometry (LDUV). <i>IEEE Transactions on Medical Imaging</i> , 2013, 32, 247-261.	5.4	55
1224	Myocardial Ultrasound Tissue Characterization of Patients With Primary Aldosteronism. <i>Ultrasound in Medicine and Biology</i> , 2013, 39, 54-61.	0.7	17
1225	Standard and etiology-directed evidence-based therapies in myocarditis: state of the art and future perspectives. <i>Heart Failure Reviews</i> , 2013, 18, 761-795.	1.7	45
1226	Diabetic cardiomyopathy. <i>Human and Experimental Toxicology</i> , 2013, 32, 571-590.	1.1	87
1227	The Ski/Zeb2/Meox2 pathway provides a novel mechanism for regulation of the cardiac myofibroblast phenotype. <i>Journal of Cell Science</i> , 2014, 127, 40-9.	1.2	41

#	ARTICLE	IF	CITATIONS
1228	Calreticulin overexpression correlates with integrin- α 5 and transforming growth factor- β 1 expression in the atria of patients with rheumatic valvular disease and atrial fibrillation. <i>International Journal of Cardiology</i> , 2013, 168, 2177-2185.	0.8	16
1229	Effects of mineralocorticoid receptor antagonist spironolactone on cardiac sympathetic nerve activity and prognosis in patients with chronic heart failure. <i>International Journal of Cardiology</i> , 2013, 167, 244-249.	0.8	23
1230	The Renaissance of Primary Aldosteronism: What Has it Taught Us?. <i>Heart Lung and Circulation</i> , 2013, 22, 412-420.	0.2	8
1231	Effect of Early Initiation of Dialysis on Cardiac Structure and Function: Results From the Echo Substudy of the IDEAL Trial. <i>American Journal of Kidney Diseases</i> , 2013, 61, 262-270.	2.1	45
1232	Angiotensin-converting enzyme 2 antagonizes angiotensin II-induced pressor response and NADPH oxidase activation in Wistar-Kyoto rats and spontaneously hypertensive rats. <i>Experimental Physiology</i> , 2013, 98, 109-122.	0.9	56
1233	Devices in the management of advanced, chronic heart failure. <i>Nature Reviews Cardiology</i> , 2013, 10, 98-110.	6.1	56
1234	The Symptoms of Aortic Stenosis. <i>JACC: Cardiovascular Imaging</i> , 2013, 6, 147-149.	2.3	10
1235	Evolving strategies for the use of spironolactone in cardiovascular disease. <i>European Journal of Internal Medicine</i> , 2013, 24, 303-309.	1.0	6
1236	Modified cine inversion recovery pulse sequence for the quantification of myocardial T1 and gadolinium partition coefficient. <i>Journal of Magnetic Resonance Imaging</i> , 2013, 37, 109-118.	1.9	8
1237	Direct Reprogramming of Mouse Fibroblasts into Cardiac Myocytes. <i>Journal of Cardiovascular Translational Research</i> , 2013, 6, 37-45.	1.1	38
1238	Increased Left Ventricular Mass as a Predictor of Sudden Cardiac Death. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2013, 6, 212-217.	2.1	80
1239	Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2013, 15, 92.	1.6	864
1240	Oxidative stress, fibrosis, and early afterdepolarization-mediated cardiac arrhythmias. <i>Frontiers in Physiology</i> , 2013, 4, 19.	1.3	24
1241	Role of Mitogen-Activated Protein Kinase Pathways in Multifactorial Adverse Cardiac Remodeling Associated with Metabolic Syndrome. <i>Mediators of Inflammation</i> , 2013, 2013, 1-11.	1.4	24
1242	Noninvasive imaging of myocardial extracellular matrix for assessment of fibrosis. <i>Current Opinion in Cardiology</i> , 2013, 28, 282-289.	0.8	33
1243	Response to Letters Regarding Article, "Myocardial Fibrosis as a Key Determinant of Left Ventricular Remodeling in Idiopathic Dilated Cardiomyopathy: A Contrast-Enhanced Cardiovascular Magnetic Study." <i>Circulation: Cardiovascular Imaging</i> , 2013, 6, e79.	1.3	3
1244	Left Ventricular Global Function Index by Magnetic Resonance Imaging—A Novel Marker for Assessment of Cardiac Performance for the Prediction of Cardiovascular Events. <i>Hypertension</i> , 2013, 61, 770-778.	1.3	70
1245	Relation of N-Terminal Pro-B-Type Natriuretic Peptide With Diastolic Function in Hypertensive Heart Disease. <i>American Journal of Hypertension</i> , 2013, 26, 1234-1241.	1.0	17

#	ARTICLE	IF	CITATIONS
1246	Hemodialysis-Induced Acute Myocardial Dyssynchronous Impairment in Children. <i>Nephron Clinical Practice</i> , 2013, 123, 83-92.	2.3	21
1247	Acute aortocaval fistula: role of low perfusion pressure and subendocardial remodeling on left ventricular function. <i>International Journal of Experimental Pathology</i> , 2013, 94, 178-187.	0.6	7
1248	Angiotensin II-induced cardiac hypertrophy and fibrosis are promoted in mice lacking <i>GF16</i> . <i>Genes To Cells</i> , 2013, 18, 544-553.	0.5	47
1249	Cardiac Microvascular Rarefaction in Hyperthyroidism-Induced Left Ventricle Dysfunction. <i>Microcirculation</i> , 2013, 20, 590-598.	1.0	11
1250	Diastolic Dysfunction in Rheumatoid Arthritis: A Meta-Analysis and Systematic Review. <i>Arthritis Care and Research</i> , 2013, 65, 534-543.	1.5	84
1251	Quercetin provides greater cardioprotective effect than its glycoside derivative rutin on isoproterenol-induced cardiac fibrosis in the rat. <i>Canadian Journal of Physiology and Pharmacology</i> , 2013, 91, 951-959.	0.7	63
1252	Heart regeneration using reprogramming technology. <i>Proceedings of the Japan Academy Series B: Physical and Biological Sciences</i> , 2013, 89, 118-128.	1.6	7
1253	Involvement of mast cell chymase in burn wound healing in hamsters. <i>Experimental and Therapeutic Medicine</i> , 2013, 5, 643-647.	0.8	19
1254	The Efficacy and Tolerability of Azilsartan in Mice With Left Ventricular Pressure Overload or Acute Myocardial Infarction. <i>Journal of Cardiovascular Pharmacology</i> , 2013, 61, 437-443.	0.8	8
1255	Arrhythmia insensitive rapid cardiac <i>T₁</i> mapping pulse sequence. <i>Magnetic Resonance in Medicine</i> , 2013, 70, 1274-1282.	1.9	56
1256	Gene mutations that promote adrenal aldosterone production, sodium retention, and hypertension. <i>The Application of Clinical Genetics</i> , 2013, 7, 1.	1.4	4
1257	Left ventricular dysfunction in normotensive type II diabetic patients in Port Harcourt, Nigeria. <i>Vascular Health and Risk Management</i> , 2013, 9, 529.	1.0	12
1258	Heart Development and Regeneration via Cellular Interaction and Reprogramming. <i>Keio Journal of Medicine</i> , 2013, 62, 99-106.	0.5	15
1259	Losartan Prevents Heart Fibrosis Induced by Long-Term Intensive Exercise in an Animal Model. <i>PLoS ONE</i> , 2013, 8, e55427.	1.1	47
1260	Aldosterone and Mortality in Hemodialysis Patients: Role of Volume Overload. <i>PLoS ONE</i> , 2013, 8, e57511.	1.1	23
1261	Effects of Direct Renin Inhibition on Myocardial Fibrosis and Cardiac Fibroblast Function. <i>PLoS ONE</i> , 2013, 8, e81612.	1.1	31
1262	Autophagy. , 2013, , 141-157.		2
1263	Effect of Direct Renin Inhibitor on Left Ventricular Remodeling in Patients With Primary Acute Myocardial Infarction. <i>International Heart Journal</i> , 2014, 55, 17-21.	0.5	5

#	ARTICLE	IF	CITATIONS
1264	Investigational drugs targeting cardiac fibrosis. <i>Expert Review of Cardiovascular Therapy</i> , 2014, 12, 111-125.	0.6	59
1265	Potential Reduction of Interstitial Myocardial Fibrosis With Renal Denervation. <i>Journal of the American Heart Association</i> , 2014, 3, e001353.	1.6	41
1266	Left Ventricular Hypertrophy: The Relationship between the Electrocardiogram and Cardiovascular Magnetic Resonance Imaging. <i>Annals of Noninvasive Electrocardiology</i> , 2014, 19, 524-533.	0.5	39
1267	Evaluation of extracellular volume fraction thresholds corresponding to myocardial late-gadolinium enhancement using cardiac magnetic resonance. <i>International Journal of Cardiovascular Imaging</i> , 2014, 30, 137-144.	0.7	9
1268	Interstitial Fibrosis, Left Ventricular Remodeling, and Myocardial Mechanical Behavior in a Population-Based Multiethnic Cohort. <i>Circulation: Cardiovascular Imaging</i> , 2014, 7, 292-302.	1.3	86
1269	A deficiency of apoptosis inducing factor (AIF) in Harlequin mouse heart mitochondria paradoxically reduces ROS generation during ischemia-reperfusion. <i>Frontiers in Physiology</i> , 2014, 5, 271.	1.3	13
1270	How to measure propagation velocity in cardiac tissue: a simulation study. <i>Frontiers in Physiology</i> , 2014, 5, 267.	1.3	14
1271	Myocardial extracellular volume fraction quantified by cardiovascular magnetic resonance is increased in diabetes and associated with mortality and incident heart failure admission. <i>European Heart Journal</i> , 2014, 35, 657-664.	1.0	297
1272	How is the Heart Best Protected in Chronic Dialysis Patients?. <i>Seminars in Dialysis</i> , 2014, 27, 328-332.	0.7	3
1273	Association of Longitudinal Changes in Left Ventricular Structure and Function With Myocardial Fibrosis. <i>Hypertension</i> , 2014, 64, 508-515.	1.3	67
1274	Characterization of diffuse fibrosis in the failing human heart via diffusion tensor imaging and quantitative histological validation. <i>NMR in Biomedicine</i> , 2014, 27, 1378-1386.	1.6	40
1275	Increased expression of NF-AT3 and NF-AT4 in the atria correlates with procollagen I carboxyl terminal peptide and TGF- β 1 levels in serum of patients with atrial fibrillation. <i>BMC Cardiovascular Disorders</i> , 2014, 14, 167.	0.7	9
1276	The Requirement of CD8+ T Cells To Initiate and Augment Acute Cardiac Inflammatory Response to High Blood Pressure. <i>Journal of Immunology</i> , 2014, 192, 3365-3373.	0.4	44
1277	Cardiac fibrosis as a determinant of ventricular tachyarrhythmias. <i>Journal of Arrhythmia</i> , 2014, 30, 389-394.	0.5	69
1278	Cardiolipin remodeling in diabetic heart. <i>Chemistry and Physics of Lipids</i> , 2014, 179, 75-81.	1.5	68
1279	Correlation Between Extent of Myocardial Fibrosis Assessed by Cardiac Magnetic Resonance and Cardiac Troponin T Release in Patients With Nonischemic Heart Failure. <i>American Journal of Cardiology</i> , 2014, 113, 1697-1704.	0.7	19
1280	Beneficial neurohumoral profile in left ventricular systolic dysfunction following acute myocardial infarction. <i>Open Medicine (Poland)</i> , 2014, 9, 64-73.	0.6	0
1281	Therapeutic Targets in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2014, 63, 2188-2198.	1.2	124

#	ARTICLE	IF	CITATIONS
1282	Left ventricular geometry and outcomes in patients with atrial fibrillation: The AFFIRM Trial. <i>International Journal of Cardiology</i> , 2014, 170, 303-308.	0.8	36
1283	Direct Reprogramming of Fibroblasts into Myocytes to Reverse Fibrosis. <i>Annual Review of Physiology</i> , 2014, 76, 21-37.	5.6	30
1284	Impact of repeated intravenous bone marrow mesenchymal stem cells infusion on myocardial collagen network remodeling in a rat model of doxorubicin-induced dilated cardiomyopathy. <i>Molecular and Cellular Biochemistry</i> , 2014, 387, 279-285.	1.4	36
1285	Markers of left ventricular decompensation in aortic stenosis. <i>Expert Review of Cardiovascular Therapy</i> , 2014, 12, 901-912.	0.6	23
1286	Biomarker and imaging responses to spironolactone in subclinical diabetic cardiomyopathy. <i>European Heart Journal Cardiovascular Imaging</i> , 2014, 15, 776-786.	0.5	20
1287	Adverse Cardiovascular Effects from the Use of Anabolic-Androgenic Steroids as Ergogenic Resources. <i>Substance Use and Misuse</i> , 2014, 49, 1132-1137.	0.7	30
1288	The role of post-translational modifications in acute and chronic cardiovascular disease. <i>Proteomics - Clinical Applications</i> , 2014, 8, 506-521.	0.8	34
1289	New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. <i>European Heart Journal</i> , 2014, 35, 2797-2815.	1.0	304
1290	Management Strategies for Heart Failure with Preserved Ejection Fraction. <i>Heart Failure Clinics</i> , 2014, 10, 591-598.	1.0	12
1291	Heterozygote loss of ACE2 is sufficient to increase the susceptibility to heart disease. <i>Journal of Molecular Medicine</i> , 2014, 92, 847-858.	1.7	34
1292	An emerging role for the miR-26 family in cardiovascular disease. <i>Trends in Cardiovascular Medicine</i> , 2014, 24, 241-248.	2.3	65
1293	Left Ventricular Strain and Transmural Distribution of Structural Remodeling in Hypertensive Heart Disease. <i>Hypertension</i> , 2014, 63, 500-506.	1.3	132
1294	Midkine exacerbates pressure overload-induced cardiac remodeling. <i>Biochemical and Biophysical Research Communications</i> , 2014, 443, 205-210.	1.0	30
1295	Myocardial T1 Mapping: Techniques and Potential Applications. <i>Radiographics</i> , 2014, 34, 377-395.	1.4	80
1296	Heart failure with preserved ejection fraction. <i>Expert Review of Cardiovascular Therapy</i> , 2014, 12, 743-750.	0.6	8
1297	Calcium handling proteins: structure, function, and modulation by exercise. <i>Heart Failure Reviews</i> , 2014, 19, 207-225.	1.7	19
1298	Fibrosis and heart failure. <i>Heart Failure Reviews</i> , 2014, 19, 173-185.	1.7	291
1300	3,3'-Diindolylmethane attenuates cardiac H9c2 cell hypertrophy through 5'-adenosine monophosphate-activated protein kinase- β . <i>Molecular Medicine Reports</i> , 2015, 12, 1247-1252.	1.1	13

#	ARTICLE	IF	CITATIONS
1301	Prognostic Impact of Statin Use in Patients With Heart Failure and Preserved Ejection Fraction. <i>Circulation Journal</i> , 2015, 79, 574-582.	0.7	55
1302	MRI and serum high-sensitivity C reactive protein predict long-term mortality in non-ischaemic cardiomyopathy. <i>Open Heart</i> , 2015, 2, e000298.	0.9	11
1303	The Implications and Assessment of Myocardial Fibrosis in Older Cardiovascular Patients. <i>Current Geriatrics Reports</i> , 2015, 4, 362-367.	1.1	0
1304	Procollagen type III amino terminal peptide and myocardial fibrosis: A study in hypertensive patients with and without left ventricular hypertrophy. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2015, 34, 309-314.	0.2	1
1305	Diverse Fibrosis Architecture and Premature Stimulation Facilitate Initiation of Reentrant Activity Following Chronic Atrial Fibrillation. <i>Journal of Cardiovascular Electrophysiology</i> , 2015, 26, 1352-1360.	0.8	25
1306	Cardiac Physiology of Aging: Extracellular Considerations. , 2015, 5, 1069-1121.		35
1307	Alcohol Effects on Cardiac Function. , 2015, 5, 791-802.		70
1308	Pathophysiology of Heart Failure. , 2015, 6, 187-214.		335
1309	Anthracycline-Induced Cardiomyopathy in Adults. , 2015, 5, 1517-1540.		52
1310	Adaptive registration of varying contrast-weighted images for improved tissue characterization (ARCTIC): Application to T ₁ mapping. <i>Magnetic Resonance in Medicine</i> , 2015, 73, 1469-1482.	1.9	63
1311	Aldosterone, mortality, cardiovascular events and reverse epidemiology in end stage renal disease. <i>European Journal of Clinical Investigation</i> , 2015, 45, 1077-1086.	1.7	8
1312	Heart Failure With Preserved Ejection Fraction. <i>Cardiology in Review</i> , 2015, 23, 161-167.	0.6	10
1313	Prognostic significance of myocardial extracellular volume fraction in nonischaemic dilated cardiomyopathy. <i>Journal of Cardiovascular Medicine</i> , 2015, 16, 681.	0.6	61
1314	Effect of dehydroepiandrosterone treatment on hormone levels and antioxidant parameters in aged rats. <i>Genetics and Molecular Research</i> , 2015, 14, 11300-11311.	0.3	9
1315	Dasatinib Attenuates Pressure Overload Induced Cardiac Fibrosis in a Murine Transverse Aortic Constriction Model. <i>PLoS ONE</i> , 2015, 10, e0140273.	1.1	29
1316	Modulation of Immunity and Inflammation by the Mineralocorticoid Receptor and Aldosterone. <i>BioMed Research International</i> , 2015, 2015, 1-14.	0.9	51
1317	Treatment Modalities for Heart Failure with Preserved Ejection Fraction (HFpEF) - Current State of Evidence and Future Perspective. <i>Journal of Clinical & Experimental Cardiology</i> , 2015, 06, .	0.0	0
1319	Eplerenone in chronic heart failure with depressed systolic function. <i>International Journal of Cardiology</i> , 2015, 200, 12-14.	0.8	6

#	ARTICLE	IF	CITATIONS
1320	Recommendations on the use of echocardiography in adult hypertension: a report from the European Association of Cardiovascular Imaging (EACVI) and the American Society of Echocardiography (ASE) &sup><xref ref-type="fn" rid="AN1">&at</xref></sup>. European Heart Journal Cardiovascular Imaging, 2015, 16, 577-605.	0.5	190
1321	Myocardial T1 Mapping in Pediatric and Congenital Heart Disease. Circulation: Cardiovascular Imaging, 2015, 8, e002504.	1.3	55
1322	The association of left ventricular mass with coronary atherosclerosis and myocardial ischemia: cause and effect or simple association?. European Heart Journal Cardiovascular Imaging, 2015, 16, 156-157.	0.5	2
1323	Long-term effects of adrenalectomy or spironolactone on blood pressure control and regression of left ventricle hypertrophy in patients with primary aldosteronism. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2015, 16, 1109-1117.	1.0	29
1324	Think Small and Examine the Constituents of Left Ventricular Hypertrophy and Heart Failure: Cardiomyocytes Versus Fibroblasts, Collagen, and Capillaries in the Interstitium. Journal of the American Heart Association, 2015, 4, e002491.	1.6	11
1325	Cardiomyocyte-specific Bmal1 deletion in mice triggers diastolic dysfunction, extracellular matrix response, and impaired resolution of inflammation. American Journal of Physiology - Heart and Circulatory Physiology, 2015, 309, H1827-H1836.	1.5	75
1326	Persistent change in cardiac fibroblast physiology after transient ACE inhibition. American Journal of Physiology - Heart and Circulatory Physiology, 2015, 309, H1346-H1353.	1.5	18
1327	Effects of high doses of enalapril and benazepril on the pharmacologically activated renin-angiotensin-aldosterone system in clinically normal dogs. American Journal of Veterinary Research, 2015, 76, 1041-1050.	0.3	23
1328	Update in Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 1-10.	1.8	62
1329	Determinants of Discrepancies in Detection and Comparison of the Prognostic Significance of Left Ventricular Hypertrophy by Electrocardiogram and Cardiac Magnetic Resonance Imaging. American Journal of Cardiology, 2015, 115, 515-522.	0.7	65
1330	ACE inhibition attenuates radiation-induced cardiopulmonary damage. Radiotherapy and Oncology, 2015, 114, 96-103.	0.3	97
1331	Relationship of left ventricular mass to coronary atherosclerosis and myocardial ischaemia: the CORE320 multicenter study. European Heart Journal Cardiovascular Imaging, 2015, 16, 166-176.	0.5	14
1332	Prognostic Value of Aldosterone and Cortisol in Patients Hospitalized for Acutely Decompensated Chronic Heart Failure With and Without Mineralocorticoid Receptor Antagonism. Journal of Cardiac Failure, 2015, 21, 208-216.	0.7	17
1333	Histological validation of cardiac magnetic resonance analysis of regional and diffuse interstitial myocardial fibrosis. European Heart Journal Cardiovascular Imaging, 2015, 16, 14-22.	0.5	195
1334	T1 mapping: characterisation of myocardial interstitial space. Insights Into Imaging, 2015, 6, 189-202.	1.6	50
1335	Assessment of Diffuse Myocardial Fibrosis by Using MR Imaging in Asymptomatic Patients with Aortic Stenosis. Radiology, 2015, 274, 359-369.	3.6	118
1336	Augmentation of autophagy by atorvastatin via Akt/mTOR pathway in spontaneously hypertensive rats. Hypertension Research, 2015, 38, 813-820.	1.5	32
1337	Recommendations on the Use of Echocardiography in Adult Hypertension: A Report from the European Association of Cardiovascular Imaging (EACVI) and the American Society of Echocardiography (ASE)â€. Journal of the American Society of Echocardiography, 2015, 28, 727-754.	1.2	298

#	ARTICLE	IF	CITATIONS
1338	Interferon Regulatory Factor Signalings in Cardiometabolic Diseases. <i>Hypertension</i> , 2015, 66, 222-247.	1.3	43
1340	Myocardial factor revisited: The importance of myocardial fibrosis in adults with congenital heart disease. <i>International Journal of Cardiology</i> , 2015, 189, 204-210.	0.8	29
1341	Exercise improves cardiac function and attenuates insulin resistance in Dahl salt-sensitive rats. <i>International Journal of Cardiology</i> , 2015, 186, 154-160.	0.8	9
1342	Left Ventricular Hypertrophy and Arrhythmogenesis. <i>Cardiac Electrophysiology Clinics</i> , 2015, 7, 207-220.	0.7	35
1343	Progression of matrixin and cardiokine expression patterns in an ovine model of heart failure and recovery. <i>International Journal of Cardiology</i> , 2015, 186, 77-89.	0.8	10
1344	Biomarkers of cardiomyocyte injury and stress identify left atrial and left ventricular remodelling and dysfunction: A population-based study. <i>International Journal of Cardiology</i> , 2015, 185, 177-185.	0.8	31
1347	T 1 Mapping Techniques in Assessment of Ventricular Stiffness. <i>Current Cardiovascular Imaging Reports</i> , 2015, 8, 1.	0.4	7
1348	Antagonism of angiotensin 1 ^α 7 prevents the therapeutic effects of recombinant human ACE2. <i>Journal of Molecular Medicine</i> , 2015, 93, 1003-1013.	1.7	38
1349	Spinal NF- κ B and Chemokine Ligand 5 Expression during Spinal Glial Cell Activation in a Neuropathic Pain Model. <i>PLoS ONE</i> , 2015, 10, e0115120.	1.1	35
1350	Selective activation of angiotensin AT_2 receptors attenuates progression of pulmonary hypertension and inhibits cardiopulmonary fibrosis. <i>British Journal of Pharmacology</i> , 2015, 172, 2219-2231.	2.7	75
1351	Assessment of the relationship between nondipping phenomenon and microvolt T-wave alternans. <i>Blood Pressure Monitoring</i> , 2015, 20, 2-7.	0.4	0
1352	Drug therapies in older adults (part 2). <i>Clinical Medicine</i> , 2015, 15, 155-159.	0.8	5
1354	Role of the Renin-Angiotensin-Aldosterone System in the Management of Neonatal Heart Failure. <i>NeoReviews</i> , 2015, 16, e575-e585.	0.4	2
1355	Current and Future Strategies for the Diagnosis and Treatment of Cardiac Fibrosis. , 2015, , 181-217.		2
1356	Left ventricular hypertrophy on long-term cardiovascular outcomes in patients with ST-elevation myocardial infarction. <i>Clinical and Experimental Hypertension</i> , 2015, 37, 674-679.	0.5	14
1357	Imaging in Deciphering Histological Substrates in Hypertrophic Cardiomyopathy. <i>Current Cardiovascular Imaging Reports</i> , 2015, 8, 1.	0.4	0
1358	Hydrogen sulfide suppresses transforming growth factor- β 1-induced differentiation of human cardiac fibroblasts into myofibroblasts. <i>Science China Life Sciences</i> , 2015, 58, 1126-1134.	2.3	23
1359	Procollagen type III amino terminal peptide and myocardial fibrosis: A study in hypertensive patients with and without left ventricular hypertrophy. <i>Revista Portuguesa De Cardiologia</i> , 2015, 34, 309-314.	0.2	2

#	ARTICLE	IF	CITATIONS
1360	Intracellular Signaling of Cardiac Fibroblasts. , 2015, 5, 721-760.		34
1361	Left ventricular global longitudinal strain is associated with cardiovascular risk factors and arterial stiffness in chronic kidney disease. BMC Nephrology, 2015, 16, 106.	0.8	28
1362	Myocardial interstitial remodelling in non-ischaemic dilated cardiomyopathy: insights from cardiovascular magnetic resonance. Heart Failure Reviews, 2015, 20, 731-749.	1.7	45
1363	Relationship Between Left Ventricular Structural and Metabolic Remodeling in Type 2 Diabetes. Diabetes, 2016, 65, 44-52.	0.3	177
1364	Tissue Characterization of the Myocardium. Radiologic Clinics of North America, 2015, 53, 413-423.	0.9	25
1365	Markers of fibrosis, inflammation, and remodeling pathways in heart failure. Clinica Chimica Acta, 2015, 443, 29-38.	0.5	70
1366	Cardiac MRI: a central prognostic tool in myocardial fibrosis. Nature Reviews Cardiology, 2015, 12, 18-29.	6.1	164
1367	The Impact of Risk Factors on the Diastolic Dysfunction in Patients with Hypertension. Insights in Blood Pressure, 2016, 02, .	0.2	0
1368	T1 and ECV Mapping in Myocardial Disease. Cardiovascular Innovations and Applications, 2017, 2, .	0.1	0
1369	EFFECTS OF AEROBIC TRAINING ON THE CARDIOMYOCYTES OF THE RIGHT ATRIUM OF MICE. Revista Brasileira De Medicina Do Esporte, 2016, 22, 345-349.	0.1	1
1370	Aldosterone and right ventricular dysfunction. Journal of Cardiovascular Medicine, 2016, 17, 1-3.	0.6	2
1371	Mathematical modeling of cardiac growth and remodeling. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 2016, 8, 211-226.	6.6	37
1372	Heart rate-induced modifications of concentric left ventricular hypertrophy: exploration of a novel therapeutic concept. American Journal of Physiology - Heart and Circulatory Physiology, 2016, 311, H1031-H1039.	1.5	18
1373	Managing dystrophinopathic cardiomyopathy. Expert Opinion on Orphan Drugs, 2016, 4, 1159-1178.	0.5	3
1374	The cardioprotective efficacy of <sc>TVP</sc> 1022 against ischemia/reperfusion injury and cardiac remodeling in rats. Pharmacology Research and Perspectives, 2016, 4, e00272.	1.1	9
1375	Reversed association between aldosterone and mortality in hemodialysis patients: Role of volume overload. Steroids, 2016, 111, 60-62.	0.8	1
1376	Role of the ACE2/Angiotensin 1â€“7 Axis of the Reninâ€“Angiotensin System in Heart Failure. Circulation Research, 2016, 118, 1313-1326.	2.0	664
1377	Myocardial ECV Fraction Assessed by CMRâ€“Is Associated With Type of Hemodynamic Load and Arrhythmia in Repaired Tetralogy of Fallot. JACC: Cardiovascular Imaging, 2016, 9, 1-10.	2.3	117

#	ARTICLE	IF	CITATIONS
1378	NT-proBNP is a powerful predictor for incident atrial fibrillation â€” Validation of a multimarker approach. <i>International Journal of Cardiology</i> , 2016, 223, 74-81.	0.8	42
1379	Primary Aldosteronism: Changing Definitions and New Concepts of Physiology and Pathophysiology Both Inside and Outside the Kidney. <i>Physiological Reviews</i> , 2016, 96, 1327-1384.	13.1	119
1380	Body Mass Index Predicts 24-Hour Urinary Aldosterone Levels in Patients With Resistant Hypertension. <i>Hypertension</i> , 2016, 68, 995-1003.	1.3	42
1381	From Left Ventricular Hypertrophy to Dysfunction and Failure. <i>Circulation Journal</i> , 2016, 80, 555-564.	0.7	108
1382	Heart Development, Diseases, and Regenerationâ€”â€” New Approaches From Innervation, Fibroblasts, and Reprogramming â€”. <i>Circulation Journal</i> , 2016, 80, 2081-2088.	0.7	8
1383	Amelioration of cardiac dysfunction and ventricular remodeling after myocardial infarction by danhong injection are critically contributed by anti-TGF- β -mediated fibrosis and angiogenesis mechanisms. <i>Journal of Ethnopharmacology</i> , 2016, 194, 559-570.	2.0	47
1384	Native T1 mapping in children and young adults with hypertrophic cardiomyopathy. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2016, 18, Q44.	1.6	0
1385	Assessment of relationship between galectin-3 and ambulatory ECG-based microvolt T-wave alternans in sustained systolic-diastolic hypertension patients. <i>Blood Pressure Monitoring</i> , 2016, 21, 265-270.	0.4	6
1386	FGF23 from bench to bedside. <i>American Journal of Physiology - Renal Physiology</i> , 2016, 310, F1168-F1174.	1.3	56
1387	Cardiac changes in pediatric liver transplant recipients: are they truly irreversible?. <i>Hepatology International</i> , 2016, 10, 390-393.	1.9	0
1388	Relationship of Office and Ambulatory Blood Pressure With Left Ventricular Global Longitudinal Strain. <i>American Journal of Hypertension</i> , 2016, 29, 1261-1267.	1.0	10
1389	Evaluation of subacute change in RAAS activity (as indicated by urinary aldosterone:creatinine, after) Tj ETQq1 1 0.784314 rgBT /Over Renin-Angiotensin-Aldosterone System, 2016, 17, 147032031663389.	1.0	23
1390	Revascularization in Patients With Severe Left Ventricular Dysfunction. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2874-2887.	1.2	45
1391	The Effects of Nandrolone Decanoate Along with Prolonged Low-Intensity Exercise on Susceptibility to Ventricular Arrhythmias. <i>Cardiovascular Toxicology</i> , 2016, 16, 23-33.	1.1	15
1392	High serum levels of thrombospondin-2 correlate with poor prognosis of patients with heart failure with preserved ejection fraction. <i>Heart and Vessels</i> , 2016, 31, 52-59.	0.5	30
1393	Are There Deleterious Cardiac Effects of Acute and Chronic Endurance Exercise?. <i>Physiological Reviews</i> , 2016, 96, 99-125.	13.1	164
1394	Persistent phenotypic shift in cardiac fibroblasts: impact of transient renin angiotensin system inhibition. <i>Journal of Molecular and Cellular Cardiology</i> , 2016, 93, 125-132.	0.9	27
1395	State of the Art: Clinical Applications of Cardiac T1 Mapping. <i>Radiology</i> , 2016, 278, 658-676.	3.6	158

#	ARTICLE	IF	CITATIONS
1396	Necroptotic cell death in failing heart: relevance and proposed mechanisms. <i>Heart Failure Reviews</i> , 2016, 21, 213-221.	1.7	63
1397	Interleukin-10 deficiency aggravates angiotensin II-induced cardiac remodeling in mice. <i>Life Sciences</i> , 2016, 146, 214-221.	2.0	17
1398	Androgen receptor (AR) in cardiovascular diseases. <i>Journal of Endocrinology</i> , 2016, 229, R1-R16.	1.2	58
1399	Automatic Measurement of the Myocardial Interstitium. <i>JACC: Cardiovascular Imaging</i> , 2016, 9, 54-63.	2.3	127
1400	Treatment of diabetes and heart failure: joint forces. <i>European Heart Journal</i> , 2016, 37, 1535.2-1537.	1.0	12
1401	The fibrosis-cell death axis in heart failure. <i>Heart Failure Reviews</i> , 2016, 21, 199-211.	1.7	214
1402	The role of cardiac biochemical markers in aortic stenosis. <i>Biomarkers</i> , 2016, 21, 316-327.	0.9	15
1403	Many Paths Lead to CV Outcomes. <i>JACC: Cardiovascular Imaging</i> , 2016, 9, 24-26.	2.3	5
1404	The risk of life-threatening ventricular arrhythmias in presence of high-intensity endurance exercise along with chronic administration of nandrolone decanoate. <i>Steroids</i> , 2016, 105, 106-112.	0.8	11
1405	A perspective on sympathetic renal denervation in chronic congestive heart failure. <i>Heart Failure Reviews</i> , 2016, 21, 1-10.	1.7	6
1406	Therapeutic options of Angiotensin Receptor Neprilysin inhibitors (ARNis) in chronic heart failure with reduced ejection fraction: Beyond RAAS and sympathetic nervous system inhibition. <i>International Journal of Cardiology</i> , 2017, 226, 132-135.	0.8	7
1407	Arterial (Aortic) Stiffness in Patients with Resistant Hypertension: from Assessment to Treatment. <i>Current Hypertension Reports</i> , 2017, 19, 2.	1.5	24
1408	Right ventricular Dysfunction in Tetralogy of Fallot: INhibition of the renin-angiotensin-aldosterone system (REDEFINE) trial: Rationale and design of a randomized, double-blind, placebo-controlled clinical trial. <i>American Heart Journal</i> , 2017, 186, 83-90.	1.2	3
1409	Native T ₁ value in the remote myocardium is independently associated with left ventricular dysfunction in patients with prior myocardial infarction. <i>Journal of Magnetic Resonance Imaging</i> , 2017, 46, 1073-1081.	1.9	13
1410	Low dose eplerenone treatment decreases aortic stiffness in patients with resistant hypertension. <i>Journal of Clinical Hypertension</i> , 2017, 19, 669-676.	1.0	24
1411	Synthesis of the novel PARP-1 inhibitor AG-690/11026014 and its protective effects on angiotensin II-induced mouse cardiac remodeling. <i>Acta Pharmacologica Sinica</i> , 2017, 38, 638-650.	2.8	16
1412	Developmental stage-dependent effects of cardiac fibroblasts on function of stem cell-derived engineered cardiac tissues. <i>Scientific Reports</i> , 2017, 7, 42290.	1.6	39
1413	Manipulating PML SUMOylation via Silencing UBC9 and RNF4 Regulates Cardiac Fibrosis. <i>Molecular Therapy</i> , 2017, 25, 666-678.	3.7	49

#	ARTICLE	IF	CITATIONS
1414	Screening for Endocrine Hypertension: An Endocrine Society Scientific Statement. <i>Endocrine Reviews</i> , 2017, 38, 103-122.	8.9	76
1415	Lack of effect of prolonged treatment with liraglutide on cardiac remodeling in rats after acute myocardial infarction. <i>Peptides</i> , 2017, 93, 1-12.	1.2	16
1416	Modeling the Human Scarred Heart In Vitro: Toward New Tissue Engineered Models. <i>Advanced Healthcare Materials</i> , 2017, 6, 1600571.	3.9	25
1417	Employing Extracellular Volume Cardiovascular Magnetic Resonance Measures of Myocardial Fibrosis to Foster Novel Therapeutics. <i>Circulation: Cardiovascular Imaging</i> , 2017, 10, .	1.3	52
1418	Association of renin-angiotensin-aldosterone system gene polymorphisms with left ventricular hypertrophy in patients with heart failure with preserved ejection fraction: A case-control study. <i>Clinical and Experimental Hypertension</i> , 2017, 39, 371-376.	0.5	16
1419	Mitochondria in Structural and Functional Cardiac Remodeling. <i>Advances in Experimental Medicine and Biology</i> , 2017, 982, 277-306.	0.8	51
1420	Redefining the role of biomarkers in heart failure trials: expert consensus document. <i>Heart Failure Reviews</i> , 2017, 22, 263-277.	1.7	18
1421	Distinctive Risk Factors and Phenotype of Younger Patients With Resistant Hypertension. <i>Hypertension</i> , 2017, 69, 827-835.	1.3	12
1422	A novel aldosterone synthase inhibitor ameliorates mortality in pressure-overload mice with heart failure. <i>European Journal of Pharmacology</i> , 2017, 795, 58-65.	1.7	7
1423	Myocyte-Derived Hsp90 Modulates Collagen Upregulation via Biphasic Activation of STAT-3 in Fibroblasts during Cardiac Hypertrophy. <i>Molecular and Cellular Biology</i> , 2017, 37, .	1.1	75
1424	Late graft dysfunction after pediatric heart transplantation is associated with fibrosis and microvasculopathy by automated, digital whole-slide analysis. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 1336-1343.	0.3	15
1425	Swim training attenuates the adverse remodeling of LV structural and mechanical properties in the early compensated phase of hypertension. <i>Life Sciences</i> , 2017, 187, 42-49.	2.0	10
1426	Risk stratification of sudden cardiac death in hypertension. <i>Journal of Electrocardiology</i> , 2017, 50, 798-801.	0.4	20
1427	T1 and T2 Mapping in Cardiology: "Mapping the Obscure Object of Desire". <i>Cardiology</i> , 2017, 138, 207-217.	0.6	51
1428	Bone Marrow-Derived Tenascin-C Attenuates Cardiac Hypertrophy by Controlling Inflammation. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1601-1615.	1.2	41
1429	Tracking Adventitial Fibroblast Contribution to Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 1598-1607.	1.1	55
1430	Temporal Relation Between Myocardial Fibrosis and Heart Failure With Preserved Ejection Fraction. <i>JAMA Cardiology</i> , 2017, 2, 995.	3.0	164
1431	Fibroblasts and the extracellular matrix in right ventricular disease. <i>Cardiovascular Research</i> , 2017, 113, 1453-1464.	1.8	74

#	ARTICLE	IF	CITATIONS
1432	Cardiomyocyte specific overexpression of a 37 amino acid domain of regulator of G protein signalling 2 inhibits cardiac hypertrophy and improves function in response to pressure overload in mice. <i>Journal of Molecular and Cellular Cardiology</i> , 2017, 108, 194-202.	0.9	14
1433	Effects of renal denervation on cardiac oxidative stress and local activity of the sympathetic nervous system and renin-angiotensin system in acute myocardial infarcted dogs. <i>BMC Cardiovascular Disorders</i> , 2017, 17, 65.	0.7	26
1434	Comparison of left ventricular structure and function in primary aldosteronism and essential hypertension by echocardiography. <i>Hypertension Research</i> , 2017, 40, 243-250.	1.5	27
1435	T1 mapping in children and young adults with hypertrophic cardiomyopathy. <i>International Journal of Cardiovascular Imaging</i> , 2017, 33, 109-117.	0.7	24
1436	Deliberations on Diastolic Heart Failure. <i>American Journal of Cardiology</i> , 2017, 119, 138-144.	0.7	9
1437	Adiponectin attenuates profibrotic extracellular matrix remodeling following cardiac injury by up-regulating matrix metalloproteinase 9 expression in mice. <i>Physiological Reports</i> , 2017, 5, e13523.	0.7	17
1438	Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: A consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI). <i>Journal of Cardiovascular Magnetic Resonance</i> , 2017, 19, 75.	1.6	1,074
1439	The Effects of Diabetes Induction on the Rat Heart: Differences in Oxidative Stress, Inflammatory Cells, and Fibrosis between Subendocardial and Interstitial Myocardial Areas. <i>Oxidative Medicine and Cellular Longevity</i> , 2017, 2017, 1-11.	1.9	23
1440	Formation of a TBX20-CASZ1 protein complex is protective against dilated cardiomyopathy and critical for cardiac homeostasis. <i>PLoS Genetics</i> , 2017, 13, e1007011.	1.5	24
1441	Association between left ventricular mechanics and diffuse myocardial fibrosis in patients with repaired Tetralogy of Fallot: a cross-sectional study. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2017, 19, 100.	1.6	29
1442	Differences in left ventricular functional adaptation to arterial stiffness and neurohormonal activation in patients with hypertension: a study with two-dimensional layer-specific speckle tracking echocardiography. <i>Clinical Hypertension</i> , 2017, 23, 21.	0.7	19
1443	Korean Guidelines for Diagnosis and Management of Chronic Heart Failure. <i>Korean Circulation Journal</i> , 2017, 47, 555.	0.7	56
1444	Prognostic Application of Thoracic Aortic Calcium Scoring for Adverse Clinical Outcome Risk in Elderly Patients with Left Ventricular Hypertrophy. <i>Korean Circulation Journal</i> , 2017, 47, 918.	0.7	5
1445	ALDOSTERONE ANTAGONISTS. MODERN VIEWS ON THE MECHANISM OF ACTION AND EFFECTS OF SPIRONOLACTONE. <i>Rational Pharmacotherapy in Cardiology</i> , 2017, 13, 263-269.	0.3	2
1446	Effect of <i>Atractylodes macrocephala</i> rhizoma on isoproterenol-induced ventricular remodeling in rats. <i>Molecular Medicine Reports</i> , 2018, 17, 2607-2613.	1.1	5
1447	Multimodality imaging assessment of mitral valve anatomy in planning for mitral valve repair in secondary mitral regurgitation. <i>Journal of Thoracic Disease</i> , 2017, 9, S640-S660.	0.6	15
1448	Treatment of Heart Failure with Preserved Ejection Fraction. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1067, 67-87.	0.8	39
1449	Blockade of AT1 type receptors for angiotensin II prevents cardiac microvascular fibrosis induced by chronic stress in Sprague-Dawley rats. <i>Stress</i> , 2018, 21, 484-493.	0.8	9

#	ARTICLE	IF	CITATIONS
1451	Myocardial Extracellular Volume Fraction and Change in Hematocrit Level: MR Evaluation by Using T1 Mapping in an Experimental Model of Anemia. <i>Radiology</i> , 2018, 288, 93-98.	3.6	13
1452	The Association Between Myocardial Fibrosis and Depressed Capillary Density in Rat Model of Left Ventricular Hypertrophy. <i>Cardiovascular Toxicology</i> , 2018, 18, 304-311.	1.1	18
1453	Prevalence of Cardiovascular Disease and Its Risk Factors in Primary Aldosteronism. <i>Hypertension</i> , 2018, 71, 530-537.	1.3	144
1454	Nonrigid active shape model-based registration framework for motion correction of cardiac T ₁ mapping. <i>Magnetic Resonance in Medicine</i> , 2018, 80, 780-791.	1.9	15
1455	Overexpression of collagen type III in injured myocardium prevents cardiac systolic dysfunction by changing the balance of collagen distribution. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2018, 156, 217-226.e3.	0.4	30
1456	Current Management and Future Directions of Heart Failure With Preserved Ejection Fraction: a Contemporary Review. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2018, 20, 28.	0.4	13
1457	Letter by Lewis et al Regarding Article, "Effect of Intensive Blood Pressure Lowering on Left Ventricular Hypertrophy in Patients With Hypertension: SPRINT (Systolic Blood Pressure Intervention) Trial." <i>Stroke</i> , 2018, 49, 1011-1012.	0.0	0
1458	Extracellular volume fraction assessed using cardiovascular magnetic resonance can predict improvement in left ventricular ejection fraction in patients with dilated cardiomyopathy. <i>Heart and Vessels</i> , 2018, 33, 1195-1203.	0.5	9
1459	Systemic Angiotensinogen Concentrations Are Independently Associated With Left Ventricular Diastolic Function in a Community Sample. <i>American Journal of Hypertension</i> , 2018, 31, 212-219.	1.0	3
1460	Noncontrast Myocardial T1 Mapping by Cardiac Magnetic Resonance Predicts Outcome in Patients With Aortic Stenosis. <i>JACC: Cardiovascular Imaging</i> , 2018, 11, 974-983.	2.3	113
1461	Resident fibroblast expansion during cardiac growth and remodeling. <i>Journal of Molecular and Cellular Cardiology</i> , 2018, 114, 161-174.	0.9	110
1462	Role of renin-angiotensin aldosterone system on short-term blood pressure variability in hypertensive patients. <i>Clinical and Experimental Hypertension</i> , 2018, 40, 624-630.	0.5	5
1463	Effect of Losartan on Right Ventricular Dysfunction. <i>Circulation</i> , 2018, 137, 1463-1471.	1.6	39
1464	Myocardial Cell Signaling During the Transition to Heart Failure. <i>Journal of Cellular Biochemistry</i> , 2018, 9, 75-125.		12
1465	Protein Kinase A as a Promising Target for Heart Failure Drug Development. <i>Archives of Medical Research</i> , 2018, 49, 530-537.	1.5	32
1466	Analysis of the Correlation between the Myocardial Expression of DPP-4 and the Clinical Parameters of Patients with Heart Failure. <i>International Heart Journal</i> , 2018, 59, 1303-1311.	0.5	2
1467	Immunopharmacology of Post-Myocardial Infarction and Heart Failure Medications. <i>Journal of Clinical Medicine</i> , 2018, 7, 403.	1.0	11
1468	T1 Mapping in Cardiac Hypertrophy. <i>Journal of Magnetic Resonance Imaging</i> , 2018, 48, 15-25.		0

#	ARTICLE	IF	CITATIONS
1469	Cardiac fibrosis: new insights into the pathogenesis. <i>International Journal of Biological Sciences</i> , 2018, 14, 1645-1657.	2.6	225
1470	Comparison of Seated With Recumbent Saline Suppression Testing for the Diagnosis of Primary Aldosteronism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 4113-4124.	1.8	68
1471	T1-Mapping in Myocardial Disease. , 2018, , .		1
1472	No need for urgent revisiting of kalaemia levels in guidelines despite use of mineralocorticoid receptor antagonists: bring in more evidence. <i>European Journal of Heart Failure</i> , 2018, 20, 1252-1254.	2.9	5
1473	Cardiac fibrosis can be attenuated by blocking the activity of transglutaminase 2 using a selective small-molecule inhibitor. <i>Cell Death and Disease</i> , 2018, 9, 613.	2.7	65
1474	Basic Aspects of Cardiac Remodelling. , 2018, , 91-144.		1
1475	Prognostic value of T1 mapping and extracellular volume fraction in cardiovascular disease: a systematic review and meta-analysis. <i>Heart Failure Reviews</i> , 2018, 23, 723-731.	1.7	37
1476	Heart failure with mid-range ejection fraction and with preserved ejection fraction. <i>Herz</i> , 2018, 43, 392-405.	0.4	6
1477	Effects of the cardiac myosin activator Omecamtiv-mecarbil on severe chronic aortic regurgitation in Wistar rats. <i>BMC Cardiovascular Disorders</i> , 2018, 18, 99.	0.7	5
1478	Cardiac Remodeling: Endothelial Cells Have More to Say Than Just NO. <i>Frontiers in Physiology</i> , 2018, 9, 382.	1.3	121
1479	Obstacles to mineralocorticoid receptor antagonists in a community-based heart failure population. <i>Cardiovascular Therapeutics</i> , 2018, 36, e12459.	1.1	13
1480	Effects of eplerenone on markers of myocardial fibrosis, 6-minute walk distance, and quality of life in adults with tetralogy of Fallot and complete transposition of the great arteries. <i>Baylor University Medical Center Proceedings</i> , 2018, 31, 12-19.	0.2	5
1481	Evaluation of the inhibitory effects of telmisartan on drug-induced renin-angiotensin-aldosterone system activation in normal dogs. <i>Journal of Veterinary Cardiology</i> , 2018, 20, 376-383.	0.3	9
1482	Association of isolated minor nonspecific ST-T abnormalities with left ventricular hypertrophy and diastolic dysfunction. <i>Scientific Reports</i> , 2018, 8, 8791.	1.6	6
1483	Why Clinicians Should Care About the Cardiac Interstitium. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 2305-2318.	2.3	20
1484	Serum-soluble (pro)renin receptor concentration as a biomarker for organ damage in primary aldosteronism. <i>Hypertension Research</i> , 2019, 42, 1951-1960.	1.5	4
1485	Angiotensin II Type 1 Receptor Blocker, Fimasartan, Reduces Vascular Smooth Muscle Cell Senescence by Inhibiting the CYR61 Signaling Pathway. <i>Korean Circulation Journal</i> , 2019, 49, 615.	0.7	11
1486	Myocardial global longitudinal strain: An early indicator of cardiac interstitial fibrosis modified by spironolactone, in a unique hypertensive rat model. <i>PLoS ONE</i> , 2019, 14, e0220837.	1.1	22

#	ARTICLE	IF	CITATIONS
1488	Expression of Concern: Preventive effect of nerolidol on isoproterenol induced myocardial damage in Wistar rats: Evidences from biochemical and histopathological studies. Drug Development Research, 2019, 80, 814-823.	1.4	22
1489	Serum Aldosterone Is Related to Left Ventricular Geometry and Function in Young Adults with Never-Treated Primary Hypertension. Journal of Clinical Medicine, 2019, 8, 1045.	1.0	9
1490	Maintenance of long-term blood pressure control and vascular health by low-dose amiloride-based therapy in hyperaldosteronism. Journal of Clinical Hypertension, 2019, 21, 1183-1190.	1.0	6
1491	Prognostic power of anaerobic threshold parameters in patients with transposition of the great arteries and systemic right ventricle. Cardiology in the Young, 2019, 29, 1445-1451.	0.4	6
1493	Effect of etelcalcetide on cardiac hypertrophy in hemodialysis patients: a randomized controlled trial (ETECAR-HD). Trials, 2019, 20, 601.	0.7	7
1494	The Interstitium in the Hypertrophied Heart. JACC: Cardiovascular Imaging, 2019, 12, 2357-2368.	2.3	25
1495	A comparison between statin with ACE inhibitor or ARB therapy in STEMI patients who underwent successful PCI with drug-eluting stents. Atherosclerosis, 2019, 289, 109-117.	0.4	9
1496	Ca ²⁺ Signaling in Cardiac Fibroblasts and Fibrosis-Associated Heart Diseases. Journal of Cardiovascular Development and Disease, 2019, 6, 34.	0.8	44
1497	In Vivo and In Vitro Effects of Vasopressin V2 Receptor Antagonism on Myocardial Fibrosis in Rats. American Journal of the Medical Sciences, 2019, 357, 151-159.	0.4	0
1498	Imaging and Impact of Myocardial Fibrosis in Aortic Stenosis. JACC: Cardiovascular Imaging, 2019, 12, 283-296.	2.3	161
1499	Long-term BP control and vascular health in patients with hyperaldosteronism treated with low-dose, amiloride-based therapy. Journal of Clinical Hypertension, 2019, 21, 922-928.	1.0	6
1500	Alamandine attenuates long-term hypertension-induced cardiac fibrosis independent of blood pressure. Molecular Medicine Reports, 2019, 19, 4553-4560.	1.1	18
1501	QiShenYiQi Pills® ameliorates ischemia/reperfusion-induced myocardial fibrosis involving RP S19-mediated TGF β 1/Smads signaling pathway. Pharmacological Research, 2019, 146, 104272.	3.1	27
1502	Left Ventricular Fibrosis in Patients with Aortic Stenosis. , 2019, , 127-139.		0
1503	Cardiac fibrosis: potential therapeutic targets. Translational Research, 2019, 209, 121-137.	2.2	118
1504	Aldosterone Antagonists, Amiloride, and Triamterene. , 2019, , 368-373.e1.		0
1505	The renin-angiotensin-aldosterone system and its suppression. Journal of Veterinary Internal Medicine, 2019, 33, 363-382.	0.6	251
1506	Myocardial Scar and Fibrosis. Heart Failure Clinics, 2019, 15, 179-189.	1.0	12

#	ARTICLE	IF	CITATIONS
1507	Primary Aldosteronism: A Glimpse into the Most Common Endocrine Cause of Arterial Hypertension. , 2019, , .		0
1508	Cardiac hypertrophy with obesity is augmented after pregnancy in C57BL/6 mice. <i>Biology of Sex Differences</i> , 2019, 10, 59.	1.8	6
1509	Kaempferol Prevents Against Ang II-induced Cardiac Remodeling Through Attenuating Ang II-induced Inflammation and Oxidative Stress. <i>Journal of Cardiovascular Pharmacology</i> , 2019, 74, 326-335.	0.8	45
1510	The prognostic impact of a concentric left ventricular structure evaluated by transthoracic echocardiography in patients with acute decompensated heart failure: A retrospective study. <i>International Journal of Cardiology</i> , 2019, 287, 73-80.	0.8	6
1511	Organ System Response to Cardiac Functionâ€™Renal. , 2019, , 160-173.e5.		0
1512	Active-site directed peptide l-Phe-d-His-l-Leu inhibits angiotensin converting enzyme activity and dexamethasone-induced hypertension in rats. <i>Peptides</i> , 2019, 112, 34-42.	1.2	9
1513	Fibrotic Signaling in Cardiomyopathies. <i>Molecular and Translational Medicine</i> , 2019, , 273-317.	0.4	1
1514	Lin28a Regulates Pathological Cardiac Hypertrophic Growth Through Pck2-Mediated Enhancement of Anabolic Synthesis. <i>Circulation</i> , 2019, 139, 1725-1740.	1.6	32
1515	Areas of Cartilaginous and Osseous Metaplasia After Experimental Myocardial Infarction in Rats. <i>Anatomical Record</i> , 2019, 302, 947-953.	0.8	7
1516	Effects of mineralocorticoid receptor antagonists on left ventricular diastolic function, exercise capacity, and quality of life in heart failure with preserved ejection fraction: a meta-analysis of randomized controlled trials. <i>Heart and Vessels</i> , 2019, 34, 597-606.	0.5	14
1517	Sex and Cardiovascular Involvement in Inflammatory Joint Diseases. <i>Clinical Reviews in Allergy and Immunology</i> , 2019, 56, 278-292.	2.9	13
1518	Analysis of ventricular synchrony: A complex puzzle. <i>Journal of Nuclear Cardiology</i> , 2019, 26, 1659-1666.	1.4	3
1519	Extracellular Volume Associates With Outcomes More Strongly Than Native or Post-Contrast Myocardial T1. <i>JACC: Cardiovascular Imaging</i> , 2020, 13, 44-54.	2.3	68
1520	Myocardial Tissue Characterization and Fibrosis by Imaging. <i>JACC: Cardiovascular Imaging</i> , 2020, 13, 1221-1234.	2.3	111
1521	Evaluation of stimulus-effect relations in left ventricular growth using a simple multiscale model. <i>Biomechanics and Modeling in Mechanobiology</i> , 2020, 19, 263-273.	1.4	7
1522	Left Ventricular Longitudinal Strain as a Marker for Point of No Return in Hypertensive Heart Failure Treatment. <i>Journal of the American Society of Echocardiography</i> , 2020, 33, 226-233.e1.	1.2	4
1523	Cardiac organ damage in patients with Parkinson's disease and reverse dipping. <i>Journal of Hypertension</i> , 2020, 38, 289-294.	0.3	10
1524	A transmural gradient of myocardial remodeling in early stage heart failure with preserved ejection fraction in the pig. <i>Journal of Anatomy</i> , 2020, 236, 531-539.	0.9	10

#	ARTICLE	IF	CITATIONS
1525	Current Understanding of the Biomechanics of Ventricular Tissues in Heart Failure. <i>Bioengineering</i> , 2020, 7, 2.	1.6	21
1526	Myofibroblasts and Fibrosis. <i>Circulation Research</i> , 2020, 127, 427-447.	2.0	186
1527	Prognostic implications of left ventricular geometry in coronary artery bypass grafting patients. <i>Quantitative Imaging in Medicine and Surgery</i> , 2020, 10, 2274-2284.	1.1	8
1528	The association of the metabolic syndrome with target organ damage: focus on the heart, brain, and central arteries. <i>Expert Review of Cardiovascular Therapy</i> , 2020, 18, 601-614.	0.6	12
1530	Lipid profile and left ventricular geometry pattern in obese children. <i>Lipids in Health and Disease</i> , 2020, 19, 109.	1.2	12
1531	The relationship of plasma renin, angiotensin, and aldosterone levels to blood pressure variability and target organ damage in children with essential hypertension. <i>BMC Cardiovascular Disorders</i> , 2020, 20, 296.	0.7	14
1532	Sex related differences in the pathogenesis of organ fibrosis. <i>Translational Research</i> , 2020, 222, 41-55.	2.2	31
1533	Inhibition of histone demethylase JMJD1C attenuates cardiac hypertrophy and fibrosis induced by angiotensin II. <i>Journal of Receptor and Signal Transduction Research</i> , 2020, 40, 339-347.	1.3	18
1534	Tenascin α C aggravates ventricular dilatation and angiotensin α converting enzyme activity after myocardial infarction in mice. <i>ESC Heart Failure</i> , 2020, 7, 2113-2122.	1.4	17
1535	Elevated Angiotensin 1 α 7/Angiotensin II Ratio Predicts Favorable Outcomes in Patients With Heart Failure. <i>Circulation: Heart Failure</i> , 2020, 13, e006939.	1.6	28
1536	Telmisartan improves myocardial remodeling by inhibiting leptin autocrine activity and activating PPAR γ . <i>Experimental Biology and Medicine</i> , 2020, 245, 654-666.	1.1	14
1537	Loop diuretic use is associated with skeletal muscle wasting in patients with heart failure. <i>Journal of Cardiology</i> , 2020, 76, 109-114.	0.8	12
1538	Pathophysiology of Hypertensive Heart Disease: Beyond Left Ventricular Hypertrophy. <i>Current Hypertension Reports</i> , 2020, 22, 11.	1.5	86
1539	Strategies to Prevent Cardiotoxicity. <i>Current Treatment Options in Oncology</i> , 2020, 21, 32.	1.3	12
1540	Clinical Implications of SARS-CoV-2 Δ Interaction With Renin Angiotensin System. <i>Journal of the American College of Cardiology</i> , 2020, 75, 3085-3095.	1.2	129
1541	The cardiovascular consequences of hyperaldosteronism. <i>Annales D'Endocrinologie</i> , 2021, 82, 174-178.	0.6	9
1542	Primary aldosteronism: Higher volume load, cardiac output and arterial stiffness than in essential hypertension. <i>Journal of Internal Medicine</i> , 2021, 289, 29-41.	2.7	15
1543	Myocardial strain indices and coronary flow reserve are only mildly affected in healthy hypertensive patients. <i>International Journal of Cardiovascular Imaging</i> , 2021, 37, 69-79.	0.7	2

#	ARTICLE	IF	CITATIONS
1544	Low-intensity pulsed ultrasound ameliorates cardiac diastolic dysfunction in mice: a possible novel therapy for heart failure with preserved left ventricular ejection fraction. <i>Cardiovascular Research</i> , 2021, 117, 1325-1338.	1.8	28
1545	Detection of patients at risk of developing heart failure responsive to mineralocorticoid receptor antagonists (MRAs): new insights and opportunities. <i>European Heart Journal</i> , 2021, 42, 697-699.	1.0	4
1546	Prognostic impact of multiple fragmented QRS on cardiac events in idiopathic dilated cardiomyopathy. <i>Europace</i> , 2021, 23, 287-297.	0.7	10
1547	Predictors of subclinical systemic sclerosis primary heart involvement characterised by microvasculopathy and myocardial fibrosis. <i>Rheumatology</i> , 2021, 60, 2934-2945.	0.9	18
1548	Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. <i>European Heart Journal</i> , 2021, 42, 152-161.	1.0	249
1549	Possible value of galectin-3 on follow-up of cardiac remodeling during glucocorticoid treatment. <i>Journal of Biochemical and Molecular Toxicology</i> , 2021, 35, e22717.	1.4	1
1550	Pathology of Aldosterone Biosynthesis and its Action. <i>Tohoku Journal of Experimental Medicine</i> , 2021, 254, 1-15.	0.5	10
1551	Pivotal Role of TGF- β /Smad Signaling in Cardiac Fibrosis: Non-coding RNAs as Effectual Players. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 588347.	1.1	65
1552	Genistein Prevents Nitric Oxide Deficiency-Induced Cardiac Dysfunction and Remodeling in Rats. <i>Antioxidants</i> , 2021, 10, 237.	2.2	13
1553	Cardiac extracellular volume fraction in cats with preclinical hypertrophic cardiomyopathy. <i>Journal of Veterinary Internal Medicine</i> , 2021, 35, 812-822.	0.6	11
1554	Resveratrol and cardiac fibrosis prevention and treatment. <i>Current Pharmaceutical Biotechnology</i> , 2021, 22, .	0.9	12
1556	Complex Relationship Between Cardiac Fibroblasts and Cardiomyocytes in Health and Disease. <i>Journal of the American Heart Association</i> , 2021, 10, e019338.	1.6	86
1557	Distinct Phenotypes Induced by Different Degrees of Transverse Aortic Constriction in C57BL/6N Mice. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 641272.	1.1	10
1558	Multimodality Imaging Assessment of Myocardial Fibrosis. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 2457-2469.	2.3	34
1559	Myocardial Strain Imaging in Resistant Hypertension. <i>Current Hypertension Reports</i> , 2021, 23, 24.	1.5	8
1560	DL-3-n-Butylphthalide Attenuates Myocardial Hypertrophy by Targeting Gasdermin D and Inhibiting Gasdermin D Mediated Inflammation. <i>Frontiers in Pharmacology</i> , 2021, 12, 688140.	1.6	10
1561	Comparative studies on regional variations in PM2.5 in the induction of myocardial hypertrophy in mice. <i>Science of the Total Environment</i> , 2021, 775, 145179.	3.9	9
1562	Oxidative Stress as A Mechanism for Functional Alterations in Cardiac Hypertrophy and Heart Failure. <i>Antioxidants</i> , 2021, 10, 931.	2.2	67

#	ARTICLE	IF	CITATIONS
1563	Novel factors that activate and deactivate cardiac fibroblasts: A new perspective for treatment of cardiac fibrosis. <i>Wound Repair and Regeneration</i> , 2021, 29, 667-677.	1.5	14
1564	Effects of mineralocorticoid receptor antagonist eplerenone on cardiac sympathetic nerve activity and left ventricular remodeling after reperfusion therapy in patients with first ST-segment elevation myocardial infarction. <i>Journal of Nuclear Cardiology</i> , 2022, 29, 2325-2335.	1.4	2
1565	Prevention of Post-Operative Adhesions: A Comprehensive Review of Present and Emerging Strategies. <i>Biomolecules</i> , 2021, 11, 1027.	1.8	40
1566	Potential Adverse Effects of Dexamethasone Therapy on COVID-19 Patients: Review and Recommendations. <i>Infectious Diseases and Therapy</i> , 2021, 10, 1907-1931.	1.8	38
1567	Positron Emission Tomography Techniques to Measure Active Inflammation, Fibrosis and Angiogenesis: Potential for Non-invasive Imaging of Hypertensive Heart Failure. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 719031.	1.1	9
1568	Multiscale simulations of left ventricular growth and remodeling. <i>Biophysical Reviews</i> , 2021, 13, 729-746.	1.5	13
1569	Potential of valsartan+sacubitril therapy in hypertensive heart disease. <i>Russian Journal of Cardiology</i> , 2021, 26, 4568.	0.4	1
1570	NR3C2 Genotype is Associated with Response to Spironolactone in Diastolic Heart Failure Patients from the Aldoà€œDHF Trial. <i>Pharmacotherapy</i> , 2021, , .	1.2	7
1571	Targeting Sirtuin1 to treat aging-related tissue fibrosis: From prevention to therapy. , 2022, 229, 107983.		35
1572	Restoring perturbed oxylipins with Danqi Tongmai Tablet attenuates acute myocardial infarction. <i>Phytomedicine</i> , 2021, 90, 153616.	2.3	1
1573	Basement Membrane Extracellular Matrix Proteins in Pulmonary Vascular and Right Ventricular Remodeling in Pulmonary Hypertension. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2021, 65, 245-258.	1.4	18
1574	Chrelin ameliorates cardiac fibrosis after myocardial infarction by regulating the Nrf2/NADPH/ROS pathway. <i>Peptides</i> , 2021, 144, 170613.	1.2	10
1575	Management of Overt Heart Failure. , 0, , 659-680.		1
1576	Cardiovascular Effects of Alcohol. , 1998, 14, 135-166.		20
1577	Regulatory Role of TGF- β 2 in Cardiac Myofibroblast Function and Post-MI Cardiac Fibrosis: Key Roles of Smad7 and c-Ski. , 2008, , 249-266.		1
1578	Pathophysiology of Heart Failure in Regurgitant Valvular Diseases: Relation to Ventricular Dysfunction and Clinical Debility. , 1999, , 43-56.		1
1579	Matrix Metalloproteinases and Myocardial Remodeling in Heart Failure. , 2003, , 157-189.		1
1580	Pharmacology of Cav3 (T-Type) Channels. , 2004, , 183-236.		5

#	ARTICLE	IF	CITATIONS
1581	Therapeutics in Congestive Heart Failure: From Hemodynamics to Neurohormones. Progress in Experimental Cardiology, 2003, , 17-34.	0.0	3
1582	Biomedical Research and Changing Concepts of Disease and Aging: Implications for Long-Term Health Forecasts for Elderly Populations. , 1993, , 319-365.		19
1583	Molecular Phenotype of the Developing Heart with a Congenital Anomaly. Progress in Experimental Cardiology, 2002, , 197-212.	0.0	1
1584	The Heart in Acromegaly. Growth Hormone, 2001, , 33-43.	0.2	6
1585	Cardiac Extracellular Matrix and its Role in the Development of Heart Failure. Developments in Cardiovascular Medicine, 1995, , 75-90.	0.1	3
1587	Diastolic Dysfunction in Chronic Pressure and Volume Overload. , 1994, , 283-288.		2
1588	Physiological Versus Pathological Hypertrophy. Advances in Experimental Medicine and Biology, 1997, , 145-158.	0.8	5
1589	Regulation and Role of Myocardial Collagen Matrix Remodeling in Hypertensive Heart Disease. Advances in Experimental Medicine and Biology, 1997, 432, 35-44.	0.8	92
1590	Effects of Inhibition of Angiotensin-Converting Enzyme on Myocardial and Myocyte Remodeling in Chronic Volume Overload-Induced Cardiac Hypertrophy in the Dog. Progress in Experimental Cardiology, 1998, , 323-343.	0.0	1
1591	Role of Angiotensin II Receptor Blockade During Remodeling After Myocardial Infarction. Progress in Experimental Cardiology, 1998, , 437-449.	0.0	1
1592	Ventricular Remodeling: From Bedside to Molecule. Advances in Experimental Medicine and Biology, 1997, 430, 257-266.	0.8	14
1593	Angiotensin II in Cell Growth and Matrix Production. Advances in Experimental Medicine and Biology, 1995, 377, 217-223.	0.8	38
1594	Biochemistry and Cell Biology of Angiotensin-Converting Enzyme and Converting Enzyme Inhibitors. Advances in Experimental Medicine and Biology, 1995, 377, 141-168.	0.8	13
1595	Regulation of Gene Transcription of Angiotensin II Receptor Subtypes in the Heart. Advances in Experimental Medicine and Biology, 1996, 396, 23-32.	0.8	5
1596	Pathophysiology and Clinical Recognition of Heart Failure. , 2007, , 1379-1396.		1
1597	Heart Failure due to Left Ventricular Systolic Dysfunction. , 2020, , 149-175.		2
1598	Factors associated with reactive and reparative fibrosis of the myocardium. , 1992, 87 Suppl 1, 291-301.		28
1599	Myocardial fibrosis: role of angiotensin II and aldosterone. , 1993, 88 Suppl 1, 107-124.		53

#	ARTICLE	IF	CITATIONS
1600	Myocardial Interstitial Collagen Matrix Remodeling in Response to a Chronic Elevation in Ventricular Preload or Afterload. , 1997, , 19-31.		2
1601	Early Hypertrophic Signals After Myocardial Stretch. Role of Reactive Oxygen Species and the Sodium/Hydrogen Exchanger. , 2010, , 327-371.		6
1602	The Role of Mechanosensitive Fibroblasts in the Heart: Evidence from Acutely Isolated Single Cells, Cultured Cells and from Intracellular Microelectrode Recordings on Multicellular Preparations from Healthy and Diseased Cardiac Tissue. , 2010, , 239-266.		4
1603	Left Ventricular Hypertrophy, Congestive Heart Failure, and Coronary Flow Reserve Abnormalities in Hypertension. , 2005, , 250-280.		2
1605	Myocardial Recovery with Use of Ventricular Assist Devices. , 2012, , 220-238.		3
1606	Angiotensin II-induced protein tyrosine phosphorylation in neonatal rat cardiac fibroblasts.. Journal of Biological Chemistry, 1994, 269, 19626-19632.	1.6	112
1607	Neurohumoral Aspects of Heart Failure. Cardiology Clinics, 1994, 12, 9-23.	0.9	29
1608	Blockade of the Renin-Angiotensin System: Effect on Mortality in Patients with Left Ventricular Systolic Dysfunction. Cardiology Clinics, 1994, 12, 101-114.	0.9	2
1609	Treatment of the hypertensive patient with microvascular angina. Current Opinion in Cardiology, 1999, 14, 370.	0.8	6
1610	Assessment of Myocardial Fibrosis in Cardiomyopathic Hamsters with Gadolinium-DTPA Enhanced Magnetic Resonance Imaging. Investigative Radiology, 1998, 33, 22-32.	3.5	52
1611	Influence of Angiotensin-Converting Enzyme Inhibition by Fosinopril on Myocardial Perfusion in Streptozotocin-Diabetic Rats. Journal of Cardiovascular Pharmacology, 1996, 27, 64-70.	0.8	10
1612	Interaction of Myocytes and Nonmyocytes Is Necessary for Mechanical Stretch to Induce ANP/BNP Production in Cardiocyte Culture. Journal of Cardiovascular Pharmacology, 1998, 31, S357-S359.	0.8	55
1613	Hypertension and the Development of Heart Failure. Journal of Cardiovascular Pharmacology, 1998, 32, S9-S15.	0.8	12
1614	Reduced Periinfarction Mortality as a Result of Long-Term Therapy with Captopril But Not Hydralazine or Propranolol in Spontaneously Hypertensive Rats. Journal of Cardiovascular Pharmacology, 1998, 32, 884-895.	0.8	5
1615	The Role of Angiotensin II AT1 Receptor in the Maintenance of Hemodynamics in a Canine Model of Coronary Microembolization-Induced Heart Failure. Journal of Cardiovascular Pharmacology, 1999, 33, 335-340.	0.8	6
1616	Prevention of Doxorubicin (Adriamycin)-Induced Cardiomyopathy by Simultaneous Administration of Angiotensin-Converting Enzyme Inhibitor Assessed by Acoustic Densitometry. Journal of Cardiovascular Pharmacology, 2000, 36, 361-368.	0.8	62
1617	Aldosterone Receptor Blockade: A Therapy Resurrected. Heart Disease (Hagerstown, Md), 2003, 5, 85-88.	1.3	4
1618	Effects of Arginine Vasopressin on Differentiation of Cardiac Fibroblasts Into Myofibroblasts. Journal of Cardiovascular Pharmacology, 2010, 55, 489-495.	0.8	17

#	ARTICLE	IF	CITATIONS
1619	The proarrhythmic features of pathological cardiac hypertrophy in neonatal rat ventricular cardiomyocyte cultures. <i>Journal of Applied Physiology</i> , 2020, 128, 545-553.	1.2	3
1620	Low-dose dasatinib rescues cardiac function in Noonan syndrome. <i>JCI Insight</i> , 2016, 1, e90220.	2.3	39
1621	Myocardial electrical propagation in patients with idiopathic dilated cardiomyopathy.. <i>Journal of Clinical Investigation</i> , 1993, 92, 122-140.	3.9	94
1622	Characterization of angiotensin II receptors in cultured adult rat cardiac fibroblasts. Coupling to signaling systems and gene expression.. <i>Journal of Clinical Investigation</i> , 1994, 93, 2372-2378.	3.9	214
1623	Fibroblast growth factor stimulates angiotensin converting enzyme expression in vascular smooth muscle cells. Possible mediator of the response to vascular injury.. <i>Journal of Clinical Investigation</i> , 1995, 95, 377-387.	3.9	75
1624	Regulation of gene transcription of angiotensin II receptor subtypes in myocardial infarction.. <i>Journal of Clinical Investigation</i> , 1995, 95, 46-54.	3.9	403
1625	Natriuretic peptides inhibit angiotensin II-induced proliferation of rat cardiac fibroblasts by blocking endothelin-1 gene expression.. <i>Journal of Clinical Investigation</i> , 1995, 96, 1059-1065.	3.9	231
1626	Alteration of growth responses in established cardiac pressure overload hypertrophy in rats with aortic banding.. <i>Journal of Clinical Investigation</i> , 1995, 96, 2768-2774.	3.9	58
1627	Â1-Adrenergic receptors prevent a maladaptive cardiac response to pressure overload. <i>Journal of Clinical Investigation</i> , 2006, 116, 1005-1015.	3.9	127
1628	Disruption of the myocardial extracellular matrix leads to cardiac dysfunction. <i>Journal of Clinical Investigation</i> , 2000, 106, 857-866.	3.9	250
1629	The two-pore domain potassium channel TREK-1 mediates cardiac fibrosis and diastolic dysfunction. <i>Journal of Clinical Investigation</i> , 2018, 128, 4843-4855.	3.9	62
1630	Cardiac Patch Engineering. , 2008, , 542-551.		1
1631	Left Ventricular Hypertrophy: A Pathophysiological and Molecular Biological Perspective.. <i>Hypertension Research</i> , 1993, 16, 163-177.	1.5	13
1632	Effects of Angiotensin AT1 Receptor Antagonist on Volume Overload-Induced Cardiac Gene Expression in Rats.. <i>Hypertension Research</i> , 1997, 20, 133-142.	1.5	17
1633	Lisinopril Reduces Left Ventricular Hypertrophy and Cardiac Polyamine Concentrations without a Reduction in Left Ventricular Wall Stress in Transgenic Tsukuba Hypertensive Mice.. <i>Hypertension Research</i> , 2000, 23, 625-631.	1.5	6
1634	Cardiac Remodeling in Fish: Strategies to Maintain Heart Function during Temperature Change. <i>PLoS ONE</i> , 2011, 6, e24464.	1.1	112
1635	3-Pyridyl Substituted Aliphatic Cycles as CYP11B2 Inhibitors: Aromaticity Abolishment of the Core Significantly Increased Selectivity over CYP1A2. <i>PLoS ONE</i> , 2012, 7, e48048.	1.1	23
1636	The Novel Mas agonist, CGEN-856S, Attenuates Isoproterenol-Induced Cardiac Remodeling and Myocardial Infarction Injury in Rats. <i>PLoS ONE</i> , 2013, 8, e57757.	1.1	35

#	ARTICLE	IF	CITATIONS
1637	Adoptive Transfer of Regulatory T Cells Protects against Coxsackievirus B3-Induced Cardiac Fibrosis. PLoS ONE, 2013, 8, e74955.	1.1	59
1638	Early dystrophin loss is coincident with the transition of compensated cardiac hypertrophy to heart failure. PLoS ONE, 2017, 12, e0189469.	1.1	11
1639	Primary Aldosteronism With Type 2 Diabetes Mellitus Requires More Antihypertensive Drugs for Blood Pressure Control: A Retrospective Observational Study. Journal of Clinical Medicine Research, 2018, 10, 56-62.	0.6	6
1640	Effects of the Angiotensin-converting Enzyme Inhibitor Enalapril on Sympathetic Neuronal Function and .BETA.-adrenergic Desensitization in Heart Failure after Myocardial Infarction in Rats.. International Heart Journal, 2002, 43, 675-688.	0.6	5
1641	Heart Failure with Preserved Ejection Fraction – A Review. European Cardiology Review, 2012, 8, 186.	0.7	4
1642	Heart Failure with Preserved Ejection Fraction – A Review. US Cardiology Review, 2012, 9, 90-95.	0.5	1
1643	Myocardial fibrosis – a new component of heart remodeling in athletes?. Cardiovascular Therapy and Prevention (Russian Federation), 2019, 18, 126-135.	0.4	7
1644	Low coronary perfusion pressure is associated with endocardial fibrosis in a rat model of volume overload cardiac hypertrophy. Revista Do Hospital Das Clinicas, 2004, 59, 228-235.	0.5	4
1645	Quantitative study of myocardial microcirculation in arterial hypertension due to progressive inhibition of NO synthesis. Arquivos Brasileiros De Cardiologia, 1999, 73, 407-18.	0.3	3
1647	Morfometria do tecido conjuntivo do cora��o de equinos PSI. Brazilian Journal of Veterinary Research and Animal Science, 2004, 41, 162-168.	0.2	6
1648	Glycyrrhetic Acid Decreases Plasma Potassium Concentrations in Patients with Anuria. Journal of the American Society of Nephrology: JASN, 2002, 13, 191-196.	3.0	43
1649	A role of parathyroid hormone for the activation of cardiac fibroblasts in uremia.. Journal of the American Society of Nephrology: JASN, 1994, 4, 1814-1819.	3.0	219
1650	Relationship between left ventricular hypertrophy and plasma renin activity in chronic hemodialysis patients.. Journal of the American Society of Nephrology: JASN, 1997, 8, 1764-1770.	3.0	56
1651	Matrix metalloproteinases in serum of Emery-Dreifuss muscular dystrophy patients.. Acta Biochimica Polonica, 2009, 56, .	0.3	10
1652	Cardiac fibrosis in mouse expressing DsRed tetramers involves chronic autophagy and proteasome degradation insufficiency. Oncotarget, 2016, 7, 54274-54289.	0.8	10
1653	Physiological versus pathological cardiac hypertrophy. , 2005, , 117-136.		6
1654	CYP11B2 expression in HSCs and its effect on hepatic fibrogenesis. World Journal of Gastroenterology, 2000, 6, 885.	1.4	8
1655	Myocardial fibrosis in congenital and pediatric heart disease. Experimental and Therapeutic Medicine, 2017, 13, 1660-1664.	0.8	31

#	ARTICLE	IF	CITATIONS
1656	Apoptosis in Dilated Cardiomyopathy. Korean Journal of Internal Medicine, 2000, 15, 56-64.	0.7	17
1657	Effect of 3-Aminobenzamide, an Inhibitor of Poly (ADP-Ribose)Polymerase in Experimental Cardiac Hypertrophy. International Journal of Pharmacology, 2006, 2, 543-548.	0.1	15
1658	Protective Effects of Lagenaria siceraria (Molina) Fruit Juice in Isoproterenol Induced Myocardial Infarction. International Journal of Pharmacology, 2010, 6, 645-651.	0.1	24
1659	The ABCs of managing systolic heart failure: Past, present, and future. Cleveland Clinic Journal of Medicine, 2016, 83, 753-765.	0.6	7
1660	Myocardial T1 mapping: modalities and clinical applications. Cardiovascular Diagnosis and Therapy, 2014, 4, 126-37.	0.7	66
1661	Effect of vitamin E alone and in combination with lycopene on biochemical and histopathological alterations in isoproterenol-induced myocardial infarction in rats. Journal of Pharmacology and Pharmacotherapeutics, 2010, 1, 24.	0.2	25
1662	Investigation of the cardioprotective effects of Crataegus oxycantha and its molecular mechanism. Current Research Cardiology, 2015, 2, .	0.1	3
1663	Magnetic resonance imaging and multi-detector computed tomography assessment of extracellular compartment in ischemic and non-ischemic myocardial pathologies. World Journal of Cardiology, 2014, 6, 1192.	0.5	15
1664	Therapeutic interventions for heart failure with preserved ejection fraction: A summary of current evidence. World Journal of Cardiology, 2014, 6, 67.	0.5	17
1665	Severe aortic stenosis with preserved ejection fraction and evidence of impairment in structure, myocardial strain and ventricular function: A new contribution to clinical decision making. Cardiology Journal, 2015, 22, 613-621.	0.5	3
1666	Neprilysin inhibition: A brief review of past pharmacological strategies for heart failure treatment and future directions. Cardiology Journal, 2016, 23, 591-598.	0.5	10
1667	Physical Exercise and Regulation of Intracellular Calcium in Cardiomyocytes of Hypertensive Rats. Arquivos Brasileiros De Cardiologia, 2018, 111, 172-179.	0.3	16
1668	The Role of Endoglin in Myocardial Fibrosis. Acta Cardiologica Sinica, 2017, 33, 461-467.	0.1	20
1669	Akute kardiale Dyspnoe und LungenÄrdem. , 2000, , 527-538.		0
1670	Cardiac Remodeling in Cardiomyopathic Hamster Hearts. Progress in Experimental Cardiology, 2000, , 383-392.	0.0	0
1671	Markers and Triggers of Sudden Death in Athletes. Developments in Cardiovascular Medicine, 2000, , 71-88.	0.1	0
1672	Pathophysiologie der chronischen Herzinsuffizienz. , 2000, , 545-595.		0
1673	Control of cardiomyocyte gene expression as drug target. , 2000, , 135-142.		0

#	ARTICLE	IF	CITATIONS
1674	Neurohumoral modulation of metalloproteinases in cardiac failure: impact on remodeling. , 2000, , 247-261.		0
1675	Klinik und Symptomatologie der chronischen Herzinsuffizienz. , 2000, , 597-610.		0
1676	Definition und Epidemiologie der chronischen Herzinsuffizienz. , 2000, , 539-543.		0
1677	Transactivation of EGF receptor induced by angiotensin II regulates fibronectin and TGF- β 2 gene expression via transcriptional and post-transcriptional mechanisms. , 2000, , 187-201.		0
1678	Genetics of the renin-angiotensin-aldosterone system and risk of arterial disease. , 2001, , 11-27.		0
1679	The contribution of angiotensin-converting enzyme (ACE) to the metabolism of kinins (bradykinin and) Tj ETQq1 1 0.784314 rgBT /Over 129-144.		1
1680	Inflammatory Cell Infiltration, Cytokines, and Mechanisms of Myocyte Necrosis in Cardiac Transplant Rejection. , 2001, , 65-88.		0
1681	Angiotensin-converting Enzyme Inhibition and Angiotensin Receptor Blockade. , 2002, , 193-209.		0
1682	Diastolic Compliance. Basic Science for the Cardiologist, 2002, , 169-183.	0.1	0
1683	Diastolic Dysfunction: Pathophysiology, Clinical Features, and Treatment. , 2002, , 259-286.		2
1684	Molecular and Cellular Events in Myocardial Hypertrophy and Failure. , 2002, , 65-85.		2
1685	Integrins and the Myocardium. , 2002, 24, 87-105.		5
1686	Matrix Degradative Enzyme Activities on Cardiac Remodeling in Heart Failure. Progress in Experimental Cardiology, 2003, , 305-318.	0.0	0
1687	The role of endothelin-1 in myocardial inflammation and fibrosis. , 2003, , 371-384.		0
1688	Cardiac Remodelling in Pressure Overload Hypertrophy. , 2003, , 127-137.		0
1689	Electrical and Structural Remodeling of the Ventricular Myocardium in Disease. Contemporary Cardiology, 2003, , 127-152.	0.0	0
1691	Quinapril inhibits progression of heart failure and fibrosis in rats with dilated cardiomyopathy after Myocarditis. , 2003, , 77-82.		6
1692	Smad Cofactors/Corepressors in the Fibrosed Post-MI Heart: Possible Therapeutic Targets. Progress in Experimental Cardiology, 2004, , 485-511.	0.0	0

#	ARTICLE	IF	CITATIONS
1693	Primary hyperaldosteronism: diagnosis and treatment. Arterial Hypertension (Russian Federation), 2004, 10, 109-114.	0.1	0
1694	Inhibition of the Renin-Angiotensin-Aldosterone System. , 2005, , 195-212.		0
1695	Diastolic Dysfunction: Pathophysiology, Clinical Features, and Treatment. , 2005, , 271-301.		0
1696	Molecular and Cellular Events in Myocardial Hypertrophy and Failure. , 2005, , 61-81.		0
1697	Additive Effects of Spironolactone to Angiotensin II Receptor Blocker Monotherapy on Aldosterone Breakthrough in Patients with Essential Hypertension. Japanese Journal of Clinical Pharmacology and Therapeutics, 2006, 37, 49-54.	0.1	1
1698	Diastolic Heart Failure. Fundamental and Clinical Cardiology, 2006, , 227-246.	0.0	1
1699	Angiotensin II antagonists and protection against subclinical cardiac and vascular damage. , 2006, , 111-126.		3
1700	RELATIONS OF SERUM ALDOSTERONE AND MICROALBUMINURIA TO LEFT VENTRICULAR HYPERTROPHY IN PATIENTS WITH ESSENTIAL HYPERTENSION. Mansoura Medical Journal, 2006, 35, 467-486.	0.0	0
1701	The Medical Management of Heart Failure. , 2007, , 1397-1416.		0
1702	Surgical Treatment. , 2007, , 341-365.		0
1703	Efeitos da espironolactona sobre as alteraÃ§Ãµes miocÃ¡rdicas induzidas pelo hormÃªnio tireoideano em ratos. Arquivos Brasileiros De Cardiologia, 2007, 89, 398-402.	0.3	3
1704	The role of aldosterone blocker on left ventricular remodeling. Japanese Journal of Electrocardiology, 2008, 28, 22-31.	0.0	0
1705	Myocardial Growth and the Development and Regression of Increased Ventricular Mass. , 2009, , 460-473.		1
1706	Heart Failure: From Epidemiology to Pathophysiology. , 2009, , 3-11.		0
1707	Alteraciones estructurales precoces asociadas al remodelado elÃ©ctrico de la fibrilaciÃ³n auricular en un modelo canino de estimulaciÃ³n auricular sostenida a altas frecuencias. Efecto protector del lrbesartÃ¡n. Revista Iberoamericana De ArritmologÃ­a, 0, , .	0.1	0
1708	A Case of Primary Aldosteronism with GIST (Gastrointestinal Stromal Tumor) Treated by Adrenalectomy and Partial Gastric Resection. Juntendol,, Igaku, 2009, 55, 351-356.	0.1	0
1709	Aldosterone Antagonists, Amiloride, and Triamterene. , 2009, , 562-565.		0
1710	Left ventricular dysfunction measured by tissue Doppler imaging and strain rate imaging in hypertensive adolescents. Korean Journal of Pediatrics, 2010, 53, 72.	1.9	1

#	ARTICLE	IF	CITATIONS
1711	Advances in diastolic heart failure. World Journal of Cardiology, 2010, 2, 58.	0.5	2
1712	The Future of Old Age. , 2010, , 11-17.		0
1713	è,¥æ°€é«~è;€âœSâ«ãšãã,«éÿÿâ;©æ,,ÿâ←æ€Sè†“á™™”éšœâ®³ã•ãã®ãfjã,«ãf<ã,°ãf(2.éÿÿâ;©ã•é«~è;€âœS,«ç%°¹é†lã.ç¬¬73ã»ãæ—¥æœ¬		
1714	Post-infarction Remodeling and Arrhythmogenesis: Molecular, Ionic, and Electrophysiological Substrates. , 2011, , 283-304.		0
1715	Type 1 angiotensin II receptor antagonists in cardiovascular diseases: Valsartan. Arterial Hypertension (Russian Federation), 2011, 17, 325-332.	0.1	1
1716	Is target organ damage more frequent in primary aldosteronism than in essential hypertension?. Cor Et Vasa, 2011, 53, 449-453.	0.1	0
1717	Effects of the Supercritical Fluid Extraction of Dahurian Angelica Root and Szechwan Lovage Rhizome on Spontaneous Hypertension Rats. Chinese Medicine, 2012, 03, 209-214.	1.0	1
1719	Sleep-Disordered Breathing and Cardiac Arrhythmias: Role of Intermittent Hypoxia. , 2012, , 3-14.		0
1720	Reducing Oxidative Stress and Manipulating Molecular Signaling Events Using Resveratrol as a Therapy for Pathological Cardiac Hypertrophy. , 2013, , 227-254.		0
1721	Direct cardiac reprogramming by defined factors. Inflammation and Regeneration, 2013, 33, 190-196.	1.5	0
1722	Cardiac Resynchronization in Advanced Heart Failure: Biventricular Pacing. , 2013, , 71-91.		0
1723	Effect of adrenalectomy on the condition of the myocardium and arteries in hypertensive patient with primary hyperaldosteronism. Systemic Hypertension, 2013, 10, 70-75.	0.1	0
1724	Induced Cardiomyocytes. , 2013, , 258-275.		0
1725	Possible Contribution of Mineralocorticoid Receptor Activation on Glucocorticoid-Induced Left Ventricular Remodeling in Adrenalectomized Rat. Journal of Bangladesh Society of Physiologists, 2013, 8, 6-15.	0.0	0
1727	Direct reprogramming into cardiomyocytes. Inflammation and Regeneration, 2014, 34, 217-223.	1.5	0
1728	Aldosterone and Cardiovascular Diseases. , 2014, , 155-196.		0
1730	Angiotensin II Potentiates Collagen Synthesis in the Hypertrophied Heart. , 1992, , 199-201.		2
1731	Biological adaptation of the myocardium to a permanent change in loading conditions. , 1992, 87 Suppl 2, 1-10.		4

#	ARTICLE	IF	CITATIONS
1732	Myokardfibrose: Die Rolle von Angiotensin II und Aldosteron. , 1993, , 115-134.		0
1734	Angiotensin-converting enzyme inhibitors in the treatment of clinical heart failure. , 1993, 88 Suppl 1, 203-209.		1
1735	Regression of Cardiac Hypertrophy with Pharmacotherapeutic Regimen. , 1993, , 195-206.		0
1736	Arterial system, left ventricular structure and function. Developments in Cardiovascular Medicine, 1993, , 155-179.	0.1	0
1737	Health Forecasting and Models of Aging. , 1993, , 79-106.		1
1738	Myocardial Fibrosis: Structural Basis for Diastolic Dysfunction. , 1994, , 213-220.		0
1739	Inhibiting the Effects of Angiotensin on Cardiovascular Hypertrophy. , 1994, , 235-253.		4
1740	Interplay of Hypertrophy and Myocardial Ischemia. , 1994, , 203-211.		1
1741	Diastolic Dysfunction in Tachycardia-Induced Heart Failure. , 1994, , 243-263.		1
1742	Chest Pain And Angiographically Normal Coronary Arteries In Patients With Systemic Hypertension And Left Ventricular Hypertrophy: Mechanisms. Developments in Cardiovascular Medicine, 1994, , 89-109.	0.1	0
1743	Coronary Circulation in Patients with Pressure-Overloaded Left Ventricular Hypertrophy. , 1994, , 241-253.		0
1744	EVOLVING ROLE OF CARDIOPULMONARY EXERCISE TESTING IN CARDIOVASCULAR DISEASE. Clinics in Chest Medicine, 1994, 15, 271-285.	0.8	6
1746	Chronic hibernating myocardium: Interstitial changes. , 1995, , 35-42.		0
1747	Angiotensin II signalling pathways in cardiac fibroblasts: Conventional versus novel mechanisms in mediating cardiac growth and function. , 1996, , 15-21.		0
1748	Secondary prevention of myocardial infarction: the roles of Î²-adrenergic blockers, calcium-channel blockers, angiotensin converting enzyme inhibitors, and aspirin. Developments in Cardiovascular Medicine, 1996, , 367-394.	0.1	7
1749	Ventricular Remodeling Following Coronary Artery Constriction and Hypertension. Developments in Cardiovascular Medicine, 1996, , 381-400.	0.1	0
1750	Myocardial Perfusion in Hypertensive Patients with Normal Coronary Arteries. Advances in Experimental Medicine and Biology, 1997, 432, 215-233.	0.8	0
1751	Development of pressure overload induced cardiac hypertrophy is unaffected by long-term treatment with losartan. , 1998, , 225-233.		6

#	ARTICLE	IF	CITATIONS
1752	The extracellular matrix in hibernating myocardium â€” a significant factor causing structural defects and cardiac dysfunction. , 1998, , 147-158.		18
1753	Hypertension and the Development of Heart Failure. Journal of Cardiovascular Pharmacology, 1998, 32, S9-S15.	0.8	0
1755	Molecular Mechanism of Cardiovascular Remodeling. , 1998, , 131-145.		0
1756	Microvascular Angina and Hypertensive Left Ventricular Hypertrophy. Developments in Cardiovascular Medicine, 1999, , 269-279.	0.1	0
1757	Pathophysiologische Erkenntnisse und Therapieempfehlungen bei ischämischer Kardiomyopathie. , 1999, , 69-81.		0
1758	Kardiale Schädigungen bei arterieller Hypertonie. , 1999, , 83-89.		0
1759	Adding T1 Mapping and Extracellular Volume Fraction for Myocardial Fibrosis Assessment: Implications for Cardiovascular Risk Assessment. , 2015, , 137-151.		0
1760	Impact of Aortic Stiffness on Exercise Tolerance and Left Ventricular Filling Pressure after Percutaneous Coronary Intervention for Patients with Chronic Stable Coronary Artery Disease. Journal of Cardiology & Current Research, 2015, 4, .	0.1	0
1761	Ischemic Kidney Disease: a Modern Approach to the Problem. PoÄki, 2016, .	0.1	0
1762	Complementary and Synergic Role of Combined Beta-blockers and Ivabradine in Patients with Chronic Heart Failure and Depressed Systolic Function: A New Therapeutic Option?. Cardiac Failure Review, 2016, 2, 130-136.	1.2	2
1764	Does Late Gadolinium Enhancement Still have Value? Right Ventricular Internal Mechanical Work, Ea/Emax and Late Gadolinium Enhancement as Prognostic Markers in Patients with Advanced Pulmonary Hypertension via Cardiac MRI. Cardiology Research and Cardiovascular Medicine, 2017, 2, .	0.0	9
1765	Heart Failure with Preserved Ejection Fraction (HFpEF). , 2017, , 197-209.		0
1766	Structural Remodeling in the Development of Chronic Systolic Heart Failure: Implication for Treatment. , 2017, , 247-265.		0
1767	Recommendations on the use of echocardiography in adult hypertension: a report from the European Association of Cardiovascular Imaging (EACVI) and the American Society of Echocardiography (ASE). Systemic Hypertension, 2017, 14, 6-28.	0.1	3
1768	Ein¼hrung in das Herz-Kreislauf-System. , 2018, , 57-103.		2
1769	Symptomatic presentations of severe aortic stenosis. Precision and Future Medicine, 2017, 1, 122-128.	0.5	0
1770	QT Dispersion Changes after Transcatheter Aortic Valve Implantation in Patients with Aortic Stenosis. Brazilian Journal of Cardiovascular Surgery, 2019, 34, 704-710.	0.2	0
1771	Methodical, Diagnostic and Prognostic Aspects Using Transmitral Blood Flow Indicators as Markers of Diastolic Dysfunction During the Progression of Chronic Heart Failure. Family Medicine, 2019, .	0.1	0

#	ARTICLE	IF	CITATIONS
1773	Update on the Diagnosis and Management of Primary Aldosteronism. , 2020, , 129-137.		0
1774	Comparison of the shortened and standard saline infusion tests for primary aldosteronism diagnostics. Hypertension Research, 2020, 43, 1113-1121.	1.5	2
1775	TRIF/miR-34a mediates aldosterone-induced cardiac inflammation and remodeling. Clinical Science, 2020, 134, 1319-1331.	1.8	3
1776	TRIF/EGFR signalling mediates angiotensin-II-induced cardiac remodelling in mice. Journal of Molecular Endocrinology, 2020, 65, 11-20.	1.1	1
1778	Addition of Amlodipine or Valsartan for Improvement of Diastolic Dysfunction Associated with Hypertension. Journal of Cardiovascular Imaging, 2020, 28, 174.	0.2	3
1781	Cellular Oxidative Stress, Aging, and the Local RAS. , 2006, , 201-217.		1
1782	Arterielle Hypertonie bei Diabetes mellitus. , 2005, , 26-39.		0
1784	Pathophysiology of Contractile Dysfunction in Heart Failure. , 1999, , 1-13.		0
1787	Outpatient management of congestive heart failure. Texas Heart Institute Journal, 1998, 25, 238-50.	0.1	1
1788	A stereological method for estimating the total number of ventricular myocyte nuclei in fetal and postnatal hearts. Journal of Anatomy, 1995, 187 (Pt 3), 641-7.	0.9	12
1789	Interstitial myocardial fibrosis in a captive chimpanzee (Pan troglodytes) population. Comparative Medicine, 2008, 58, 389-94.	0.4	57
1790	Laboratory investigation of primary aldosteronism. Clinical Biochemist Reviews, 2010, 31, 39-56.	3.3	63
1791	An updated concept for left ventricular hypertrophy risk in hypertension. Ochsner Journal, 2009, 9, 181-90.	0.5	5
1792	Increased collagen, per se, may not affect left ventricular function in spontaneously hypertensive rats. Ochsner Journal, 2011, 11, 241-5.	0.5	1
1793	Targeting cardiac fibrosis: a new frontier in antiarrhythmic therapy?. American Journal of Cardiovascular Disease, 2011, 1, 101-9.	0.5	21
1794	Early loss of cardiac function in acute myocardial infarction is associated with redox imbalance. Experimental and Clinical Cardiology, 2012, 17, 263-7.	1.3	8
1795	A randomised, controlled, double-blind, cross-over pilot study assessing the effects of spironolactone, losartan and their combination on heart rate variability and QT dispersion in patients with chronic heart failure. Cardiovascular Journal of Africa, 2008, 19, 292-6.	0.2	12
1796	Effect of transcatheter aortic valve implantation on QT dispersion in patients with aortic stenosis. Journal of Geriatric Cardiology, 2014, 11, 286-90.	0.2	7

#	ARTICLE	IF	CITATIONS
1797	ACE2-Ang (1-7) axis is induced in pressure overloaded rat model. International Journal of Clinical and Experimental Pathology, 2015, 8, 1443-50.	0.5	9
1798	Managing Heart Failure in Transposition of the Great Arteries. Ochsner Journal, 2015, 15, 290-6.	0.5	7
1799	Sleep Disordered Breathing and the Pathogenesis of Atrial Fibrillation. Journal of Atrial Fibrillation, 2013, 6, 818.	0.5	2
1800	Heart Failure: A Class Review of Pharmacotherapy. P and T, 2017, 42, 464-472.	1.0	7
1801	Does Late Gadolinium Enhancement still have Value? Right Ventricular Internal Mechanical Work, E/E and Late Gadolinium Enhancement as Prognostic Markers in Patients with Advanced Pulmonary Hypertension via Cardiac MRI. Cardiology Research and Cardiovascular Medicine, 2017, 2017, .	0.0	7
1802	Neurohumoral, cardiac and inflammatory markers in the evaluation of heart failure severity and progression. Journal of Geriatric Cardiology, 2021, 18, 47-66.	0.2	1
1803	Targeting monocytes/macrophages in fibrosis and cancer diseases: Therapeutic approaches. , 2022, 234, 108031.		17
1804	Research Update on the Pathophysiological Mechanisms of Heart Failure with Preserved Ejection Fraction. Current Molecular Medicine, 2023, 23, 54-62.	0.6	5
1805	Tissue Characterization in Cardiology: Moving Beyond Function. Advances in Experimental Medicine and Biology, 2021, 1337, 89-97.	0.8	0
1806	Fibrosis-4 index: A new marker to predict non-dipper blood pressure pattern in patients with newly diagnosed hypertension. Iberoamerican Journal of Medicine, 0, , 52-59.	0.1	0
1807	Myocardial fibrosis by T1 mapping magnetic resonance imaging predicts incident cardiovascular events and all-cause mortality: the Multi-Ethnic Study of Atherosclerosis. European Heart Journal Cardiovascular Imaging, 2022, 23, 1407-1416.	0.5	13
1808	Rationale and Design of the Efficacy and Safety of Esaxerenone in Hypertensive Patients With Left Ventricular Hypertrophy (ESES-LVH) Studyâ€œâ€• Protocol for a Multicenter, Open-Label, Exploratory Interventional Study â€œ. Circulation Reports, 2022, 4, 99-104.	0.4	2
1809	Cerebro-Cardiovascular Risk, Target Organ Damage, and Treatment Outcomes in Primary Aldosteronism. Frontiers in Cardiovascular Medicine, 2021, 8, 798364.	1.1	11
1810	ADAMTS8 Promotes Cardiac Fibrosis Partly Through Activating EGFR Dependent Pathway. Frontiers in Cardiovascular Medicine, 2022, 9, 797137.	1.1	6
1811	Fragmented QRS in inferior leads is associated with non-alcoholic fatty liver disease, body-mass index, and interventricular septum thickness in young men. , 2022, 26, 100-104.		1
1812	The extracellular matrix in hibernating myocardiumâ€œa significant factor causing structural defects and cardiac dysfunction. Molecular and Cellular Biochemistry, 1998, 186, 147-58.	1.4	11
1813	Development of pressure overload induced cardiac hypertrophy is unaffected by long-term treatment with losartan. Molecular and Cellular Biochemistry, 1998, 188, 225-33.	1.4	5
1814	Control of cardiomyocyte gene expression as drug target. Molecular and Cellular Biochemistry, 2000, 212, 135-42.	1.4	3

#	ARTICLE	IF	CITATIONS
1815	Quinapril inhibits progression of heart failure and fibrosis in rats with dilated cardiomyopathy after myocarditis. <i>Molecular and Cellular Biochemistry</i> , 2003, 251, 77-82.	1.4	3
1816	Diabetes and Myocardial Fibrosis. <i>JACC: Cardiovascular Imaging</i> , 2022, 15, 796-808.	2.3	25
1817	Strain Imaging for the Early Detection of Cardiac Remodeling and Dysfunction in Primary Aldosteronism. <i>Diagnostics</i> , 2022, 12, 543.	1.3	4
1818	Myocardial tissue imaging with cardiovascular magnetic resonance. <i>Journal of Cardiology</i> , 2022, 80, 377-385.	0.8	7
1819	The multifaceted role of cytochrome P450-Derived arachidonic acid metabolites in diabetes and diabetic cardiomyopathy. <i>Drug Metabolism Reviews</i> , 2022, 54, 141-160.	1.5	11
1820	Oridonin Relieves Angiotensin II-Induced Cardiac Remodeling via Inhibiting GSDMD-Mediated Inflammation. <i>Cardiovascular Therapeutics</i> , 2022, 2022, 1-17.	1.1	3
1821	Multiparametric CMR imaging of myocardial structure and function changes in diabetic mini-pigs with preserved LV function: a preliminary study. <i>BMC Cardiovascular Disorders</i> , 2022, 22, 143.	0.7	1
1822	Zerumbone, a humulane sesquiterpene from <i>Syringa pinnatifolia</i> , attenuates cardiac fibrosis by inhibiting of the TGF- β 1/Smad signaling pathway after myocardial infarction in mice. <i>Phytomedicine</i> , 2022, 100, 154078.	2.3	11
1823	Myocardial Extracellular Volume Fraction and T1 Mapping by Cardiac Magnetic Resonance Compared Between Patients With and Without Type 2 Diabetes, and the Effect of ECV and T2D on Cardiovascular Outcomes. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 771363.	1.1	6
1824	Echocardiographic Global Longitudinal Strain Is Associated With Myocardial Fibrosis and Predicts Outcomes in Aortic Stenosis. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 750016.	1.1	19
1834	Therapeutic Approaches in Heart Failure with Preserved Ejection Fraction (HFpEF) in Children: Present and Future. <i>Paediatric Drugs</i> , 2022, 24, 235-246.	1.3	3
1835	A case of a pregnant woman with primary aldosteronism and superimposed preeclampsia treated with esaxerenone. <i>Journal of the Endocrine Society</i> , 0, , .	0.1	1
1836	lncRNA NBR2 attenuates angiotensin II-induced myocardial hypertrophy through repressing ER stress via activating LKB1/AMPK/Sirt1 pathway. <i>Bioengineered</i> , 2022, 13, 13667-13679.	1.4	7
1837	Future scope and challenges for congestive heart failure: Moving towards development of pharmacotherapy. <i>Canadian Journal of Physiology and Pharmacology</i> , 0, , .	0.7	2
1838	Near-Infrared Spectroscopic Characterization of Cardiac and Renal Fibrosis in Fixed and Fresh Rat Tissue. <i>Analysis & Sensing</i> , 2023, 3, .	1.1	2
1840	Empagliflozin reduces diffuse myocardial fibrosis by extracellular volume mapping: A meta-analysis of clinical studies. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	3
1841	Personalised physiological medicine: Orthostatic hypotension. <i>Medical Hypotheses</i> , 2022, 167, 110928.	0.8	1
1842	Glutamine uptake and catabolism is required for myofibroblast formation and persistence. <i>Journal of Molecular and Cellular Cardiology</i> , 2022, 172, 78-89.	0.9	13

#	ARTICLE	IF	CITATIONS
1843	The extracellular matrix in cardiovascular aging. , 2023, , 523-545.		0
1844	Biochemical evidence of PM2.5 critical components for inducing myocardial fibrosis in vivo and in vitro. <i>Science of the Total Environment</i> , 2023, 857, 159258.	3.9	4
1845	Myocardial fibrosis in congenital heart disease. <i>Frontiers in Pediatrics</i> , 0, 10, .	0.9	2
1846	Exploring the cardiac ECM during fibrosis: A new era with next-gen proteomics. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	8
1847	Role of Cardiac Natriuretic Peptides in Heart Structure and Function. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14415.	1.8	21
1848	Apitherapy combination improvement of blood pressure, cardiovascular protection, and antioxidant and anti-inflammatory responses in dexamethasone model hypertensive rats. <i>Scientific Reports</i> , 2022, 12, .	1.6	4
1849	Serum aldosterone effect on left ventricular structure and diastolic function in essential hypertension. <i>Journal of Clinical Hypertension</i> , 0, , .	1.0	1
1851	Renin-angiotensin-aldosterone system and blood pressure regulation. , 2023, , 63-75.		1
1852	Editorial: Endocrine-related cardiovascular diseases: Recent advances in diagnosis and treatment. <i>Frontiers in Endocrinology</i> , 0, 14, .	1.5	0
1853	Characterizing the Heart and the Myocardium With Photon-Counting CT. <i>Investigative Radiology</i> , 2023, 58, 505-514.	3.5	6
1854	Dynamic mechanobiology of cardiac cells and tissues: Current status and future perspective. <i>Biophysics Reviews</i> , 2023, 4, .	1.0	6
1855	The role of the renin-angiotensin-aldosterone system in the development of cardiovascular complications in COVID-19. <i>Pediatrician (St Petersburg)</i> , 2023, 14, 98-118.	0.1	0
1856	Cardiac Microvascular Endothelial Cells and Pressure Overload-Induced Cardiac Fibrosis. <i>Cardiac and Vascular Biology</i> , 2023, , 229-264.	0.2	0
1857	A novel caffeic acid derivative prevents angiotensin II-induced cardiac remodeling. <i>Biomedicine and Pharmacotherapy</i> , 2023, 162, 114709.	2.5	1
1859	Case report: Diagnosis of apical hypertrophic cardiomyopathy that escaped clinical and echocardiographic investigations for twenty years: Reasons and clinical implications. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	1.1	1